Methods for expansion of natural killer (NK) cell subset and related compositions and methods

The described method effectively expands FcRγ-deficient NK cells using 221.AEH feeder cells and IL-2, overcoming low abundance and phenotypic challenges, achieving high yields of potent g-NK cells for therapeutic applications.

JP2024161503AInactive Publication Date: 2024-11-19INDAPTA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024135820
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-21
Filing Date
2024-08-16
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods face challenges in efficiently expanding specialized subsets of natural killer (NK) cells, particularly FcRγ-deficient g-NK cells, due to their low abundance and lack of specific surface phenotypic characteristics, limiting their utility in therapeutic applications.

Method used

A method involving the irradiation of enriched NK cell populations with 221.AEH feeder cells and culturing in the presence of recombinant IL-2, with specific ratios and optional inclusion of irradiated PBMC feeder cells and anti-CD3 antibodies, to enhance the expansion of FcRγ-deficient NK cells, including subsets like CD3-NK, CD3-CD56+, CD3-CD57+, and CD3-CD16+ cells.

Benefits of technology

The method achieves a high yield (>1000-fold) expansion of functional g-NK cells, maintaining their potency for antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine production, suitable for therapeutic use, even with previously frozen cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161503000023
    Figure 2024161503000023
  • Figure 2024161503000024
    Figure 2024161503000024
  • Figure 2024161503000025
    Figure 2024161503000025
Patent Text Reader

Abstract

To provide an improved method for obtaining an NK cell composition for therapeutic use.SOLUTION: Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or disease-associated cells, such as tumor cells or infected cells.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 770,686, filed November 21, 2018, entitled "METHODS FOR EXPANSION OF NATURAL KILLER (NK) CELL SUBSET AND RELATED COMPOSITIONS AND METHODS," the contents of which are incorporated herein by reference in their entirety.

[0002] INCORPORATION BY REFERENCE TO SEQUENCE LISTING This application is filed with an electronic Sequence Listing. The Sequence Listing is provided as a file named 776032000540SeqList.txt, created on November 21, 2019, and is 7.8 kilobytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

[0003] Field The present disclosure provides methods for the ex vivo expansion of specialized subsets of natural killer (NK) cells and compositions containing such NK cells. Methods for identifying or detecting specialized subsets of NK cells are also provided. Methods for treating diseases and conditions, such as cancer, using the compositions of the present disclosure, including in combination with antibodies capable of binding to disease-associated tissues or disease-associated cells, such as tumor cells or infected cells, are also provided. [Background technology]

[0004] background Antibody-based therapies are increasingly used to treat cancer and other diseases. While responses to antibody therapy have typically focused on the direct inhibitory effects of these antibodies on tumor cells (e.g., growth factor receptor blockade and subsequent apoptosis induction), the in vivo effects of these antibodies appear to be more complex and may involve the host immune system. Natural killer (NK) cells are immune effector cells that mediate antibody-dependent cellular cytotoxicity upon binding of an Fc receptor (CD16; FcγRIII) to the Fc portion of an antibody bound to an antigen-bearing cell. NK cells, including their specialized subsets, can be used in therapeutic methods, such as to improve responses to antibody therapy. However, major obstacles to the application of NK cells in cell therapies, such as adoptive cell therapy, are their relatively low abundance in human peripheral blood and the lack of surface phenotypic characteristics of specific specialized subsets. Improved methods are needed to obtain NK cell compositions for therapeutic applications. Embodiments that meet this need are provided herein. Summary of the Invention

[0005] overview FcRγ-deficient NK cells (g - Provided herein is a method for expanding CD3-negative and CD57-positive (CD3 NK) cells, the method comprising: (a) extracting from a sample from a human subject: (i) CD3-negative and CD57-positive (CD3 neg CD57 pos ), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg (b) isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are 221.AEH feeder cells to enriched NK cells; and (b) culturing the enriched NK cell population in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population.

[0006] FcRγ-deficient NK cells (g - Provided herein are methods for increasing CD3-negative (CD3 NK) cells, the methods comprising: (a) extracting from a sample from a human subject: (i) CD3-negative (CD3 neg ), (ii) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (iii) cells that are CD3 negative and CD57 positive (CD3 neg CD57 pos ), or (iv) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos (b) isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are 221.AEH feeder cells to enriched NK cells; and (b) culturing the enriched NK cell population in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population.

[0007] FcRγ-deficient NK cells (g - Provided herein is a method for expanding CD3-negative and CD57-positive (CD3 NK) cells, the method comprising: (a) extracting from a sample from a human subject: (i) CD3-negative and CD57-positive (CD3 neg CD57 pos), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos ), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg (b) isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are 221.AEH feeder cells and irradiated peripheral blood mononuclear (PBMC) feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is 1:10 to 10:1, and the ratio of PBMC feeder cells to enriched NK cells is from at or about 1:1 to 5:1 or about 5:1, inclusive. Optionally, the PBMC feeder cells are autologous to the subject. The method also involves (c) culturing the population of (b) in the presence of recombinant IL-2 and an anti-CD3 antibody or antigen-binding fragment, wherein the cell culture medium is replaced with fresh medium containing recombinant IL-2 within 7 days of the initiation of the culturing, and optionally, further replacing the cell culture medium with fresh medium containing recombinant IL-2 every 2 or 3 days thereafter for the duration of the culturing, wherein the culturing produces an expanded g-NK cell population; and (d) harvesting the expanded cell population.

[0008] In any of the provided embodiments, the provided methods include obtaining a sample from a human subject prior to isolating or selecting a population of NK cell-enriched cells. In some of any of the embodiments, the human subject is CMV seropositive. In some of any of the embodiments, the human subject has a CD16 158V+ NK cell genotype. In some of the provided embodiments, the sample is or comprises peripheral blood mononuclear cells (PBMCs). In some embodiments, the sample is an apheresis sample or a leukapheresis sample.

[0009] In any of the embodiments provided, the method includes isolating cells enriched for NK cells from a sample from the subject. In some embodiments, the isolating is by selecting a population of cells enriched for NK cells from the sample. In some embodiments, the selecting is by immunoaffinity-based selection. In some of the embodiments, the isolating is (i) isolating CD3-negative and CD57-positive (CD3 neg CD57 pos In some embodiments, the isolating step is a step of isolating (ii) and selecting cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD57 pos CD28 neg In some embodiments, the isolating step is a step of isolating (iii) and selecting cells that are CD3 negative (CD3 neg In some embodiments, the isolating step is a step of isolating (iv) and selecting cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos In some embodiments, the isolating step comprises selecting cells from the sample that are CD3 negative and CD57 positive (CD3 neg CD57 posIn some embodiments, the isolating step is a step of isolating (v) and selecting cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos In some embodiments, the isolating step comprises isolating (vi) and selecting from the sample cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg ) and selecting cells that are

[0010] In some of the provided methods of isolating or selecting a population of cells enriched for NK cells, the method can include cryopreserving the isolated population of enriched NK cells, e.g., prior to culturing the cells, e.g., to expand the population of cells. In some of any such embodiments, the provided methods include thawing a cryopreserved sample comprising enriched NK cells, prior to culturing the cells, e.g., to expand the population of cells.

[0011] FcRγ-deficient NK cells (g - Provided herein is a method for expanding natural killer (NK) cells, the method comprising: (a) obtaining a population of primary human cells enriched for NK cells, wherein the enriched NK cell population is (i) CD3-negative and CD57-positive (CD3 neg CD57 pos ), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg (b) culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded population of NK cells enriched for g-NK cells. In some embodiments, the step of obtaining the population of cells enriched for NK cells comprises thawing a cryopreserved sample containing enriched NK cells.

[0012] FcRγ-deficient NK cells (g - Provided herein are methods for expanding natural killer (NK) cells, the methods comprising: (a) obtaining a population of primary human cells enriched for NK cells, wherein the enriched NK cell population is: (i) CD3-negative (CD3 neg ), (ii) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (iii) cells that are CD3 negative and CD57 positive (CD3 neg CD57 pos ), or (iv) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos and (b) culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population. In some embodiments, the step of obtaining the population of cells enriched for NK cells comprises thawing a cryopreserved sample containing enriched NK cells.

[0013] In some of any such embodiments, the population of enriched NK cells is a population of (i) and is CD3 negative and CD57 positive (CD3 neg CD57 pos In some of any such embodiments, the enriched population of NK cells is a population of (ii), which is CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg In some of any such embodiments, the enriched population of NK cells is a population of (iii) and includes cells that are CD3 negative (CD3 neg In some of any such embodiments, the enriched population of NK cells is a population of (iv) and includes cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos In some of any such embodiments, the enriched population of NK cells comprises cells that are CD3 negative and CD57 positive (CD3 neg CD57 pos In some of any such embodiments, the enriched population of NK cells is a population of (v), which is CD3 negative and CD16 positive (CD3 neg CD16 pos In some of any such embodiments, the enriched population of NK cells is a population of (vi) and includes cells that are CD3 negative (CD3 neg ) and CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg ) cells.

[0014] In some of any such embodiments, the enriched population of NK cells is CD3 negative (CD3 neg In some of any such embodiments, the enriched population of NK cells includes cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos In some of any such embodiments, the enriched population of NK cells comprises cells that are CD3 negative and CD57 positive (CD3neg CD57 pos In some of any such embodiments, the enriched population of NK cells includes cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos ) cells.

[0015] FcRγ-deficient NK cells (g - Provided herein is a method for expanding natural killer (NK) cells, the method comprising culturing a population of primary human cells enriched for NK cells from a sample from a human subject, wherein the enriched NK cell population comprises cells that are CD3-negative and CD57-positive, and the culturing is carried out in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population.

[0016] In some embodiments, the method comprises isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising: (1) selecting cells that are (a) CD3-negative or (b) CD57-positive, thereby enriching a first selected population; and (2) selecting cells from the first selected population for the other of (a) CD3-negative or (b) CD57-positive cells, thereby enriching for CD3-negative and CD57-positive cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0017] In some of any of the embodiments, the method includes isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step including (1) selecting cells from the sample that are CD3 negative to produce a first selected population, and (2) selecting cells from the first selected population that are CD57 positive, thereby enriching for CD4 negative and CD57 positive cells.

[0018] FcRγ-deficient NK cells (g -Provided herein is a method for expanding natural killer (NK) cells, the method comprising culturing a population of primary human cells enriched for NK cells from a sample from a human subject, wherein the enriched NK cell population comprises cells that are CD3-negative, CD56-positive, and CD38-negative, and the culturing is carried out in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population.

[0019] In some of any of the embodiments, the method includes isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step including: (1) selecting from the sample cells that are CD3-negative, thereby enriching a first selected population; (2) selecting from the first selected population cells that are (a) CD56-positive or (b) CD38-negative, thereby enriching a second selected population; and (3) selecting from the second selected population cells for the other of (a) CD56-positive or (b) CD38-negative cells, thereby enriching for CD3-negative, CD56-positive, and CD38-negative cells.

[0020] In some of any of the embodiments, the method includes isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step including (1) selecting cells from the sample that are CD3-negative to produce a first selected population, (2) selecting cells from the first selected population that are CD56-positive to produce a second selected population, and (3) selecting cells from the second selected population that are CD38-negative, thereby enriching for cells that are CD3-negative, CD56-positive, and CD38-negative.

[0021] FcRγ-deficient NK cells (g -Provided herein is a method for expanding natural killer (NK) cells, the method comprising culturing a population of primary human cells enriched for NK cells from a sample from a human subject, wherein the enriched NK cell population comprises cells that are CD3-negative and CD16-positive, and the culturing is carried out in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded g-NK cell population.

[0022] In some embodiments, the method comprises isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising: (1) selecting cells that are (a) CD3-negative or (b) CD16-positive, thereby enriching a first selected population; and (2) selecting cells from the first enriched selected population for the other of (a) CD3-negative or (b) CD16-positive cells, thereby enriching for CD3-negative and CD16-positive cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0023] In some embodiments, the method includes isolating the population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising (1) selecting cells from the sample that are CD3 negative to produce a first selected population, and (2) selecting cells from the first selected population that are CD16 positive, thereby enriching for CD3 negative and CD16 positive cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0024] FcRγ-deficient NK cells (g -Provided herein is a method for expanding natural killer (NK) cells, the method comprising culturing a population of primary human cells enriched for NK cells from a sample from a human subject, wherein the enriched NK cell population comprises cells that are CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative, and the culturing is carried out in the presence of (i) irradiated 221.AEH feeder cells, at a ratio of irradiated 221.AEH feeder cells to enriched NK cells of 1:10 to 10:1, and (ii) recombinant IL-2, wherein the method produces an expanded NK cell population.

[0025] In some embodiments, the method comprises isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising: (1) selecting from the sample cells that are CD3-negative to produce a first selected population; (2) selecting from the first selected population cells that are CD56-positive to produce a second selected population; (3) selecting from the second selected population for cells that are (a) NKG2A-negative or (b) CD161-negative, thereby enriching a third selected population; and (4) selecting from the third selected population for the other of (a) NKG2A-negative cells or (b) CD161-negative cells, thereby enriching for CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0026] In some embodiments, the method comprises isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising: (1) selecting cells from the sample that are CD3-negative to produce a first selected population; (2) selecting cells from the first selected population that are CD56-positive to produce a second selected population; (3) selecting cells from the second selected population that are NKG2A-negative to produce a third selected population; and (4) selecting cells from the third selected population that are CD161-negative to enrich for CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0027] In some embodiments, the method comprises isolating a population of enriched NK cells from the sample prior to the culturing step, the isolating step comprising: (1) selecting cells from the sample that are CD3-negative to produce a first selected population; (2) selecting cells from the first selected population that are CD56-positive to produce a second selected population; (3) selecting cells from the second selected population that are CD161-negative to produce a third selected population; and (4) selecting cells from the third selected population that are NKG2A-negative to enrich for CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative cells. In some embodiments, the selecting comprises immunoaffinity-based selection.

[0028] In some of the provided embodiments, the sample comprises peripheral blood mononuclear cells (PBMCs). In some of the provided embodiments, the method includes obtaining the sample from the human subject prior to the culturing step. In some embodiments, the human subject is CMV seropositive. In some embodiments, the human subject has a CD16 158V+ NK cell genotype. In some embodiments, the sample is an apheresis sample or a leukapheresis sample. In some of the provided embodiments, the enriched NK cells are derived from a cryopreserved sample previously isolated from a sample from the subject.

[0029] In some of any of the provided embodiments, the culturing step is further performed in the presence of (iii) primary human peripheral blood mononuclear cell (PBMC) feeder cells, wherein the PBMC feeder cells are irradiated. In some of any of the provided embodiments, the culturing step is performed after combining the population of enriched NK cells with irradiated 221.AEH feeder cells and irradiated PBMC feeder cells. In some such embodiments, the ratio of PBMC feeder cells to enriched NK cells is from 1:1 or about 1:1 to 5:1 or about 5:1, inclusive. In some of any of the provided embodiments, the PBMC feeder cells are autologous to the subject. In some of the provided embodiments, at least a portion of the culturing step is performed in the presence of at least one stimulatory agent capable of stimulating activation of one or more T cells in the PBMC feeder cells. In some embodiments, the stimulatory agent specifically binds to a member of the TCR complex, and optionally, the agent specifically binds to CD3, optionally CD3 epsilon. In some embodiments, the at least one stimulatory agent is an anti-CD3 antibody or an antigen-binding fragment thereof. In some embodiments, the anti-CD3 antibody or antigen-binding fragment thereof is an OKT3 antibody or antigen-binding fragment. In some embodiments, the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 10 ng / mL to at or about 100 ng / mL. In some embodiments, the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 50 ng / mL. In some of the provided embodiments, the at least one stimulatory agent is added beginning at the beginning of the culturing step or simultaneously or approximately simultaneously with the irradiated PBMC feeder cells. In some of the provided embodiments, the PBMC feeder cells are activated during at least a portion of the culturing step.

[0030] In some of the provided embodiments, the ratio of irradiated 221.AEH feeder cells to enriched NK cells is 1:1 or about 1:1 or greater. In some of the provided embodiments, the ratio of irradiated 221.AEH feeder cells to enriched NK cells is 1:1 to 5:1, inclusive. In some of the provided embodiments, the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 1:1 to 3:1, inclusive. In some of the provided embodiments, the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 2.5:1 or about 2.5:1. In some of the provided embodiments, the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 1:1 or about 1:1. In some of the provided embodiments, the ratio of PBMC feeder cells to enriched NK cells is 5:1 or about 5:1.

[0031] In some of any such embodiments, the NK cells are freshly isolated or have not been frozen or thawed. In some of any such embodiments, the NK cells have been frozen and then thawed.

[0032] In some of any of the provided embodiments, the concentration of recombinant IL-2 during at least a portion of the culturing step is from 10 IU / mL or about 10 IU / mL to 500 IU / mL or about 500 IU / mL. In some of any of the provided embodiments, the concentration of recombinant IL-2 during at least a portion of the culturing step is 100 IU / mL or about 100 IU / mL of recombinant IL-2. In some of any of the provided embodiments, the recombinant IL-2 is added beginning at or about the beginning of the culturing step.

[0033] In some of the provided embodiments, the method further comprises changing the culture medium one or more times during the culturing step. In some of the provided embodiments, the change of the culture medium is performed within 3 to 7 days or about 3 to 7 days after the initiation of the culturing step, optionally starting at 5 days or about 5 days after the initiation of the culturing step. In some of the provided embodiments, the change of the culture medium is performed every 2 or 3 days for the remainder of the duration of the culturing step. In some of the provided embodiments, the change of the culture medium reduces or removes the at least one stimulatory agent from the culture medium. In some of the provided embodiments, the method comprises adding fresh medium containing recombinant IL-2 to the culture at each change of the culture medium. In some of the provided embodiments, the recombinant IL-2 is added at a concentration of at or about 10 IU / mL to 500 IU / mL or about 500 IU / mL, inclusive. In some embodiments, recombinant IL-2 is added at a concentration of 100 IU / mL or about 100 IU / mL of recombinant IL-2.

[0034] In some of the provided embodiments, the population of enriched NK cells comprises at least 0.2 x 10 6 Or at least about 0.2 × 10 6 Enriched NK cells, at least 1.0 x 10 6 Or at least about 1.0 × 10 6 enriched NK cells, or 10 x 10 6 Or about 10 x 10 6 In some of the provided embodiments, the population of enriched NK cells at the start of the culturing step comprises 0.05 x 10 6 or approximately 0.05 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 In some of the provided embodiments, the population of enriched NK cells at the start of the culturing step is at a concentration of 0.05 x 10 enriched NK cells / mL. 6 or approximately 0.05 x 10 6From 0.5 x 10 concentrated NK cells / mL 6 or approximately 0.5 x 10 6 In some of the provided embodiments, the population of enriched NK cells at the start of the culturing step is at a concentration of 0.2 x 10 enriched NK cells / mL. 6 or approximately 0.2 x 10 6 Contains a concentration of 10 ...

[0035] In some of any of the provided embodiments, the culturing step comprises culturing at least 2.50 x 10 8 or at least about 2.50 x 10 8 In some of the provided embodiments, the culturing step is carried out until an expansion of at least 5.0 x 10 g-NK cells is achieved. 8 or at least about 5.0 × 10 8 In some of the provided embodiments, the culturing step is carried out until an expansion of at least 1.0 x 10 g-NK cells is achieved. 9 or at least about 1.0 × 10 9 In some of the provided embodiments, the culturing step is carried out until the method achieves an expansion of at least 5.0 x 10 g-NK cells. 9 or at least about 5.0 × 10 9 The treatment is continued until an expansion of g-NK cells is achieved.

[0036] In some of the provided embodiments, the culturing step is for at or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. In some embodiments, the culturing step is carried out for 14 days, or for about 14 days, or for at least 14 days, or for at least about 14 days. In some embodiments, the culturing step is carried out for 21 days, or for about 21 days, or for at least 21 days, or for at least about 21 days.

[0037] In some embodiments, the method produces an increased number of g-NK cells at the end of the culturing step compared to the beginning of the culturing step. In some of any such embodiments, the increase is greater than or about 100-fold, greater than or about 200-fold, greater than or about 300-fold, greater than or about 400-fold, greater than or about 500-fold, greater than or about 600-fold, greater than or about 700-fold, or greater than or about 800-fold. In some of any embodiments, the increase is 1000-fold or about 1000-fold. In some of any embodiments, the increase is 2000-fold or about 2000-fold. In some of any embodiments, the increase is 2500-fold or about 2500-fold.

[0038] In some of any of the provided embodiments, the expanded g-NK cell population produced by the methods provided herein is collected after the culturing step.

[0039] In some of the provided embodiments, the g-NK cells are FcRγ neg In some such embodiments, the g-NK cells further comprise CD45 pos / CD3 neg / CD56 pos In some embodiments, the g-NK cells are of the phenotype FcRγ neg / / CD45 pos / CD3 neg / CD56 pos It has.

[0040] In some of the provided embodiments, the g-NK cells are cells having a g-NK surrogate surface marker profile. In some embodiments, the g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg In some of any such embodiments, the g-NK cell surrogate surface marker profile is CD38 neg In some of any such embodiments, the g-NK cell surrogate surface marker profile is CD45 pos / CD3 neg / CD56 pos In certain embodiments, the g-NK cell surrogate surface marker profile further comprises CD45 pos / CD3 neg / CD56 pos / CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In another particular embodiment, the g-NK cell surrogate surface marker profile comprises CD45 pos / CD3 neg / CD56 pos / NKG2A neg / CD161 negIn another particular embodiment, the g-NK cell surrogate surface marker profile comprises CD45 pos / CD3 neg / CD56 pos / CD38 neg Includes.

[0041] In some of any of the provided embodiments, the method further comprises, after the culturing step, purifying or selecting from the expanded cell population a population of cells having a g-NK cell surrogate surface marker profile. In some of any such embodiments, the g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some of any such embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg In some of the embodiments, the g-NK cell surrogate surface marker profile is the surface phenotype CD45 pos / CD3 neg / CD56 pos Further includes:

[0042] In some of the provided embodiments, the method further comprises formulating the expanded g-NK cell population in a pharmaceutically acceptable excipient. In some of the provided embodiments, the method further comprises cryopreserving and / or formulating the cells in the presence of a cryoprotectant.

[0043] Also provided herein are compositions comprising g-NK cells produced by any of the provided methods. In some embodiments, the compositions comprise at least 10 8 or at least about 10 8 In some of the provided embodiments, the number of g-NK cells in the composition is 10 8 Or about 10 8 From, 10 12 Or about 10 12 g-NK cells, 10 8Or about 10 8 From, 10 11 Or about 10 11 g-NK cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 g-NK cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 g-NK cells, 10 9 Or about 10 9 From, 10 12 Or about 10 12 g-NK cells, 10 9 Or about 10 9 From, 10 11 Or about 10 11 g-NK cells, 10 9 Or about 10 9 From, 10 10 Or about 10 10 g-NK cells, 10 10 Or about 10 10 From, 10 12 Or about 10 12 g-NK cells, 10 10 Or about 10 10 From, 10 11 Or about 10 11 g-NK cells, or 10 11 Or about 10 11 From, 10 12 Or about 10 12 In some of the provided embodiments, the g-NK cells are FcRγ neg In some of the provided embodiments, the g-NK cells are cells having a g-NK surrogate surface marker profile. In some embodiments, the g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161neg In some of any of the provided embodiments, g-NK cells or cells having a g-NK surrogate marker profile have the surface phenotype CD45 pos / CD3 neg / CD56 pos In some of any of the provided embodiments, the g-NK cell surrogate surface marker profile further comprises CD38 neg is.

[0044] Also provided herein are compositions comprising g-NK cells produced by any of the provided methods. In some embodiments, the compositions comprise at least 10 6 or at least about 10 6 In some of the provided embodiments, the composition comprises 10 g-NK cells. 6 Or about 10 6 From, 10 10 Or about 10 10 g-NK cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 g-NK cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 g-NK cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 g-NK cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 g-NK cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 g-NK cells, 10 7 Or about 10 7 From, 10 8 Or about 10 8 g-NK cells, 10 8 Or about 10 8 From, 1010 Or about 10 10 g-NK cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 g-NK cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 In some of the provided embodiments, the g-NK cells are FcRγ neg In some of the provided embodiments, the g-NK cells are cells having a g-NK surrogate surface marker profile. In some embodiments, the g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg In some of any of the provided embodiments, g-NK cells or cells having a g-NK surrogate marker profile have the surface phenotype CD45 pos / CD3 neg / CD56 pos Further includes:

[0045] Provided herein are compositions comprising natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 negProvided herein are compositions comprising a natural killer (NK) cell subset, wherein at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition have a g-NK cell surrogate marker profile that is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg In some embodiments, at least 70% or at least about 70% of the cells in the composition have a g-NK cell surrogate marker profile selected from: CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, at least 80% or at least about 80% of the cells in the composition comprise a g-NK cell surrogate marker profile that is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, at least 90% or at least about 90% of the cells in the composition comprise a g-NK cell surrogate marker profile that is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg Contains a g-NK cell surrogate marker profile.

[0046] Provided herein are compositions comprising natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are NKG2A- or NKG2B-dependent. neg / CD161 neg In some of the provided embodiments, at least 70% or at least about 70% of the cells in the composition have a g-NK cell surrogate marker profile that is NKG2A neg / CD161 neg In some of any of the provided embodiments, at least 80% or at least about 80% of the cells in the composition comprise a g-NK cell surrogate marker profile that is NKG2A neg / CD161 neg In some of the provided embodiments, at least 90% or at least about 90% of the cells in the composition comprise a g-NK cell surrogate marker profile that is NKG2A. neg / CD161 neg Contains a g-NK cell surrogate marker profile.

[0047] Provided herein are compositions comprising natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are CD38 neg In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition have a g-NK cell surrogate marker profile that is CD38 neg In some of the provided embodiments, at least 80% or at least about 80% of the cells in the composition comprise a g-NK cell surrogate marker profile that is CD38 neg In some of any of the provided embodiments, at least 90% or at least about 90% of the cells in the composition comprise a g-NK cell surrogate marker profile that is CD38 neg In some embodiments, the g-NK cell surrogate surface marker profile comprises a g-NK cell surrogate marker profile having the surface phenotype CD45 pos / CD3 neg / CD56 posIn some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg In some of the provided embodiments, at least 70% or at least about 70% of the cells in the composition comprise a g-NK cell surrogate marker profile selected from: CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg In some of any of the provided embodiments, of the cells comprising the g-NK cell surrogate marker profile, more than 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg In some of the provided embodiments, the composition comprises at least 10 8 or at least about 10 8 In some of the provided embodiments, the composition comprises at least 10 cells. 6 or at least about 10 6 In some of the provided embodiments, the composition comprises 10 cells. 8 Or about 10 8 From, 10 12 Or about 10 12 cells, 10 8 Or about 10 8 From, 10 11 Or about 10 11 cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 cells, 10 9Or about 10 9 From, 10 12 Or about 10 12 cells, 10 9 Or about 10 9 From, 10 11 Or about 10 11 cells, 10 9 Or about 10 9 From, 10 10 Or about 10 10 cells, 10 10 Or about 10 10 From, 10 12 Or about 10 12 cells, 10 10 Or about 10 10 From, 10 11 Or about 10 11 cells, or 10 11 Or about 10 11 From, 10 12 Or about 10 12 In some of the provided embodiments, the composition comprises 10 cells. 6 Or about 10 6 From, 10 10 Or about 10 10 cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 cells, 10 7 Or about 10 7 From, 108 Or about 10 8 cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 Contains cells.

[0048] In some of the provided embodiments, the cells in the composition are from a single donor subject, expanded from the same sample. In some of the provided embodiments, the composition includes a pharmaceutically acceptable excipient. In some of the provided embodiments, the composition includes a cryoprotectant. In some of the provided embodiments, the composition is sterile.

[0049] Provided herein are kits that include any of the provided compositions and an additional agent for treating a disease. In some of any of the embodiments, the kit further includes instructions for administering the composition and the additional agent for treating the disease or condition.

[0050] Provided herein are kits that include any of the provided compositions and instructions for administering the composition in combination therapy with an additional agent to treat a disease.

[0051] In some of any of the provided embodiments, the additional agent is an antibody or an Fc fusion protein. In some of any such embodiments, the antibody recognizes or specifically binds to a tumor-associated antigen. In some of any such embodiments, the antibody recognizes or specifically binds to a tumor-associated antigen, such as CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, alpha-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor (SCF), or a combination thereof. The antibody recognizes or binds to an Fc receptor kinase, ganglioside, cytokeleen, frizzled receptor, VEGF, VEGFR, integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-α, phosphatidylserine, syndecan-1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin. In some of any such embodiments, the antibody is a full-length antibody and / or comprises an Fc domain.

[0052] In some of the provided methods, the additional agent is a cytotoxic agent or a cancer therapeutic agent. In some of the provided embodiments, the additional agent is an oncolytic virus.

[0053] Provided herein are articles of manufacture that include the kits of any of the provided embodiments.

[0054] Provided herein are methods of treating a disease or condition comprising administering any of the provided compositions to an individual in need thereof. In some of any such embodiments, the method comprises administering 1×10 5 or about 1 x 10 5 NK cells / kg to 1 x 10 7 or about 1 x 10 7In some of any such embodiments, the method comprises administering 5 x 10 NK cells / kg to the individual. 7 or about 5 x 10 7 From NK cells, 10 × 10 9 or about 10 x 10 9 In some of any such embodiments, the method comprises administering 1 x 10 NK cells to the individual. 8 Or about 1 x 10 8 From 1×10 10 cells / m 2 or 1 x 10 6 Or about 1 x 10 6 From 1×10 10 The method includes administering NK cells / kg.

[0055] In some of any of the provided embodiments, the method further comprises administering to the individual an additional agent to treat the disease or condition. In some embodiments, the additional agent is an antibody or an Fc fusion protein. In some embodiments, the disease or condition is cancer, and the antibody recognizes a tumor antigen associated with the cancer. In some of any such embodiments, the antibody recognizes any of the following: CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, alpha-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor receptor kinase, ganglioside, cytokelin, frizzled receptor, VEGF, VEGF-α, VEGF-β, VEGF-β-α, VEGF-β ... Recognizes or specifically binds to GF, VEGFR, integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-α, phosphatidylserine, syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin. In some of any such embodiments, the antibody comprises an Fc domain and / or is a full-length antibody.

[0056] In some of the provided embodiments, the method further comprises administering to the subject a cancer therapeutic or cytotoxic agent to treat the disease or condition. In some of the provided methods, the additional agent is an oncolytic virus.

[0057] In some of the provided methods, the additional agent and the composition are administered sequentially. In some of the provided embodiments, the additional agent is administered prior to administration of the composition. In some of the provided embodiments, the additional agent and the composition are administered simultaneously.

[0058] In some of the provided embodiments, the disease or condition is selected from the group consisting of an inflammatory condition, an infectious disease, and a cancer. In some of the provided embodiments, the disease or condition is an infectious disease, and the infectious disease is a viral or bacterial infection. In some of the provided embodiments, the disease or condition is a cancer, and the cancer is a leukemia, lymphoma, or myeloma. In some of the provided embodiments, the disease or condition is a cancer, and the cancer comprises a solid tumor. In some of the provided embodiments, the infectious disease is a viral or bacterial infection. In some of the provided embodiments, the cancer is a leukemia, lymphoma, or myeloma. In some of the provided embodiments, the cancer comprises a solid tumor.

[0059] In some of any of the provided embodiments, the disease or condition is cancer, and the cancer is selected from among gastric or gastroesophageal junction adenocarcinoma, bladder cancer, breast cancer, brain cancer, cervical cancer, colorectal cancer, endocrine / neuroendocrine cancer, head and neck cancer, gastrointestinal stromal cancer, giant cell tumor of bone, renal cancer, liver cancer, lung cancer, neuroblastoma, ovarian epithelial / fallopian tube / primary peritoneal cancer, pancreatic cancer, prostate cancer, skin cancer, and soft tissue cancer.

[0060] In some of the provided embodiments, the individual is a human. In some of the provided embodiments, the NK cells in the composition are allogeneic to the individual. In some of the provided embodiments, the NK cells in the composition are autologous to the subject.

[0061] Provided herein are kits containing multiple reagents for detecting a panel of surface markers selected from CD16, CD57, CD7 and CD161 or NKG2A and CD161.

[0062] Provided herein are kits containing multiple reagents for detecting a panel of surface markers, including NKG2A and CD161.

[0063] Provided herein are kits containing multiple reagents for detecting a panel of surface markers including CD3, CD56, and CD38.

[0064] In some of the provided embodiments, the panel of surface markers further comprises CD3, CD45, and CD56. In some of the provided embodiments, the panel further comprises CD45. In some of the provided embodiments, each of the plurality of reagents is a binding molecule specific for one marker in the panel of surface markers. In some embodiments, the binding molecule is an antibody or antigen-binding fragment. In some embodiments, the binding molecule is detectably labeled. In some of the provided embodiments, the kit further comprises instructions regarding the use of the panel of surface markers as a surrogate marker for detecting the number of g-NK cells in a cell sample.

[0065] Provided herein are methods for detecting a g-NK surrogate surface marker profile in a sample containing natural killer (NK) cells using any of the provided kits.

[0066] Provided herein is a method for detecting a g-NK surrogate surface marker profile in a sample, the method comprising: (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including CD16, CD57, CD7, and CD161; and (b) detecting the phenotype CD16. pos / CD57 pos / CD7 dim / neg / CD161 neg and detecting the presence or absence of cells in the sample, comprising:

[0067] Provided herein is a method for detecting a g-NK surrogate surface marker profile in a sample, the method comprising: (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers selected from CD16, CD57, CD7 and CD161 or NKG2A and CD161; and (b) detecting the phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg or NKG2A neg / CD161 neg and detecting the presence or absence of cells in the sample having the phenotype NKG2A. Provided herein is a method for detecting a g-NK surrogate surface marker profile in a sample, the method comprising: (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including NKG2A and CD161; neg / CD161 neg and detecting the presence or absence of cells in the sample, comprising:

[0068] In some of any such embodiments, the panel of surface markers further comprises CD45, CD3, and CD56, in which case the phenotype is CD45 pos / CD3 neg / CD56 pos Further includes:

[0069] Provided herein is a method for detecting a g-NK surrogate surface marker profile in a sample, the method comprising: (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including CD3, CD56, and CD38; and (b) detecting the phenotype CD38. pos CD56 pos / CD38 neg and detecting the presence or absence of cells in the sample, comprising:

[0070] In some of the provided embodiments, each of the plurality of reagents is a binding molecule specific for one marker of the panel of surface markers. In some of the provided embodiments, the binding molecule is an antibody or an antigen-binding fragment. In some of the provided embodiments, the binding molecule is detectably labeled. In some of the provided embodiments, detection is by flow cytometry. [Brief explanation of the drawings]

[0071] [Figure 1] Figure 1 shows the percentage of g-NK (CD45 / CD3 / CD56 / FcRγ) cells within cell subsets with either the surrogate extracellular surface phenotype CD45 / CD3 / CD56 / CD16 / CD57 / CD7dim / neg / CD161neg or CD45 / CD3 / CD56 / NKG2Aneg / CD161neg. Values ​​are means ± standard error. [Figure 2A] Figure 2A is a flow diagram of an exemplary expansion protocol involving CD3 depletion followed by CD57 enrichment, as described in Example 2. In this schematic, irradiated 221.AEH cells as well as irradiated PBMCs can be included as feeder cells during the expansion phase. [Figure 2B]Figures 2B and 2C show the expansion of g-NK cells from enriched NK cells isolated from peripheral blood mononuclear cells from CMV+ donors. All results shown are from 14 days of expansion from fresh NK cells enriched by various methods, except for thawed NK cells enriched by CD3 depletion, which were expanded for 21 days. Figure 2B shows the total number of g-NK cells after expansion by various methods described in Example 2. Figure 2C shows the percentage of g-NK cells before and after expansion by various methods described in Example 2. Values ​​are means ± standard error. [Figure 2C] See legend to Figure 2B. [Figure 2D] Figures 2D and 2E show the expansion of g-NK cells from enriched NK cells isolated from peripheral blood mononuclear cells (PBMCs) from CMV+ donors. All results shown are from a 14-day expansion of fresh NK cells enriched by various methods or thawed NK cells enriched by CD3 depletion. Figure 2D shows the total number of g-NK cells after expansion by various methods described in Example 2. Figure 2E shows the percentage of g-NK cells before and after expansion by various methods described in Example 2. Values ​​are means ± standard error. [Figure 2E] See legend to Figure 2D. [Figure 3] Figure 3 shows the cytotoxic activity of NK cells (5:1 NK cell-to-target ratio) against 221.AEH and K562 cell lines (n=8) expanded by the method described in Example 2 or an alternative method involving enrichment of CD3negCD57pos NK cells. Values ​​are means ± standard error. [Figure 4]Figures 4A and 4B show the ADCC activity of g-NK cells combined with an anti-CD20 antibody (rituximab) compared with conventional NK cells against the lymphoma cell line RAJI. Figure 4A shows the ADCC activity of g-NK cells expanded by a process starting from enriched CD3negCD57pos cells in a donor with high g-NK activity, compared with a donor with a low g-NK ratio (n=4). Figure 4B shows the ADCC (1:1 NK cell-to-target ratio) activity of g-NK cells, conventional NK cells (cNK), and NKG2Cpos (adaptive) NK cells expanded from fresh or previously frozen (and thawed) NK cells from the same donors (n=4). Values ​​are means ± standard error. [Figure 5A] Figures 5A and 5B show the ADCC activity of g-NK cells compared to conventional (cNK) NK cells. Figure 5A shows the ADCC activity of g-NK cells and cNK cells combined with anti-HER2 (trastuzumab) against the breast cancer cell line SKBR3. Figure 5B shows the ADCC activity of g-NK cells and cNK cells combined with anti-EGFR (cetuximab) against the head and neck cancer cell line CAL27. Values ​​are means ± SE. [Figure 5B] See legend to Figure 5A. [Figure 6A] Figures 6A-6C show the ADCC activity of g-NK cells compared with conventional NK cells (cNK). Figure 6A shows the ADCC activity of g-NK cells and cNK cells combined with anti-EGFR (cetuximab) against the colorectal cancer cell line HT29. Figure 6B shows the ADCC activity of g-NK cells and cNK cells combined with anti-EGFR (cetuximab) against the colorectal cancer cell line SW480. Figure 6C shows the ADCC activity of g-NK cells and cNK cells combined with anti-EGFR (cetuximab) against the lung cancer cell line A549. Values ​​are means ± SE. [Figure 6B] See legend to Figure 6A. [Figure 6C] See legend to Figure 6A. [Figure 7A]Figures 7A-7C show the persistence of g-NK (fresh or frozen) and cNK (frozen) cells in NSG mice after injection of 1 x 10 g-NK or cNK cells. Figure 7A shows the number of human NK cells present in the whole blood of NSG mice on days 5, 8, 14, 15, and 22 after injection. Figure 7B shows the number of human NK cells present in the spleen of NSG mice 22 days after NK cell injection. Figure 7C shows the number of human NK cells present in the bone marrow of NSG mice 22 days after NK cell injection. N = 3 for all three arms. Values ​​are means ± SE. [Figure 7B] See legend to Figure 7A. [Figure 7C] See legend to Figure 7A. [Figure 8A] Figures 8A and 8B show the effects of g-NK and rituximab on tumor burden and survival in a lymphoma xenograft model. Figure 8A shows the effect of g-NK and rituximab treatment (rituximab + g-NK) on Raji tumor burden measured by bioluminescence (BLI) in NSG mice, compared with untreated mice or mice treated with rituximab alone. Values ​​are mean ± SE. Figure 8B shows the effect of g-NK and rituximab treatment (rituximab + g-NK) on survival in Raji-inoculated NSG mice, compared with untreated mice or mice treated with rituximab alone. N = 8 per arm. [Figure 8B] See legend to Figure 8A. [Figure 9A]Figures 9A and 9B show the ADCC activity of g-NK cells compared to conventional NK cells (cNK). Figure 9A shows the ADCC activity of freshly isolated g-NK cells and cNK cells combined with anti-CD38 (daratumumab; Dara) or anti-SLAMF7 (elotuzumab; Elo) against the multiple myeloma cell line MM.1S (n=16). Figure 9B shows the ADCC activity of expanded g-NK cells and cNK cells combined with anti-CD38 (daratumumab; Dara) or anti-SLAMF7 (elotuzumab; Elo) against the multiple myeloma cell line MM.1S (n=5). Values ​​are means ± SE. [Figure 9B] See legend to Figure 9A. [Figure 10] Figures 10A and 10B show the effect of g-NK on the in vivo efficacy of daratumumab (Dara) and elotuzumab (Elo) in a multiple myeloma xenograft model. Figure 10A shows the effect of g-NK and daratumumab treatment (Dara + g-NK) on MM.1S tumor burden (BLI) in NSG mice compared with untreated mice or mice treated with cNK and daratumumab (Dara + cNK), Dara alone, vehicle, or g-NK alone. Figure 10B shows the effect of g-NK and elotuzumab treatment (Elo + g-NK) on MM.1S tumor burden (BLI) in NSG mice compared with untreated mice or mice treated with cNK and elotuzumab (Elo + cNK), Elo alone, vehicle, or g-NK alone. N = 6 in each arm. Values ​​are mean ± SE. [Figure 11]Figures 11A and 11B show the effect of g-NK on survival in MM.1S-inoculated NSG mice treated with daratumumab (Dara) or elotuzumab (Elo). Figure 11A shows the effect of g-NK and daratumumab treatment on survival in MM.1S-inoculated NSG mice (Dara + g-NK) compared with untreated mice or mice treated with cNK and daratumumab (Dara + cNK), Dara alone, vehicle, or g-NK alone. Figure 11B shows the effect of g-NK and elotuzumab treatment on survival in MM.1S-inoculated NSG mice (Elo + g-NK) compared with untreated mice or mice treated with cNK and elotuzumab (Elo + cNK), Elo alone, vehicle, or g-NK alone. N = 6 in each arm. [Figure 12A] Figures 12A-12C show the persistence and homing of g-NK and cNK to the bone marrow and spleen when combined with daratumumab (dara) or elotuzumab (elo) in a xenograft model of multiple myeloma. Figure 12A shows the number of g-NK and cNK in the spleen of MM.1S-inoculated NSG mice treated with daratumumab or elotuzumab. Figure 12B shows the number of g-NK and cNK in the bone marrow of MM.1S-inoculated NSG mice treated with daratumumab or elotuzumab. Figure 12C shows the number of g-NK and cNK in the blood of MM.1S-inoculated NSG mice treated with daratumumab or elotuzumab. N = 6 per arm. Values ​​are mean ± SE. [Figure 12B] See legend to Figure 12A. [Figure 12C] See legend to Figure 12A. [Figure 13A]Figures 13A-13D show the expression of CD20 (the target of rituximab), CD38 (the target of daratumumab), and SLAMF7 (the target of elotuzumab) on g-NK and cNK. Figure 13A shows the percentage of expanded g-NK cells, non-expanded NK cells (CD3- / CD56+), and MM.1S cells that express CD20. Figure 13B shows the percentage of expanded g-NK cells, non-expanded NK cells (CD3- / CD56+), and MM.1S cells that express CD38. Figure 13C shows the percentage of expanded g-NK cells, non-expanded NK cells (CD3- / CD56+), and MM.1S cells that express SLAMF7. Figure 13D shows the percentage of cNK and g-NK cells that express CD38 before and after expansion. N=3 per arm. Values ​​are mean ± SE. [Figure 13B] See legend to Figure 13A. [Figure 13C] See legend to Figure 13A. [Figure 13D] See legend to Figure 13A. [Figure 14A] Figures 14A-14C show the ADCC activity of g-NK cells compared to conventional NK cells (cNK). Figure 14A shows the ADCC activity of freshly isolated g-NK and cNK cells combined with anti-Her2 (trastuzumab; Tras) against the ovarian cancer cell line SKOV3 (n=16). Figure 14B shows the ADCC activity of expanded g-NK and cNK cells combined with anti-Her2 (trastuzumab; Tras) against the ovarian cancer cell line SKOV3 (n=5). Figure 14C shows the ADCC activity of expanded g-NK and cNK cells combined with anti-EGFR (cetuximab) against the ovarian cancer cell line SKOV3 (n=4). Values ​​are means ± SE. [Figure 14B] See legend to Figure 14A. [Figure 14C] See legend to Figure 14A. [Figure 15A]Figures 15A-15C show the effect of g-NK on the in vivo efficacy of trastuzumab (Tras) in an ovarian cancer xenograft model. Figure 15A shows the effect of g-NK and trastuzumab treatment on SKOV3 tumor burden in NSG mice (Tras+g-NK) compared with mice treated with trastuzumab alone (Tras only). Figure 15B shows the effect of g-NK and trastuzumab treatment on survival in SKOV3-inoculated NSG mice (Tras+g-NK) compared with mice treated with cNK and trastuzumab (Tras+cNK). N=10 in each arm. Figure 15C shows the effect of treatment with g-NK and trastuzumab (Tras+g-NK) on survival in SKOV3-inoculated NSG mice compared with mice treated with cNK and trastuzumab (Tras+cNK), Tras only, or vehicle. [Figure 15B] See legend to Figure 15A. [Figure 15C] See legend to Figure 15A. [Figure 16A] Figures 16A-16C show the persistence of g-NK and cNK in combination with trastuzumab in an ovarian cancer xenograft model. Figure 16A shows the number of g-NK and cNK in the blood of SKOV3-inoculated NSG mice treated with trastuzumab. Figure 16B shows the number of g-NK and cNK in the spleen of SKOV3-inoculated NSG mice treated with trastuzumab. Figure 16C shows the number of g-NK and cNK in the bone marrow of SKOV3-inoculated NSG mice treated with trastuzumab. N=6 per arm. Values ​​are mean ± SE. [Figure 16B] See legend to Figure 16A. [Figure 16C] See legend to Figure 16A. [Figure 17A]Figures 17A and 17B show the ADCC activity of g-NK cells compared to conventional NK cells (cNK). Figure 17A shows the ADCC activity of enhanced g-NK and cNK cells in combination with anti-CD38 (daratumumab; Dara) against the multiple myeloma cell line ARH-77 (n=4). Figure 17B shows the ADCC activity of enhanced g-NK and cNK cells in combination with anti-CD38 (daratumumab; Dara) against the multiple myeloma cell line MM.1R (n=4). Values ​​are means ± SE. [Figure 17B] See legend to Figure 17A. [Figure 18A] Figures 18A and 18B show the ADCC activity of g-NK cells compared to conventional NK cells (cNK). Figure 18A shows the ADCC activity of freshly isolated g-NK cells and cNK cells combined with anti-EGFR (cetuximab; Cet) against the colorectal cancer cell line SW-480 (n=16). Figure 18B shows the ADCC activity of expanded g-NK cells and cNK cells combined with anti-EGFR (cetuximab) against the colorectal cancer cell line SW-480 (n=5). Values ​​are means ± SE. [Figure 18B] See legend to Figure 18A. [Figure 19] Figure 19 compares ADCC against SW-480 (with cetuximab, Cet), SKOV3 (with trastuzumab, Tras or cetuximab, Cet), and MM.1S cells (with daratumumab, Dara or elotuzumab, Elo) among cNK (n=4), g-NK (n=7), and CD16 158V g-NK cells (n=5). Values ​​are means ± SE. [Figure 20A]Figures 20A-20D show the relationship between CD16 gene expression by g-NK cells and ADCC against multiple myeloma and solid tumor cell lines. Figure 20A shows a positive correlation between g-NK CD16 expression and ADCC against MM.1S cells (treated with daratumumab, Dara). Figure 20B shows a positive correlation between g-NK CD16 expression and ADCC against MM.1S cells (treated with elotuzumab, Elo). Figure 20C shows a positive correlation between g-NK CD16 expression and ADCC against ovarian cancer SKOV3 (treated with trastuzumab, Tras). Figure 20D shows a positive correlation between g-NK CD16 expression and ADCC against colorectal cancer SW-480 (treated with cetuximab, Cet). N=4 g-NK cell lines. [Figure 20B] See legend to Figure 20A. [Figure 20C] See legend to Figure 20A. [Figure 20D] See legend to Figure 20A. DETAILED DESCRIPTION OF THE INVENTION

[0072] Detailed Description NKG2C-positive (NKG2C) cells include a specialized subset of natural killer (NK) cells (called g-NK cells) that lack or are deficient in the FceRIγ (FcRγ) chain. pos (G) Methods for the ex vivo expansion of NK cells are provided herein. Kits and methods for detecting g-NK subsets of cells based on surrogate surface marker profiles are also provided herein. Thus, reference to g-NK cells in this disclosure can optionally encompass NK cells that are FcRγ chain deficient or cells having a surrogate surface marker profile for such cells.

[0073] Natural killer (NK) cells are innate lymphocytes important for mediating antiviral and anticancer immunity through the secretion of cytokines and chemokines and the release of cytotoxic granules (Vivier et al. Science 331(6013):44-49(2011); Caligiuri, Blood 112(3):461-469(2008); Roda et al., Cancer Res. 66(1):517-526(2006)). NK cells are effector cells that constitute the third largest population of lymphocytes and are important for host immune surveillance against tumor cells and pathogen-infected cells. However, unlike T and B lymphocytes, NK cells are thought to have only a limited capacity for target recognition using germline-encoded activating receptors (Bottino et al., Curr Top Microbiol Immunol. 298:175-182 (2006); Stewart et al., Curr Top Microbiol Immunol. 298:1-21 (2006)).

[0074] NK cell activation can occur either through direct binding of the NK cell receptor to a ligand on the target cell, as seen in direct tumor cell killing, or through cross-linking of the Fc receptor (also known as CD16, CD16a, or FcγRIIIa) by binding to the Fc portion of an antibody bound to an antigen-bearing cell. Upon activation, NK cells abundantly produce cytokines and chemokines and simultaneously exhibit potent cytolytic activity. NK cells can kill tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC). In some cases, ADCC is triggered when receptors on the NK cell surface (such as CD16) recognize IgG1 or IgG3 antibodies bound to the cell surface. This triggers the release of cytoplasmic granules containing perforin and granzymes, which leads to the death of the target cell. NK cells express the activating Fc receptor CD16, which recognizes IgG-coated target cells, thus broadening target recognition (Ravetch & Bolland, Annu Rev Immunol. 19:275-290 (2001); Lanier Nat. Immunol. 9(5):495-502 (2008); Bryceson & Long, Curr Opin Immunol. 20(3):344-352 (2008)). ADCC and antibody-dependent cytokine / chemokine production are primarily mediated by NK cells.

[0075] In addition to CD16, which is expressed on NK cells and participates in antibody-dependent responses (such as NK cell-mediated ADCC), CD16 also exists in a glycosylphosphatidylinositol-anchored form (also known as FcγRIIIB or CD16B). As used herein, CD16 refers to the CD16a form expressed on NK cells, not the glycosylphosphatidylinositol-anchored form. The CD16 receptor associates with the adaptor ζ chain of the TCR-CD3 complex (CD3ζ) and / or the FcRγ chain, and can signal via immunoreceptor tyrosine-based activation motifs (ITAMs). In certain aspects, CD16 engagement (CD16 cross-linking) initiates NK cell responses via intracellular signals generated by one or both of the CD16-associated adaptor chains, FcRγ and CD3ζ. CD16 triggering leads to phosphorylation of the γ or ζ chains, which then recruits the tyrosine kinases syk and ZAP-70 to initiate a signaling cascade that leads to rapid and potent effector functions. The most well-known effector function is the release of cytoplasmic granules carrying toxic proteins to kill nearby target cells by the process of antibody-dependent cellular cytotoxicity. CD16 crosslinking also leads to the production of cytokines and chemokines, which then activate and orchestrate a range of immune responses.

[0076] This release of cytokines and chemokines may play a role in the anticancer activity of NK cells in vivo. NK cells also have small granules in their cytoplasm that contain perforin and proteases (granzymes). Upon release from NK cells, perforin forms small pores in the plasma membrane of target cells, through which granzymes and related molecules can enter and induce apoptosis. The fact that NK cells induce apoptosis rather than necrosis in target cells is important—necrosis of virus-infected cells would result in the release of virions, whereas apoptosis leads to the destruction of the virus within the cell.

[0077] A specialized subset of NK cells lacking the FcRγ adaptor protein, also known as g-NK cells, can mediate robust ADCC responses (see, e.g., Patent Application No. US2013 / 0295044). The mechanism of enhanced responses may be due to altered epigenetic modifications affecting FcRγ expression. g-NK cells abundantly express the signaling adaptor ζ chain but lack expression of the signaling adaptor γ chain. Compared to conventional NK cells, these gamma-deficient g-NK cells exhibit dramatically enhanced activity when activated by antibodies. For example, g-NK cells can be activated by antibody-mediated crosslinking of CD16 or by antibody-coated tumor cells. In some aspects, g-NK cells produce greater amounts of cytokines (e.g., IFN-γ or TNF-α) and chemokines (e.g., MIP-1α, MIP-1β, and RANTES) and / or exhibit a more extensive degranulation response than gamma-chain-expressing conventional NK cells. g-NK cells express elevated levels of granzyme B, a component of the cytotoxic machinery of natural killer cells. Furthermore, g-NK cells have a longer lifespan than conventional NK cells, and their existence is maintained for extended periods of time. In some embodiments, g-NK cells are functionally and phenotypically stable.

[0078] In some embodiments, g-NK cells are more effective than conventional NK cells, e.g., NK cells that are not gamma chain deficient, at inducing ADCC responses. In some cases, ADCC is the mechanism of action of therapeutic antibodies, including anti-cancer antibodies. In some aspects, cell therapy by administering NK cells can be used in conjunction with antibodies for therapeutic and related purposes. Provided herein are methods involving the combined administration of compositions containing g-NK cells, e.g., compositions produced by the provided methods, with antibodies, e.g., anti-cancer antibodies. In some embodiments, antibody-directed targeting of g-NK cells leads to improved outcomes for patients due to improved affinity, cytotoxicity, and / or cytokine-mediated effector function of g-NK cell subsets.

[0079] In some embodiments, g - NK cells produce significantly more cytokines than natural killer cells, which express FcRγ. In another embodiment, the cytokine is interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), or a combination thereof. In one embodiment, - NK cells produce significantly higher amounts of chemokines. In one embodiment, the chemokines are MIP-1α, MIP-1β, or a combination thereof. In another embodiment, - NK cells produce cytokines or chemokines when stimulated via the Fc receptor CD16.

[0080] g-NK cells represent a relatively small percentage of NK cells in peripheral blood, which limits the availability of these cells for therapeutic use. Specifically, clinical use of g-NK cells requires a high preferential expansion rate, as g-NK cells are generally a rare population. Other methods of NK cell expansion can achieve a 1000-fold expansion rate in 14 days, but they result in poorly differentiated NKG2C cells. neg , FceRIγ pos (FcRγ pos (Fujisaki et al. (2009) Cancer Res., 69:4010-4017; Shah et al. (2013) PLoS One, 8:e76781). Furthermore, it is shown herein that optimized expansion of NK cells with phenotypes overlapping with g-NK cells does not preferentially expand g-NK cells to therapeutically acceptable levels. Specifically, the use of HLA-E-transfected 221.AEH cells results in the production of NKG2C cells with phenotypes overlapping with g-NK cells. pos It has been previously reported that culture with such HLA-expressing cells, which constitutively express HLA-E, can preferentially expand NK cells (Bigley et al. (2016) Clin. Exp. Immunol., 185:239-251). NK cells are differentiated into NKG2C pos / NKG2A neg(NKG2C is an activating receptor for HLA-E, while NKG2A is an inhibitory receptor for HLA-E.) Because such cells contain g-NK cells, it was thought that such a method would be sufficient to expand g-NK cells. However, as shown in the Examples herein, this method does not achieve robust expansion of g-NK cells.

[0081] The provided methods overcome these limitations. The provided methods utilize a higher ratio of 221.AEH cells to NK cells compared to previous methods. Specifically, previous methods used lower ratios of 221.AEH cells, e.g., NK cell to 221.AEH ratios of 10:1. It has been found herein that a higher ratio of HLA-E-expressing feeder cells, e.g., 221.AEH cells, results in greater overall expansion, more strongly biased toward the g-NK phenotype. In some embodiments, a higher ratio of 221.AEH cells is achieved by irradiating the feeder cells. Furthermore, it has been found that the incorporation of activated (e.g., anti-CD3-activated) autologous PBMCs, e.g., irradiated activated PBMCs, can be used as additional feeder cells to further enhance expansion. In some aspects, the use of irradiated feeder cell lines is advantageous because it provides a method compatible with GMP. The incorporation of recombinant IL-2 during expansion has also been found to support robust expansion.

[0082] It has also been found that enriching NK cells from a cell sample prior to expansion methods, for example enriching for CD16 cells or CD57 cells prior to expansion, further substantially increases the amount of g-NK cell expansion that can be achieved compared to methods that initially enrich for NK cells based solely on CD3 depletion. In another embodiment, another enrichment that can be performed prior to expansion is enriching NK cells by positive selection for CD56 and negative selection or depletion for CD38. In a further embodiment, another enrichment that can be performed prior to expansion is positive selection for CD56 followed by NKG2A depletion. neg Negative selection or depletion for and CD161neg In some embodiments, the enrichment of NK cells from a cell sample can be achieved by negative selection or depletion for CD3. In some embodiments, the enriched NK cells can be enriched from a cell sample containing NK cells, for example, from peripheral blood mononuclear cells (PBMCs). In some embodiments, prior to enrichment of NK cells from a cell sample, T cells can be removed by negative selection or depletion for CD3.

[0083] Taken together, the provided approaches for expanding g-NK cells can achieve an expansion of NK cells from an initial 10 million enriched NK cells at the initiation of culture to over 1 billion cells, and in some cases up to 8 billion or more cells. In particular, the provided methods can result in high-yield (>1000-fold) expansion rates, with g-NK cell functionality maintained and in some cases increased after expansion. Furthermore, the provided methods prove sufficient to expand previously frozen NK cells, which is generally not achieved by many existing methods involving the rescue of thawed NK cells. In some embodiments, this is achieved by increasing the duration of the expansion protocol. In some embodiments, this is achieved by reducing the ratio of 221.AEH feeder cells to NK cells, for example, to about 1:1 221.AEH to NK cells. As demonstrated herein, the provided methods yield g-NK cells that exhibit potent antibody-dependent cell-mediated cytotoxicity (ADCC), supporting the utility of such cells for therapeutic applications.

[0084] All references mentioned in this specification, including patent applications, patent publications, and scientific literature and databases, are incorporated by reference in their entirety for all purposes to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.

[0085] For clarity of disclosure, and not by way of limitation, the detailed description is divided into the following subsections: The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0086] I. Definition Unless otherwise defined, all terminology, notations, and other technical and scientific terms and terms used herein shall have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. In some cases, terms with commonly understood meanings are defined herein for the sake of clarity and / or ready reference, but the inclusion of such definitions herein should not necessarily be construed as representing a substantial departure from what is commonly understood in the art.

[0087] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a molecule" optionally includes a combination of two or more such molecules.

[0088] The term "about" as used herein refers to a normal error range for each value that is readily apparent to one skilled in the art. When "about" is used herein with respect to a value or parameter, it encompasses (and describes) aspects that are directed to the value or parameter itself.

[0089] Aspects and embodiments of the invention described herein are understood to encompass "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.

[0090] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description encompasses both instances where the event or circumstance occurs and instances where it does not occur. For example, an optionally substituted group means that the group is unsubstituted or substituted.

[0091] As used herein, "antibody" refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or wholly synthetically, e.g., recombinantly produced, including any fragment thereof that contains at least a portion of the variable heavy and / or variable light chain region of the immunoglobulin molecule sufficient to form an antigen-binding site and, when assembled, to specifically bind to an antigen. Thus, an antibody encompasses any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody combining site). Typically, an antibody will contain, at a minimum, a variable heavy (V H ) chain and / or variable light (V L ) chain. Generally, V H and V L pair with each other to form the antigen-binding site, but in some cases, a single V H Domain or V L A single domain is sufficient for antigen binding. An antibody can also include all or a portion of a constant region. As used herein, antibodies include full-length antibodies and antigen-binding fragments. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein.

[0092] The terms "full-length antibody," "intact antibody," or "whole antibody" are used interchangeably to refer to antibodies in a substantially intact form, rather than antibody fragments. Full-length antibodies typically include antibodies having two full-length heavy chains (e.g., VH-CH1-CH2-CH3 or VH-CH1-CH2-CH3-CH4) and two full-length light chains (VL-CL) and a hinge region, such as those produced by antibody-secreting B cells from mammalian species (e.g., humans, mice, rats, rabbits, non-human primates, etc.), as well as synthetically produced antibodies having the same domains. In particular, whole antibodies include heavy and light chains, including an Fc region. The constant domains can be native-sequence constant domains (e.g., human native-sequence constant domains) or amino acid sequence variants thereof. In some cases, intact antibodies can have one or more effector functions.

[0093] An "antibody fragment" includes a portion of an intact antibody, the antigen-binding and / or variable region of the intact antibody. Antibody fragments include Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fd' fragments, diabodies, linear antibodies (see Example 2 of U.S. Pat. No. 5,641,870; Zapata et al., Protein Eng. 8(10) :1057-1062

[1995] ), single-chain antibody molecules such as single-chain Fv (scFv) or single-chain Fab (scFab), antigen-binding fragments of any of the above, and multispecific antibodies formed from antibody fragments. For purposes of this specification, antibody fragments typically include those sufficient to engage or cross-link CD16 on the surface of NK cells.

[0094] The term "autologous" refers to cells or tissues that originate within or are taken from an individual's own tissues. For example, in autologous transfer or transplantation of NK cells, the donor and recipient are the same person.

[0095] The term "allogeneic" refers to cells or tissues that belong to or are obtained from the same species but are genetically distinct and, in some cases, therefore immunologically incompatible. Typically, the term "allogeneic" is used to define cells that are transplanted from a donor into a recipient of the same species.

[0096] The term "enriched," with respect to a cell composition, refers to a composition in which the number or percentage of a cell type or cell population is increased compared to the number or percentage of that cell type in the same volume of starting composition, e.g., a starting composition obtained or isolated directly from a subject. The term does not require the complete removal of other cells, cell types, or cell populations from the composition, nor does it require that such enriched cells be 100% or even close to 100% present in the enriched composition.

[0097] The term "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcript) and / or the process by which the transcribed mRNA is then translated into a peptide, polypeptide, or protein. Collectively, the transcript and the encoded polypeptide may be referred to as the "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.

[0098] The term "heterologous" with respect to a protein or nucleic acid refers to a protein or nucleic acid that is derived from a different genetic source. For example, a protein or nucleic acid that is heterologous to a cell is derived from a different organism or individual than the cell that expresses it.

[0099] As used herein, the term "introducing" encompasses various methods of introducing DNA into cells, either in vitro or in vivo, including transformation, transduction, transfection (e.g., electroporation), and infection. Vectors are useful for introducing DNA encoding molecules into cells. Possible vectors include plasmid vectors and viral vectors. Viral vectors include retroviral vectors, lentiviral vectors, or other vectors, such as adenoviral vectors or adeno-associated vectors.

[0100] The term "composition" refers to any mixture of two or more products, substances, or compounds, including cells or antibodies. It can be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous, or any combination thereof. The preparation is generally in a form that allows the biological activity of the active ingredient (e.g., antibody) to be effective.

[0101] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0102] As used herein, a combination refers to any association between two or more items. The combination can be two or more separate items, such as two compositions or two collections, or a mixture thereof, such as a single mixture of two or more items, or any variation thereof. The elements of a combination are generally functionally related or associated.

[0103] As used herein, a kit is a packaged combination, optionally including other elements, such as additional agents, and instructions for use of the combination or elements thereof, for example, but not limited to, therapeutic use.

[0104] As used herein, the term "treatment" or "treating" refers to a clinical intervention designed to alter the natural course of the treated individual or cell during the course of clinical pathology. Desirable effects of treatment include reducing the rate of disease progression, ameliorating or alleviating the disease state, and remission or improved prognosis. An individual is successfully "treated," for example, if one or more symptoms associated with a disorder (e.g., an eosinophil-mediated disease) are alleviated or eliminated. For example, an individual is successfully "treated" if the treatment improves the quality of life of the person suffering from the disease, reduces the dosage of other medications required to treat the disease, reduces the frequency of disease recurrence, reduces the severity of the disease, delays the onset or progression of the disease, and / or prolongs the individual's survival.

[0105] An "effective amount" refers to at least an amount effective, at dosages and for periods of time necessary, to achieve a desired or indicated effect, including a therapeutic or preventative result. An effective amount can be provided one or more times. A "therapeutically effective amount" is at least the minimum dose of cells necessary to achieve a measurable improvement in a particular disorder. In some embodiments, a therapeutically effective amount is an amount of a composition that reduces the severity, duration, and / or symptoms associated with cancer, viral infection, microbial infection, or septic shock in an animal. The therapeutically effective amount herein may vary depending on factors such as the patient's disease state, age, sex, and weight. A therapeutically effective amount may also be an amount in which the therapeutically beneficial effects of the antibody outweigh any toxic or detrimental effects of the antibody. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired preventative result. Because a prophylactic dose is used in pre-diseased subjects or subjects at an early stage of disease, typically, but not necessarily, the prophylactically effective amount may be less than the therapeutically effective amount.

[0106] As used herein, an "individual" or "subject" is a mammal. With respect to treatment, "mammals" includes humans, domestic and farm animals, as well as zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual or subject is a human.

[0107] II. Methods for Expanding Natural Killer Cell Subsets Provided herein is a method for expanding a subset of NK cells from a biological sample from a human subject. In some embodiments, the method comprises: pos In some embodiments, the method includes expanding a subset of NK cells that are FcRγ-deficient NK cells (g - In some embodiments, the methods include isolating a population of cells enriched for natural killer (NK) cells from a biological sample from a human subject and culturing the cells under conditions that allow for preferential growth and / or expansion of g-NK cell subjects and / or NK cell subsets that share overlapping or common extracellular surface markers with the g-NK cell subset. For example, NK cells may be cultured with feeder cells or in the presence of cytokines to enhance the growth and / or expansion of g-NK cell subjects and / or the growth and / or expansion of NK cell subsets that share overlapping or common extracellular surface markers with the g-NK cell subset. In some aspects, the provided methods involve isolating a population of cells enriched for NKG2C cells from a biological sample from a human subject and culturing the cells under conditions that allow for preferential growth and / or expansion of g-NK cell subjects and / or NK cell subsets that share overlapping or common extracellular surface markers with the g-NK cell subset. pos Other subsets of NK cells may also be expanded, such as any NK cell that is a NK cell.

[0108] In some embodiments, the sample, e.g., biological sample, contains multiple cell populations, including an NK cell population. In some embodiments, the biological sample is or contains blood cells, e.g., peripheral blood mononuclear cells. In some aspects, the biological sample is a whole blood sample, an apheresis product, or a leukapheresis product. In some embodiments, the sample is a peripheral blood mononuclear cell (PBMC) sample. Thus, in some embodiments of the provided methods, a population of peripheral blood mononuclear cells (PBMCs) can be obtained. A sample containing multiple cell populations, including an NK cell population, can be used as cells for enriching or selecting NK cell subsets for expansion according to the provided methods.

[0109] In some embodiments, the biological sample is from a subject who is a healthy subject. In some embodiments, the biological sample is from a subject who has a disease condition, such as cancer.

[0110] In some embodiments, cells are isolated or selected from a sample, e.g., a biological sample, e.g., a biological sample obtained or derived from a subject, e.g., a subject with a particular disease or condition, or a subject in need of cell therapy or a subject to be administered cell therapy. In some aspects, the subject is a human, e.g., a patient in need of a particular therapeutic intervention, e.g., a patient in need of adoptive cell therapy, for which cells have been isolated, processed, and / or manipulated. Thus, in some embodiments, the cells are primary cells, e.g., primary human cells. Samples include tissues, body fluids, and other samples taken directly from a subject. Biological samples can be samples obtained directly from a biological source or processed samples. Biological samples include, but are not limited to, body fluids such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue, and organ samples, including processed samples derived therefrom. In some aspects, the sample is blood or a blood-derived sample, or is or is derived from an apheresis product or leukapheresis product.

[0111] In some examples, cells are obtained from a subject's circulating blood. In some aspects, the sample contains lymphocytes, including NK cells, T cells, monocytes, granulocytes, and B cells, other nucleated white blood cells, red blood cells, and / or platelets, and in some aspects, cells other than red blood cells and platelets. In some embodiments, blood cells collected from a subject are washed, for example, to remove the plasma fraction and place the cells in a buffer or medium appropriate for subsequent processing steps. In some embodiments, the cells are washed with phosphate-buffered saline (PBS). In some embodiments, the wash solution lacks calcium and / or magnesium and / or many or all divalent cations. In certain embodiments, components of the blood cell sample are removed and the cells are directly suspended in culture medium. In some embodiments, the method includes preparing white blood cells from peripheral blood using a density-based cell separation method, such as lysing red blood cells and centrifugation through a Percoll or Ficoll gradient, e.g., using Histopaque® density centrifugation.

[0112] In some embodiments, the biological sample is derived from a leukopak enriched leukopheresis product collected from normal peripheral blood. In some embodiments, the leukopak can contain fresh cells. In some embodiments, the leukopak is a frozen sample that is thawed for use in the provided methods.

[0113] In some embodiments, the source of biological cells is 5×10 5 or about 5 x 10 5 From 5 x 10 8 or about 5 x 10 8In some embodiments, the number of NK cells, or g-NK cell subsets, or NK cell subsets associated with or comprising surrogate markers for g-NK cells in the biological sample is greater than or equal to 5 x 10. 5 Or about 5 x 10 5 From 1×10 8 Or about 1 x 10 8 , 5×10 5 Or about 5 x 10 5 From 5 x 10 7 Or about 5 x 10 7 , 5×10 5 Or about 5 x 10 5 From 1×10 7 Or about 1 x 10 7 , 5×10 5 Or about 5 x 10 5 From 5 x 10 6 Or about 5 x 10 6 , 5×10 5 Or about 5 x 10 5 From 1×10 6 Or about 1 x 10 6 , 1×10 6 Or about 1 x 10 6 From 1×10 8 Or about 1 x 10 8 , 1×10 6 Or about 1 x 10 6 From 5 x 10 7 Or about 5 x 10 7 , 1×10 6 Or about 1 x 10 6 From 1×10 7 Or about 1 x 10 7 , 1×10 6 Or about 1 x 10 6 From 5 x 10 6 Or about 5 x 10 6 , 5×10 6 Or about 5 x 10 6 From 1×10 8 Or about 1 x 10 8, 5×10 6 Or about 5 x 10 6 From 5 x 10 7 Or about 5 x 10 7 , 5×10 6 Or about 5 x 10 6 From 1×10 7 Or about 1 x 10 7 , 1×10 7 Or about 1 x 10 7 From 1×10 8 Or about 1 x 10 8 , 1×10 7 Or about 1 x 10 7 From 5 x 10 7 Or about 5 x 10 7 or 5×10 7 Or about 5 x 10 7 From 1×10 8 Or about 1 x 10 8 There are individuals.

[0114] In some embodiments, the biological sample is derived from a CMV-seropositive subject. CMV infection can result in phenotypic and functional differentiation of NK cells, including the development of a high percentage of NKG2C-expressing NK cells, which exhibit enhanced antiviral activity. CMV-associated NK cells that express NKG2C exhibit altered DNA methylation patterns and reduced expression of signaling molecules such as FcRγ (Schlums et al., Immunity (2015) 42:443-56). These NK cells are associated with stronger antibody-dependent activation, expansion, and function compared to conventional NK cell subsets. NK cells with reduced FcRγ expression can be detected, albeit at low levels, even in CMV-seronegative individuals, so the biological sample can optionally be derived from a CMV-seronegative subject. Optionally, the biological sample can be derived from a CMV-seropositive individual.

[0115] In some embodiments, NK cells from a subject harbor a single nucleotide polymorphism (SNP rs396991) in the CD16 gene, nucleotide 526 [thymidine (T) → guanine (G)], resulting in an amino acid (aa) substitution of phenylalanine (F) at position 158 of the mature (processed) form of the protein with valine (V) (F158V, also referred to herein as 158V+). The CD16 F158V polymorphism has been found to be associated with substantially higher affinity for IgG1 antibodies and can elicit more robust NK cell-mediated ADCC responses (Mellor et al. (2013) Journal of Hematology & Oncology, 6:1; Musolino et al. (2008) Journal of Clinical Oncology, 26:1789-1796; and Hatjiharissi et al. (2007) Blood, 110:2561-2564). In some embodiments, antibody-directed targeting of CD16 158V+ / g- NK cells leads to improved outcomes for patients due to improved affinity, cytotoxicity and / or cytokine-mediated effector function of the CD16 158V+ / g- NK cell subset.

[0116] In some embodiments, the provided methods include enriching or isolating NK cells or subsets thereof from a biological sample of a subject identified as having the CD16 158V+ NK cell genotype. In some embodiments, the methods include screening the subject for the presence of the CD16 158V+ NK cell genotype. In some embodiments, genomic DNA is extracted from a sample from the subject that is or contains NK cells, e.g., a blood sample or a bone marrow sample. In some embodiments, the sample is or contains blood cells, e.g., peripheral blood mononuclear cells. In some embodiments, the sample is or contains isolated NK cells. In some embodiments, the sample is from a healthy donor subject. Any method for extracting DNA from a sample can be used. For example, nucleic acids can be readily isolated from a sample, e.g., cells, using standard techniques such as guanidinium thiocyanate-phenol-chloroform extraction (Chomocyznski et al. (1987) Anal. Biochem. 162:156). Commercially available kits for extracting genomic DNA are also readily available, such as the Wizard Genomic DNA Purification Kit (Promega, Madison, Wis.).

[0117] Genotyping can be carried out on any suitable sample.In any embodiment described herein, genotyping reaction can be, for example, pyrosequencing reaction, DNA sequencing reaction, MassARRAY MALDI-TOF, RFLP, allele-specific PCR, real-time allele discrimination or microarray.In some embodiments, PCR-based technique, for example, RT-PCR, of genomic DNA is carried out using allele-specific primers for polymorphism. PCR methods for amplifying target nucleic acid sequences in a sample are well known in the art and are described, for example, in Innis et al. (eds.) PCR Protocols (Academic Press, NY 1990), Taylor (1991) "Polymerase chain reaction: basic principles and automation" in "PCR: A Practical Approach" (McPherson et al. (eds.) IRL Press, Oxford), Saiki et al. (1986) Nature 324:163, and U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,889,818, all of which are incorporated herein by reference in their entireties.

[0118] Primers for detecting the 158V+ polymorphism are known or can be easily designed by those skilled in the art. See, for example, International Publication WO2012 / 061814, Kim et al. (2006) Blood, 108:2720-2725, Cartron et al. (2002) Blood, 99:754-758, Koene et al. (1997) Blood, 90:1109-1114, Hatijiharissi et al. (2007) Blood, 110:2561-2564, Somboonyosdech et al. (2012) Asian Biomedicine, 6:883-889. In some embodiments, PCR can be performed using nested primers followed by allele-specific restriction enzyme digestion. In some embodiments, the first PCR primer is a nucleic acid sequence TIFF2024161503000001.tif10158, while the second PCR primer TIFF2024161503000002.tif19164, which optionally generates a 94 bp fragment depending on the nature of the allele. In some embodiments, the primer pair is In some embodiments, the primer pair comprises the nucleic acid sequence set forth in TIFF2024161503000003.tif12167. In some embodiments, the primer pair comprises the nucleic acid sequence set forth in TIFF2024161503000004.tif12128. In some embodiments, genotyping can be performed by quantitative real-time RT-PCR following extraction of RNA using the following primer sequences: CD16 sense and antisense shown in TIFF2024161503000007.tif4128, and TaqMan probe shown in TIFF2024161503000008.tif4128.

[0119] To confirm genotyping, use a V allele-specific primer (e.g., the forward primer shown in SEQ ID NO: 13) TIFF2024161503000009.tif4128, and the reverse primer shown in SEQ ID NO: 14 TIFF2024161503000010.tif4128) or an F allele-specific primer (e.g., the forward primer shown in SEQ ID NO: 15) TIFF2024161503000011.tif4128, and the reverse primer shown in SEQ ID NO: 14 Allele-specific amplification using the RT-PCR technique (TIFF2024161503000012.tif4128) can be used.

[0120] The genomic sequence of CD16a is available at NCBI database NG_009066.1. The gene ID for CD16A is 2214. Sequence information for CD16, including genetic polymorphisms, is available at UniProt accession number P08637. The sequence of CD16(F158) is shown in SEQ ID NO:16 (residue F158 is bolded and underlined). In some embodiments, CD16(F158) is It further contains a signal peptide shown as TIFF2024161503000013.tif4128. TIFF2024161503000014.tif33158

[0121] The sequence of CD16 158V+ (the polymorphism resulting in F158V) is known as VAR_003960 and has the sequence shown in SEQ ID NO: 18 (the 158V+ polymorphism is bolded and underlined). In some embodiments, CD16(158V+) is It further contains a signal peptide shown as TIFF2024161503000015.tif4128. TIFF2024161503000016.tif33154

[0122] In some embodiments, SNP analysis is performed on genomic deoxyribonucleic acid (DNA) samples to detect specific single nucleotide polymorphism (SNP) targets using allele-specific probes containing a fluorescent dye label (e.g., FAM or VIC) at the 5' end and a minor groove binder (MGB) and nonfluorescent quencher (NFQ) at the 3' end, along with unlabeled PCR primers. In some embodiments, the assay measures or detects the presence of SNPs by changes in the fluorescence of the dye associated with the probe. In such embodiments, the probe hybridizes to the target DNA between two unlabeled primers, and the signal from the fluorescent dye at the 5' end is quenched by the NFQ at its 3' end via fluorescence resonance energy transfer (FRET). During PCR, Taq polymerase extends the unlabeled primer using the template as a guide; when the polymerase reaches the labeled probe, it cleaves the molecule to separate the dye from the quencher. In some aspects, qPCR instruments are capable of detecting fluorescence from unquenched labels. An exemplary reagent is a commercially available SNP assay, such as code C_25815666_10 for rs396991 (Applied Biosystems, catalog number 4351379, for SNP genotyping of V158F in CD16).

[0123] In some embodiments, subjects heterozygous or homozygous for the CD16 158V+(V158F) polymorphism are identified. In some embodiments, subjects homozygous for the CD16 158V+(V158F) polymorphism are identified. In some embodiments, NK cells or NK cell subsets are isolated or enriched from biological samples from subjects identified as heterozygous or homozygous for the CD16 158 V+ polymorphism. In some embodiments, NK cells or NK cell subsets are isolated or enriched from biological samples from subjects identified as homozygous for the CD16 158 V+ polymorphism.

[0124] In some embodiments, the method comprises enriching NK cells from a biological sample, for example, a population of PBMCs isolated or obtained from a subject. In some embodiments, the cell population enriched for NK cells is enriched by isolation or selection based on one or more natural killer cell-specific markers. It is within the skill of those in the art to select a particular marker or combination of surface markers. In some embodiments, the surface marker is any one or more of the following surface antigens: CD11a, CD3, CD7, CD14, CD16, CD19, CD25, CD27, CD56, CD57, CD161, CD226, NKB1, CD62L, CD244, NKG2D, NKp30, NKp44, NKp46, NKG2A, NKG2C, KIR2DL1 and / or KIR2DL3. In some embodiments, the surface marker is any one or more of the following surface antigens: CD11a, CD3, CD7, CD14, CD16, CD19, CD25, CD27, CD38 CD56, CD57, CD161, CD226, NKB1, CD62L, CD244, NKG2D, NKp30, NKp44, NKp46, NKG2A, NKG2C, SLAMF7 (CD319), KIR2DL1, and / or KIR2DL3. In certain embodiments, the one or more surface antigens comprise CD3 and one or more of the following surface antigens: CD16, CD56, or CD57. In some embodiments, the one or more surface antigens are CD3 and CD57. In some embodiments, the one or more surface antigens are CD3, CD56, and CD16. In other embodiments, the one or more surface antigens are CD3, CD56, and CD38. In further embodiments, the one or more surface antigens are CD3, CD56, NKG2A, and CD 161. Agents for detecting such surface antigens are well known and available to those skilled in the art, including fluorochrome-conjugated antibodies.

[0125] In some embodiments, the NK cell population enriched, e.g., by isolation or selection, from a sample by the provided methods comprises cells that are positive for one or more particular markers, e.g., surface markers (markers + ), or cells that express high levels of one or more particular markers, e.g., surface markers ( high ) or cells that are negative for one or more markers (markers - ), or cells that express relatively low levels of one or more markers (markers low ). Optionally, such markers are absent or expressed at relatively low levels on certain populations of NK cells, but present or expressed at relatively high levels on certain other populations of lymphocytes (such as T cells). Optionally, such markers are present or expressed at relatively high levels on certain populations of NK cells, but absent or expressed at relatively low levels on certain other populations of lymphocytes (such as T cells or subsets thereof).

[0126] In some embodiments, any known separation method based on such markers can be used. In some embodiments, the separation is affinity-based or immunoaffinity-based. For example, in some aspects, the separation involves separating cells and cell populations based on the expression or expression level of one or more markers, typically cell surface markers, for example, by incubation with an antibody or binding partner that specifically binds to the marker, followed generally by a washing step and separating cells that are bound to the antibody or binding partner from cells that are not bound to the antibody or binding partner.

[0127] Such separation steps can be based on positive selection, in which cells bound to the reagent are retained for further use, or on negative selection, in which cells that are not bound to the antibody or binding partner are retained. In some instances, both fractions are retained for further use. Separation need not result in 100% enrichment or removal of a particular cell population or cells expressing a particular marker. For example, positive selection or enrichment for a particular type of cell, e.g., cells expressing a marker, refers to increasing the number or percentage of such cells, but need not result in the complete absence of cells that do not express that marker. Similarly, negative selection, removal, or depletion of a particular type of cell, e.g., cells expressing a marker, refers to decreasing the number or percentage of such cells, but need not result in the complete removal of all such cells. For example, in some aspects, negative selection for CD3 results in CD3 - The resulting population is enriched for cells that are CD3+, but may also contain some residual or small percentage of other unselected cells, and in some cases, CD3+, + In some instances, positive selection of a CD57+ or CD16+ population will enrich for one of the populations, i.e., the CD57+ or CD16+ population, but may also contain some residual or small percentage of other unselected cells, and in some cases, the other of the CD57 or CD16 population, still present in the enriched population.

[0128] In some instances, multiple rounds of separation steps are performed, where a positively or negatively selected fraction from one step is subjected to another step, e.g., subsequent positive or negative selection. In some instances, cells expressing multiple markers can be simultaneously depleted in a single separation step, such as by incubating cells with multiple antibodies or binding partners specific to the markers targeted for negative selection. Similarly, multiple cell types can be simultaneously positively selected by incubating cells with multiple antibodies or binding partners expressed on different cell types.

[0129] In some aspects, the selection comprises a positive and / or negative selection step based on the expression of one or more surface antigens, such as, for example, in cells from a PBMC sample. In some embodiments, the isolation comprises positive selection of cells expressing CD56, CD16, or CD57, and / or negative selection of cells expressing CD38, and / or negative selection of cells expressing non-NK cell markers, such as T cell markers, for example, negative selection of cells expressing CD3 (CD3 neg For example, in some embodiments, isolation involves positive selection of cells expressing CD56, cells expressing CD16, or cells expressing CD57, and / or negative selection of cells expressing non-NK cell markers, e.g., T cell markers, e.g., negative selection of cells expressing CD3 (CD3 neg In some embodiments, the isolation includes positive selection of cells expressing CD56, cells expressing CD16, or cells expressing CD57, and / or CD38 (CD38 neg ), CD161(CD161 neg ), NKG2A(NKG2A neg ) and / or negative selection of cells expressing CD3 (CD3 neg In some embodiments, selection involves CD3 negative (CD3 neg ) isolating cells that are

[0130] In some embodiments, the isolation is performed by negative selection of cells expressing CD3 (CD3 neg ) and positive selection of cells expressing CD56 (CD56 pos In some embodiments, the selection comprises negative selection of cells expressing CD38 (CD38 neg In certain embodiments, the isolated or selected cells may further comprise CD3 neg CD56 pos CD38 neg is.

[0131] In some embodiments, the selection is performed by negative selection of cells expressing CD3 (CD3 neg ), positive selection of cells expressing CD56 (CD56 pos ) followed by NKG2A (NKG2A neg ) and CD161 (CD161 neg In certain embodiments, the isolated or selected cells include negative selection of cells expressing CD3 neg CD56 pos NKG2A neg CD161 neg is.

[0132] In some embodiments, the selection is performed by negative selection of cells expressing CD3 (CD3 neg ) and positive selection of cells expressing CD57 (CD57 pos In certain embodiments, the isolated or selected cells comprise CD3 neg CD57 pos is.

[0133] In some embodiments, the selection is performed by negative selection of cells expressing CD3 (CD3 neg ) and positive selection of cells expressing CD16 (CD16 pos In certain embodiments, the isolated or selected cells comprise CD3 neg CD16 pos In some of the provided embodiments, the g-NK cells are cells having a g-NK surrogate surface marker profile. In some embodiments, the g-NK cell surrogate surface marker profile is CD16pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg In some of any such embodiments, the g-NK cell surrogate surface marker profile is CD38 neg In some of any such embodiments, the g-NK cell surrogate surface marker profile is CD45 pos / CD3 neg / CD56 pos In certain embodiments, the g-NK cell surrogate surface marker profile further comprises CD45 pos / CD3 neg / CD56 pos / CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In another particular embodiment, the g-NK cell surrogate surface marker profile comprises CD45 pos / CD3 neg / CD56 pos / NKG2A neg / CD161 neg In another particular embodiment, the g-NK cell surrogate surface marker profile comprises CD45 pos / CD3 neg / CD56 pos / CD38 neg Includes.

[0134] In some embodiments, methods for isolating, selecting, and / or enriching cells, such as by positive or negative selection based on the expression of one or more cell surface markers, can include immunoaffinity-based selection. In some embodiments, immunoaffinity-based selection involves contacting a sample containing cells, such as PBMCs, with an antibody or binding partner that specifically binds to one or more cell surface markers. In some embodiments, the antibody or binding partner is bound to a solid support or matrix, such as spheres or beads, such as agarose-containing microbeads, nanobeads, magnetic beads, or paramagnetic beads, to allow for separation of cells for positive and / or negative selection. In some embodiments, the spheres or beads can be packed into a column to achieve immunoaffinity chromatography, in which case a sample containing cells, such as PBMCs, is contacted with the column matrix and then eluted or released therefrom.

[0135] Incubation is generally carried out under conditions such that the antibody or binding partner attached to the magnetic particle or magnetic bead that specifically binds to such an antibody or binding partner specifically binds to the cell surface molecule, if present, on cells in the sample.

[0136] In some aspects, when the sample is placed in a magnetic field, cells with attached magnetically responsive or magnetizable particles are attracted to the magnet and separated from unlabeled cells. In the case of positive selection, cells attracted to the magnet are retained, while in the case of negative selection, cells not attracted (unlabeled cells) are retained. In some aspects, a combination of positive and negative selection is performed during the same selection step, in which case the positive and negative fractions are retained for further processing or further separation steps.

[0137] In some embodiments, the magnetically responsive particles remain attached to the cells that are subsequently incubated and / or cultured, and in some aspects, the particles remain attached to the cells that are administered to the patient. In some embodiments, the magnetizable particles or magnetically responsive particles are removed from the cells. Methods for removing magnetizable particles from cells are known, including, for example, the use of competitive unlabeled antibodies, magnetizable particles or antibodies conjugated to cleavable linkers. In some embodiments, the magnetizable particles are biodegradable.

[0138] In some embodiments, affinity-based selection is by magnetic-activated cell sorting (MACS) (Miltenyi Biotech, Auburn, CA). The magnetic-activated cell sorting (MACS) system allows for high-purity selection of cells to which magnetized particles are attached. In certain embodiments, MACS operates in a mode that sequentially elutes non-target and target species after application of an external magnetic field. That is, cells attached to magnetized particles are held in place while unattached species are eluted. Then, after this first elution step is complete, species that were trapped in the magnetic field and prevented from elution are released in some way so that they can be eluted and recovered. In certain embodiments, non-target cells are labeled and depleted from a heterogeneous cell population.

[0139] In some of any such embodiments, the method includes administering IL-12, IL-15, IL-18, IL-2 and / or CCL5 to the subject prior to enriching, e.g., selecting and / or isolating, the NK cells or a subset thereof.

[0140] In embodiments of the provided methods, the enriched NK cells are incubated or cultured in the presence of feeder cells, e.g., under conditions to support the proliferation and expansion of NK cell subsets, particularly the g-NK cell subset.

[0141] In certain aspects, the feeder cells comprise cells that stimulate or promote the expansion of NKG2C+ cells and / or suppress the expansion of NKG2A+ cells. In some embodiments, the feeder cells are cells that express or are transfected with a hybrid HLA-E containing an HLA-E or HLA-A2 signal sequence. For example, a typical example of such a hybrid is an AEH hybrid gene containing an MHC class I promoter and signal sequence, such as HLA-A2, and an HLA-E mature protein sequence, which can, in some cases, produce a mature protein that is identical to that encoded by the HLA-E gene but can be stably expressed on the cell surface (see, e.g., Lee et al. (1998) Journal of Immunology, 160:4951-4960). In some embodiments, the cells are LCL 721.221, K562, or RMA-S cells transfected to express a stabilized MHC-E molecule in the presence of an MHC class I leader sequence, such as HLA-A2. Cell lines engineered to express stabilized cell surface HLA-E in the presence of MHC class I leader sequence peptides, such as HLA-A2, are known in the art (Lee et al. (1998) Journal of Immunology, 160:4951-4960; Zhongguo et al. (2005) 13:464-467; Garcia et al. (2002) Eur J. Immunol., 32:936-944). In some embodiments, irradiated 221.AEH cells or any other HLA-E transfected cell line, such as K562, which is originally HLA-negative, can be used as feeder cells. A typical example of such a cell line for use in the methods provided herein is 221-AEH cells.

[0142] In certain embodiments, the HLA-E-expressing feeder cells, e.g., 221.AEH cells, added to the culture are made non-dividing, e.g., by gamma irradiation. In some embodiments, the HLA-E-expressing feeder cells are irradiated with gamma rays in the range of about 1,000 to 10,000 rads, e.g., 1,000 to 5,000 rads, to prevent cell division. In some embodiments, the HLA-E-expressing feeder cells are irradiated with gamma rays in the range of about 10 Gy to 100 Gy, e.g., 10 to 50 Gy, to prevent cell division.

[0143] In some embodiments, the enriched, selected and / or isolated NK cells are incubated or cultured in the presence of HLA-E-expressing feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, at a ratio of feeder cells to enriched NK cells of greater than or greater than about 1:10 HLA-E feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, to enriched NK cells, e.g., from 1:10 or about 1:10 to 10:1 or about 10:1 of said feeder cells to enriched NK cells.

[0144] In some embodiments, the ratio of HLA-E-expressing feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, is from 1:10 or about 1:10, 10:1 or about 10:1, 1:10 or about 1:10, 5:1 or about 5:1, 1:10 or about 1:10, 2.5:1 or about 2.5:1, 1:10 or about 1:10, 1:1 or about 1:1, 1:1 From 0 or about 1:10, 1:2.5 or about 1:2.5, 1:10 or about 1:10, 1:5 or about 1:5, 1:5 or about 1:5, 10:1 or about 10:1, 1:5 or about 1:5, 5:1 or about 5:1, 1:5 or about 1:5, 2.5:1 or about 2.5:1, 1:5 or about 1:5, 1:1 or about 1:1, 1:5 or about 1:5 from 1:2.5 or about 1:2.5, from 1:2.5 or about 1:2.5, to 10:1 or about 10:1, from 1:2.5 or about 1:2.5, to 5:1 or about 5:1, from 1:2.5 or about 1:2.5, to 2.5:1 or about 2.5:1, from 1:2.5 or about 1:2.5, from 1:1 or about 1:1, from 1:1 or about 1:1, to 10:1 or about 10:1, from 1:1 or The ratio of feeder cells to enriched NK cells is from about 1:1 to 5:1 or about 5:1, 1:1 or about 1:1 to 2.5:1 or about 2.5:1, 2.5:1 or about 2.5:1 to 10:1 or about 10:1, 2.5:1 or about 2.5:1 to 5:1 or about 5:1, or 5:1 or about 5:1 to 10:1 or about 10:1 (inclusive).

[0145] In some embodiments, the ratio of HLA-expressing feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, is 1.25:1, 1.5:1, 1.75:1, 2.0:1, 2.25:1, 2:5:1, 2.75:1, 3.0:1, 3.25:1, 3.5:1, 3.75:1, 4.0:1, 4.25:1, 4.5:1, 4.75:1 or The ratio of feeder cells to enriched NK cells is 5:1, or about 1.25:1, 1.5:1, 1.75:1, 2.0:1, 2.25:1, 2:5:1, 2.75:1, 3.0:1, 3.25:1, 3.5:1, 3.75:1, 4.0:1, 4.25:1, 4.5:1, 4.75:1, or 5:1, or any value between any of the foregoing. In some embodiments, the ratio of HLA-expressing feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, is less than or less than about 5:1. In some embodiments, the ratio of HLA-expressing feeder cells (e.g., 221.AEH cells), e.g., irradiated populations thereof, is 1:1 to 2.5:1 or about 1:1 to 2.5:1, inclusive. In some embodiments, the ratio of HLA-expressing feeder cells (eg, 221.AEH cells), eg, irradiated populations thereof, is at or about a 2.5:1 ratio.

[0146] In some cases, if the starting NK cell population has been cryopreserved, i.e., subjected to freeze / thawing, prior to expansion, a lower 221.AEH to NK cell ratio can be used than in methods using fresh NK cells. Here, it is seen that a 1:1 ratio of 221.AEH to frozen / thawed NK cells resulted in expansion comparable to that in cultures containing a 2.5:1 ratio of 221.AEH to fresh NK cells. In some aspects, this lower ratio ensures a larger number of NK cells in culture, allowing for more cell-to-cell contact, which may play a role in promoting initial growth and expansion. In some embodiments, if the initial enriched population of NK cells from a sample has been subjected to freeze / thawing, a 221.AEH to frozen / thawed NK cell ratio of 2:1 to 1:2 or about 2:1 to 1:2 is used. In certain embodiments, the ratio is 1:1. It is understood that a higher ratio of 221.AEH to frozen / thawed NK cells, for example 2.5:1, can be used, but in that case a longer culture period, for example 21 days or about 21 days, may be required to reach the desired threshold density or number.

[0147] In some embodiments, the NK cells are expanded by further adding non-dividing peripheral blood mononuclear cells (PBMCs) to the culture. In some aspects, the non-dividing feeder cells can comprise gamma-irradiated PBMC feeder cells. In some embodiments, the PBMCs are irradiated with gamma rays in the range of about 1,000 to 10,000 rads, e.g., 1,000 to 5,000 rads, to inhibit cell division. In some embodiments, the PBMCs are irradiated with gamma rays in the range of about 10 Gy to 100 Gy, e.g., 10 to 50 Gy, to inhibit cell division. In some aspects, the irradiated feeder cells are present in the culture medium simultaneously with the non-dividing (e.g., irradiated) HLA-E-expressing feeder cells during at least a portion of the incubation. In some aspects, the non-dividing (e.g., irradiated) PBMC feeder cells, the HLA-E-expressing feeder cells, and the enriched NK cells are added to the culture on the same day, e.g., the day the incubation is initiated, e.g., at the same time, or at about the same time, or nearly the same time.

[0148] In some embodiments, the incubation or culture is further carried out in the presence of irradiated PBMCs as feeder cells. In some embodiments, the irradiated PBMC feeder cells are autologous to the subject from which the enriched NK cells are isolated or selected, or are derived from the same subject from which the enriched NK cells are isolated or selected. In certain embodiments, the PBMCs are obtained from the same biological sample used to enrich NK cells, such as whole blood or leukapheresis product or apheresis product. Once obtained, a portion of the PBMCs is reserved for irradiation prior to the enrichment of NK cells as described above.

[0149] In some embodiments, irradiated PBMCs are used as feeder cells at a ratio of 1:10 or about 1:10, 10:1 or about 10:1, 1:10 or about 1:10, 5:1 or about 5:1, 1:10 or about 1:10, 2.5:1 or about 2.5:1, 1:10 or about 1:10, 1:1 or about 1:1, 1:10 or about 1:10, 1:2. 5 or about 1:2.5, 1:10 or about 1:10, 1:5 or about 1:5, 1:5 or about 1:5, 10:1 or about 10:1, 1:5 or about 1:5, 5:1 or about 5:1, 1:5 or about 1:5, 2.5:1 or about 2.5:1, 1:5 or about 1:5, 1:1 or about 1:1, 1:5 or about 1:5, also 1:2.5 or about 1:2.5, 1:2.5 or about 1:2.5 to 10:1 or about 10:1, 1:2.5 or about 1:2.5 to 5:1 or about 5:1, 1:2.5 or about 1:2.5 to 2.5:1 or about 2.5:1, 1:2.5 or about 1:2.5 to 1:1 or about 1:1, 1:1 or about 1:1 to 10:1 or about 10:1, 1:1 or are present in a ratio of said feeder cells to enriched NK cells that is from about 1:1 to 5:1 or about 5:1, 1:1 or about 1:1 to 2.5:1 or about 2.5:1, 2.5:1 or about 2.5:1 to 10:1 or about 10:1, 2.5:1 or about 2.5:1 to 5:1 or about 5:1, or 5:1 or about 5:1 to 10:1 or about 10:1.

[0150] In some embodiments, irradiated PBMCs are used as feeder cells in a concentration of from 1:1 or about 1:1 to 5:1 or about 5:1, e.g., 1.25:1, 1.5:1, 1.75:1, 2.0:1, 2.25:1, 2:5:1, 2.75:1, 3.0:1, 3.25:1, 3.5:1, 3.75:1, 4.0:1, 4.25:1, 4.5:1, 4.75:1 or are present at a ratio of said feeder cells to enriched NK cells that is 5:1, or about 1.25:1, 1.5:1, 1.75:1, 2.0:1, 2.25:1, 2:5:1, 2.75:1, 3.0:1, 3.25:1, 3.5:1, 3.75:1, 4.0:1, 4.25:1, 4.5:1, 4.75:1 or 5:1, or any value between any of the foregoing. In some embodiments, irradiated PBMCs are present at a ratio of said feeder cells to enriched cells that is 5:1 or about 5:1.

[0151] In certain embodiments, during at least a portion of the incubation or culture, one or more cells or cell types of the irradiated PBMCs, such as T cells, are activated, and / or the incubation or culture is carried out in the presence of at least one stimulatory agent that can stimulate the activation of one or more T cells of the PBMC feeder cells. In some embodiments, the at least one stimulatory agent specifically binds to a member of the TCR complex. In some embodiments, the at least one stimulatory agent specifically binds to CD3, optionally CD3 epsilon. In some aspects, the at least one stimulatory agent is an anti-CD3 antibody or antigen-binding fragment. An exemplary anti-CD3 antibody is mouse anti-human CD3 (OKT3).

[0152] In some embodiments, the anti-CD3 antibody or antigen-binding fragment is present during at least a portion of the incubation with irradiated PBMC feeder cells. In some embodiments, the anti-CD3 antibody or antigen-binding fragment is added to the culture or incubation simultaneously or nearly simultaneously with the irradiated PBMCs. For example, the anti-CD3 antibody or antigen-binding fragment is added at or near the beginning of the incubation or culture. In certain aspects, the anti-CD3 antibody or antigen-binding fragment can be removed or its concentration reduced during the course of the culture or incubation, for example, by changing the culture medium or washing away the culture medium. In certain embodiments, the method does not include re-adding or replenishing the culture medium containing the anti-CD3 antibody or antigen-binding fragment after changing or washing.

[0153] In some embodiments, the anti-CD3 antibody or antigen-binding fragment is administered at a concentration of from 10 ng / mL or about 10 ng / mL, 5 μg / mL or about 5 μg / mL, e.g., from 10 ng / mL or about 10 ng / mL, 2 μg / mL or about 2 μg / mL, 10 ng / mL or about 10 ng / mL, 1 μg / mL or about 1 μg / mL, 10 ng / mL or about 10 ng / mL, 500 ng / mL or about 500 ng / mL, 10 ng / mL or about 10 ng / mL, 100ng / mL or about 100ng / mL, 10ng / mL or about 10ng / mL, 50ng / mL or about 50ng / mL, 50ng / mL or about 50ng / mL, 5μg / mL or about 5μg / mL, for example 50ng / mL or about 50ng / mL, 2μg / mL or about 2μg / mL, 50ng / mL or about 50ng / mL, 1μg / mL or about 1μg / mL, 50ng / mL or about 50ng / mL, 500ng / mL or about 500ng / mL, 50ng from 100ng / mL or about 100ng / mL, from 100ng / mL or about 100ng / mL, from 5μg / mL or about 5μg / mL, from 100ng / mL or about 100ng / mL, from 2μg / mL or about 2μg / mL, from 100ng / mL or about 100ng / mL, from 1μg / mL or about 1μg / mL, from 100ng / mL or about 100ng / mL, from 500ng / mL or about 500ng / mL, from 500ng / mL or about 500ng / mL, or is added or present at a concentration of from about 5 μg / mL, 500 ng / mL or about 500 ng / mL, 2 μg / mL or about 2 μg / mL, 500 ng / mL or about 500 ng / mL, 1 μg / mL or about 1 μg / mL, 1 μg / mL or about 1 μg / mL, 5 μg / mL or about 5 μg / mL, 1 μg / mL or about 1 μg / mL, 2 μg / mL or about 2 μg / mL, or 2 μg / mL or about 2 μg / mL, 5 μg / mL or about 5 μg / mL (inclusive).In some embodiments, the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 10 ng / mL, 20 ng / mL, 30 ng / mL, 40 ng / mL, 50 ng / mL, 60 ng / mL, 70 ng / mL, 80 ng / mL, 90 ng / mL, or 100 ng / mL, or any value between any of the foregoing. In some embodiments, the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 50 ng / mL.

[0154] In some embodiments, the term "antibody" refers to immunoglobulin molecules and antigen-binding portions or fragments of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds to (immunoreacts with) an antigen. The term antibody encompasses intact polyclonal or monoclonal antibodies as well as fragments thereof, such as dAb, Fab, Fab', F(ab')2, Fv), single-chain antibodies (scFv), or single-domain antibodies (sdAb). Typically, an "antigen-binding fragment" contains at least one CDR of an immunoglobulin heavy and / or light chain that binds to at least one epitope of the antigen of interest. In this regard, an antigen-binding fragment can contain one, two, three, four, five, or all six CDRs of the variable heavy (VH) and variable light (VL) chain sequences that bind to the antigen, e.g., generally six CDRs ("CDR1," "CDR2," and "CDR3" for the heavy and light chain, respectively) in the case of an antibody containing a VH and a VL, or three CDRs in the case of an antibody containing a single variable domain.

[0155] "Antibody fragment" refers to a molecule other than an intact antibody that contains the portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, variable heavy chain (V), and H) domains, single chain antibody molecules, such as scFv and single domain V H These include, but are not limited to, single antibodies and multispecific antibodies formed from antibody fragments. In certain embodiments, the antibody is a single-chain antibody fragment, such as an scFv, that contains a variable heavy chain region and / or a variable light chain region.

[0156] In some embodiments, the incubation or culture is performed at a temperature of 0.05×10 6 or approximately 0.05 x 10 6 or at least 0.05 × 10 6 or approximately 0.05 x 10 6 0.1 x 10 concentrated NK cells / mL 6 or approximately 0.1 x 10 6 0.2 x 10 concentrated NK cells / mL 6 or approximately 0.2 x 10 6 0.5 x 10 concentrated NK cells / mL 6 Or about 0.5 x 10 6 concentrated NK cells / mL, or 1.0 x 10 6 or approximately 1.0 x 10 6 In embodiments of the provided methods, the incubation or culture is initiated in the presence of the enriched NK cells, e.g., selected and / or isolated NK cells, at a concentration of 0.05 x 10 enriched NK cells / mL. 6 or approximately 0.05 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 Number of concentrated NK cells / mL, e.g., 0.05 x 10 6 or approximately 0.05 x 10 6 From 0.75 x 10 concentrated NK cells / mL 6 Or about 0.75 x 10 6 , 0.05×10 6 or approximately 0.05 x 10 6 From 0.5 x 10 concentrated NK cells / mL 6 Or about 0.5 x 10 6 , 0.05×10 6 or approximately 0.05 x 106 From 0.20 x 10 concentrated NK cells / mL 6 or approximately 0.20 x 10 6 0.05 x 10 concentrated NK cells / mL 6 or approximately 0.05 x 10 6 From 0.1 x 10 concentrated NK cells / mL 6 or approximately 0.1 x 10 6 0.1 x 10 concentrated NK cells / mL 6 or approximately 0.1 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 0.1 x 10 concentrated NK cells / mL 6 or approximately 0.1 x 10 6 From 0.75 x 10 concentrated NK cells / mL 6 Or about 0.75 x 10 6 , 0.1×10 6 or approximately 0.1 x 10 6 From 0.5 x 10 concentrated NK cells / mL 6 Or about 0.5 x 10 6 , 0.1×10 6 or approximately 0.1 x 10 6 From 0.20 x 10 concentrated NK cells / mL 6 or approximately 0.20 x 10 6 0.20 x 10 concentrated NK cells / mL 6 or approximately 0.20 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 0.20 x 10 concentrated NK cells / mL 6 or approximately 0.20 x 10 6 From 0.75 x 10 concentrated NK cells / mL 6 Or about 0.75 x 10 6 , 0.20×10 6 or approximately 0.20 x 10 6 From 0.5 x 10 concentrated NK cells / mL 6 Or about 0.5 x 10 6 , 0.5×10 6 Or about 0.5 x 10 6From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 0.5 x 10 concentrated NK cells / mL 6 Or about 0.5 x 10 6 From 0.75 x 10 concentrated NK cells / mL 6 Or about 0.75 x 10 6 , 0.75×10 6 Or about 0.75 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 In some embodiments, the incubation or culture is initiated in the presence of the enriched NK cells, e.g., selected and / or isolated NK cells, at a concentration of 0.2 x 10 enriched NK cells / mL (inclusive). 6 or approximately 0.2 x 10 6 In some embodiments, the amount of enriched NK cells, e.g., selected and / or isolated NK cells, added or present at the start of the incubation or culture is at least 1 x 10 enriched NK cells / mL. 5 Or at least about 1 × 10 5 cells, at least 2 x 10 5 Or at least about 2 x 10 5 cells, at least 3 x 10 5 Or at least about 3 x 10 5 cells, at least 4 x 10 5 Or at least about 4×10 5 cells, at least 5 x 10 5 Or at least about 5 x 10 5 cells, at least 6 x 10 5 Or at least about 6 x 10 5 cells, at least 7 x 10 5 Or at least about 7 x 10 5 cells, at least 8 x 10 5 Or at least about 8 x 10 5cells, at least 9 x 10 5 Or at least about 9 x 10 5 cells, at least 1 x 10 6 Or at least about 1 × 10 6 In certain embodiments, the amount of enriched NK cells, e.g., selected or isolated from PBMCs as described above, is at least 1 x 10 cells. 6 , or at least about 1 × 10 6 , or 1 × 10 6 , or approximately 1 × 10 6 Each cell is an individual cell.

[0157] In some of these embodiments, the NK cells can be cultured with a growth factor. According to some embodiments, the at least one growth factor comprises a growth factor selected from the group consisting of SCF, GSK3i, FLT3, IL-2, IL-7, IL-15, IL-12, IL-18, and IL-21. According to some embodiments, the at least one growth factor is IL-2 or IL-7 and IL-15. According to some embodiments, the at least one growth factor is IL-2, IL-21, or IL-7 and IL-15. In some embodiments, the growth factor is a recombinant cytokine, such as recombinant IL-2, recombinant IL-7, recombinant IL-21, or recombinant IL-15.

[0158] In certain embodiments, the methods provided include incubating or culturing the enriched NK cells and feeder cells in the presence of recombinant IL-2. In some embodiments, during at least a portion of the incubation, the recombinant IL-2 is administered at a concentration of from 1 IU / mL or about 1 IU / mL to 500 IU / mL or about 500 IU / mL, e.g., from 1 IU / mL or about 1 IU / mL to 250 IU / mL or about 250 IU / mL, from 1 IU / mL or about 1 IU / mL to 100 IU / mL or about 100 IU / mL, from 1 IU / mL or about 1 IU / mL to 50 IU / mL or about 50 IU / mL, from 50 IU / mL or about 50 IU / mL to 500 IU / mL or about 500 IU / mL. mL, 50 IU / mL or about 50 IU / mL to 250 IU / mL or about 250 IU / mL, 50 IU / mL or about 50 IU / mL to 100 IU / mL or about 100 IU / mL, 100 IU / mL or about 100 IU / mL to 500 IU / mL or about 500 IU / mL, 100 IU / mL or about 100 IU / mL to 250 IU / mL or about 250 IU / mL, or 250 IU / mL or about 250 IU / mL to 500 IU / mL or about 500 IU / mL (inclusive). In some embodiments, during at least a portion of the incubation, the concentration of IL-2 is 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or about 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or any value between any of the foregoing. In particular embodiments, the concentration of recombinant IL-2 is 100 IU / mL or about 100 IU / mL.

[0159] In certain embodiments, the methods provided include incubating or culturing enriched NK cells and feeder cells in the presence of recombinant IL-21. In some embodiments, during at least a portion of the incubation, the recombinant IL-21 is administered at a concentration of from 1 IU / mL or about 1 IU / mL to 500 IU / mL or about 500 IU / mL, e.g., from 1 IU / mL or about 1 IU / mL to 250 IU / mL or about 250 IU / mL, from 1 IU / mL or about 1 IU / mL to 100 IU / mL or about 100 IU / mL, from 1 IU / mL or about 1 IU / mL to 50 IU / mL or about 50 IU / mL, from 50 IU / mL or about 50 IU / mL to 500 IU / mL or about 500 IU / mL. mL, 50 IU / mL or about 50 IU / mL to 250 IU / mL or about 250 IU / mL, 50 IU / mL or about 50 IU / mL to 100 IU / mL or about 100 IU / mL, 100 IU / mL or about 100 IU / mL to 500 IU / mL or about 500 IU / mL, 100 IU / mL or about 100 IU / mL to 250 IU / mL or about 250 IU / mL, or 250 IU / mL or about 250 IU / mL to 500 IU / mL or about 500 IU / mL (inclusive). In some embodiments, during at least a portion of the incubation, the concentration of recombinant IL-21 is 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or about 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or any value between any of the foregoing. In particular embodiments, the concentration of recombinant IL-21 is 100 IU / mL or about 100 IU / mL.

[0160] In some embodiments, the method includes changing the culture medium, which in some aspects includes washing the cells. For example, during at least a portion of the culture or incubation period, the culture medium can be changed or washed out intermittently, for example, every day, every other day, every three days, or once a week. In certain embodiments, changing or washing out the culture medium begins within or about 3 to 7 days after the initiation of culture, for example, on or about day 3, 4, 5, 6, or 7. In certain embodiments, changing or washing out the culture medium begins on or about day 5.

[0161] Once the culture medium has been removed or washed away, it is replenished. In some embodiments, the replenished culture medium comprises one or more growth factors or cytokines, such as recombinant IL-2. Thus, in some embodiments, a growth factor or cytokine, e.g., recombinant IL-2, is added intermittently during incubation or culturing. In some such aspects, a growth factor or cytokine, e.g., recombinant IL-2, is added at or near the beginning of the culture or incubation, and then intermittently during the culture or incubation, e.g., each time the culture medium is changed or washed away. In some embodiments, a growth factor or cytokine, e.g., recombinant IL-2, is added to the culture or incubation beginning on day 0 (the start of incubation), and further growth factors or cytokines, e.g., recombinant IL-2, are added to the culture or incubation with each change or washout of the culture medium to replenish the culture or incubation. In some embodiments, the method comprises adding recombinant IL-2 at the beginning of incubation (day 0) and every 2 or 3 days for the duration of the incubation with each wash or change of culture medium, e.g., at or about days 5, 7, 9, 11 and 14 of culture or incubation.In any such embodiment, the recombinant IL-2 is administered at a concentration of from 1 IU / mL or about 1 IU / mL to 500 IU / mL or about 500 IU / mL, e.g., from 1 IU / mL or about 1 IU / mL to 250 IU / mL or about 250 IU / mL, from 1 IU / mL or about 1 IU / mL to 100 IU / mL or about 100 IU / mL, from 1 IU / mL or about 1 IU / mL to 50 IU / mL or about 50 IU / mL, from 50 IU / mL or about 50 ... IU / mL to 250 IU / mL or about 250 IU / mL, 50 IU / mL or about 50 IU / mL to 100 IU / mL or about 100 IU / mL, 100 IU / mL or about 100 IU / mL to 500 IU / mL or about 500 IU / mL, 100 IU / mL or about 100 IU / mL to 250 IU / mL or about 250 IU / mL, or 250 IU / mL or about 250 IU / mL to 500 IU / mL or about 500 IU / mL (each inclusive). In some embodiments, recombinant IL-2 is added to the culture or incubation at a concentration of 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or about 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 125 IU / mL, 150 IU / mL, 200 IU / mL, or any value between any of the foregoing. In particular embodiments, the concentration of recombinant IL-2 is 100 IU / mL or about 100 IU / mL.

[0162] In some embodiments, one or more additional cytokines, such as but not limited to, IL-21, IL-18, IL-7, IL-15, and / or IL-12, can be utilized in expanding NK cells. In some embodiments, one or more additional cytokines, such as but not limited to, recombinant IL-21, recombinant IL-18, recombinant IL-7, recombinant IL-15, and / or recombinant IL-12 can be utilized in expanding NK cells.

[0163] In embodiments of the provided methods, the culturing or incubating step includes providing the chemical and physical conditions (e.g., temperature, gas) necessary or useful for the maintenance of NK cells. Examples of chemical conditions that may support the proliferation of NK cells include, but are not limited to, buffers, nutrients, serum, vitamins, and antibiotics, typically provided in growth (i.e., culture) medium. In one embodiment, the NK culture medium comprises MEMα with 10% FCS or CellGro SCGM (Cell Genix) with 5% human serum / LiforCell® FBS replacement (Lifeblood Products). Other media suitable for use in the present invention include, but are not limited to, Glascow's medium (Gibco, Carlsbad, CA), RPMI medium (Sigma-Aldrich, St. Louis, MO), or DMEM (Sigma-Aldrich, St. Louis, MO). It should be noted that many culture media contain nicotinamide as a vitamin supplement, for example, MEMα (8.19 μM nicotinamide), RPMI (8.19 μM nicotinamide), DMEM (32.78 μM nicotinamide), and Glascoe medium (16.39 μM nicotinamide).

[0164] In some embodiments, e.g., in applications where cells are introduced (or reintroduced) into a human subject, culture is carried out using a serum-free formulation, such as AIM V™ Serum-Free Medium for Lymphocyte Culture, MARROWMAX™ Bone Marrow Medium, or Serum-Free Stem Cell Growth Medium (SCGM) (e.g., CellGenix® GMP SCGM). Such media formulations and supplements are available from commercial sources. Cultures can be supplemented with amino acids, antibiotics, and / or other growth factors and cytokines as described to promote optimal viability, proliferation, functionality, and / or survival. In some embodiments, serum-free media can also be supplemented with a low percentage of human serum, e.g., 0.5% to 10% human serum, e.g., 5% or about 5% human serum. In such embodiments, the human serum can be human serum from human AB plasma (human AB serum) or autologous serum.

[0165] In some embodiments, culturing with feeder cells and optionally cytokines (e.g., recombinant IL-2) is carried out under conditions suitable for the growth or expansion of human NK cells, e.g., including a temperature of at least about 25 degrees Celsius, typically at least about 30 degrees Celsius, typically at or about 37 degrees Celsius. In some embodiments, culturing is carried out at 37°C ± 2°C in 5% CO2.

[0166] In some of the provided embodiments, the culture is at least 2.50 x 10 8 or at least about 2.50 x 10 8 In some of the provided embodiments, the culturing is carried out until an expansion of at least 5.0 x 10 g-NK cells is achieved. 8 or at least about 5.0 × 10 8 In some of the provided embodiments, the culturing is carried out until an expansion of at least 1.0 x 10 g-NK cells is achieved. 9 or at least about 1.0 × 10 9 In some of the provided embodiments, the culturing is carried out until an expansion of at least 5.0 x 10 g-NK cells is achieved.9 or at least about 5.0 × 10 9 The treatment is continued until an expansion of g-NK cells is achieved.

[0167] In some of any of the provided embodiments, the culture is for at or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. or for at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or for at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. In some embodiments, the culturing is carried out for 14 days, or about 14 days, or at least 14 days, or at least about 14 days. In some embodiments, the culturing is carried out for 21 days, or about 21 days, or at least 21 days, or at least about 21 days.

[0168] In some embodiments, the provided methods include freezing, e.g., cryopreserving, the cells either before or after isolation, selection, and / or enrichment. In some embodiments, the provided methods include freezing, e.g., cryopreserving, the cells either before or after incubation and / or culture. In some embodiments, the methods include cryopreserving the cells in the presence of a cryoprotectant, thereby producing a cryopreservation composition. In some aspects, the methods include washing the cryopreservation composition under conditions to reduce or remove the cryoprotectant prior to incubation and / or administration to a subject. In some aspects, any of a variety of known freezing solutions and parameters may be used. In some embodiments, the cells are frozen, e.g., frozen or cryopreserved, in culture medium and / or solution having a final concentration of at or about 12.5%, 12.0%, 11.5%, 11.0%, 10.5%, 10.0%, 9.5%, 9.0%, 8.5%, 8.0%, 7.5%, 7.0%, 6.5%, 6.0%, 5.5%, or 5.0% DMSO, or 1% to 15%, 6% to 12%, 5% to 10%, or 6% to 8% DMSO. In certain embodiments, cells are frozen, for example, frozen or cryopreserved, in a medium and / or solution with a final concentration of 5.0%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1.5%, 1.25%, 1.0%, 0.75%, 0.5%, or 0.25% or about 5.0%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1.5%, 1.25%, 1.0%, 0.75%, 0.5%, or 0.25% HSA, or 0.1% to 5%, 0.25% to 4%, 0.5% to 2%, or 1% to 2% HSA. In some examples, PBS containing 20% ​​DMSO and 8% human serum albumin (HSA) or other suitable cell freezing medium is used. This is then diluted 1:1 with medium to give final concentrations of DMSO and HSA of 10% and 4%, respectively.The cells are then typically frozen to at or about -80°C at a rate of at or about 1 degree per minute and stored in the vapor phase of a liquid nitrogen storage tank.

[0169] In some of any of the provided embodiments, culturing or incubation according to any of the provided methods is for at or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. In some embodiments, the culturing is carried out for 14 days, or about 14 days, or at least 14 days, or at least about 14 days. In some embodiments, the culturing is carried out for 21 days, or about 21 days, or at least 21 days, or at least about 21 days. In certain embodiments, if the enriched NK cells at the initiation of culture were previously frozen or cryopreserved and then thawed, a longer culture duration is typically required. It is within the skill of one in the art to empirically determine the optimal number of days to culture the cells depending on factors such as the state of the cells at the initiation of culture, the health or viability of the cells at the initiation or during culture, and / or the desired threshold cell number at the end of culture, which depends, for example, on the desired application of the cells, e.g., the dose of cells to be administered to a subject for therapeutic purposes.

[0170] In some of the provided methods, the method comprises obtaining an increased number of NKG2C at the end of the culture compared to the beginning of the culture. posFor example, the percentage of NKG2C cells at the end of the culture compared to the beginning of the culture pos The cell increase can be greater than or about 100-fold, greater than or about 200-fold, greater than or about 300-fold, greater than or about 400-fold, greater than or about 500-fold, greater than or about 600-fold, greater than or about 700-fold, or greater than or about 800-fold. In some embodiments, the increase is 1000-fold or about 1000-fold. In some embodiments, the increase is 2000-fold or about 2000-fold. In some embodiments, the increase is 2500-fold or about 2500-fold. In some embodiments, culturing or incubation by any of the provided methods results in an increase of at least 2.50 x 10 cells by the method. 8 Or about 2.50 x 10 8 NKG2C pos cells, at least 3.0 x 10 8 Or about 3.0 x 10 8 NKG2C pos cells, at least 4.0 x 10 8 or approximately 4.0 x 10 8 NKG2C pos cells, at least 5.0 x 10 8 or approximately 5.0 x 10 8 NKG2C pos cells, at least 6.0 x 10 8 or approximately 6.0 x 10 8 NKG2C pos cells, at least 7.0 x 10 8 or approximately 7.0 x 10 8 NKG2C pos cells, at least 8.0 x 10 8 or approximately 8.0 x 10 8 NKG2C pos cells, at least 9.0 x 10 8 or approximately 9.0 x 10 8 NKG2C pos cells, at least 1.0 x 10 9 or approximately 1.0 x 10 9 NKG2C poscells, at least 1.5 x 10 9 Or about 1.5 x 10 9 NKG2C pos cells, at least 2.0 x 10 9 Or about 2.0 x 10 9 NKG2C pos cells, at least 3.0 x 10 9 Or about 3.0 x 10 9 NKG2C pos cells, at least 4.0 x 10 9 or approximately 4.0 x 10 9 NKG2C pos cells, at least 5.0 x 10 9 or approximately 5.0 x 10 9 NKG2C pos cells, at least 1.0 x 10 10 or approximately 1.0 x 10 10 NKG2C pos cells, at least 1.5 x 10 10 Or about 1.5 x 10 10 NKG2C pos cells, at least 2.0 x 10 10 Or about 2.0 x 10 10 NKG2C pos cells, at least 2.5 x 10 10 Or about 2.5 x 10 10 NKG2C pos This is carried out until cell or further expansion is achieved.

[0171] In some of the provided methods, the method produces an increased number of g-NK cells at the end of the culture compared to the beginning of the culture. For example, the increase in g-NK cells at the end of the culture compared to the beginning of the culture can be greater than or about 100-fold, greater than or about 200-fold, greater than or about 300-fold, greater than or about 400-fold, greater than or about 500-fold, greater than or about 600-fold, greater than or about 700-fold, or greater than or about 800-fold. In some of the embodiments, the increase is 1000-fold or about 1000-fold. In some of the embodiments, the increase is 2000-fold or about 2000-fold. In some of the embodiments, the increase is 2500-fold or about 2500-fold. In some embodiments, culturing or incubating by any of the provided methods results in the production of at least 2.50 x 10 cells by the method. 8 Or about 2.50 x 10 8 g-NK cells, at least 3.0 x 10 8 Or about 3.0 x 10 8 g-NK cells, at least 4.0 x 10 8 or approximately 4.0 x 10 8 g-NK cells, at least 5.0 x 10 8 or approximately 5.0 x 10 8 g-NK cells, at least 6.0 x 10 8 or approximately 6.0 x 10 8 g-NK cells, at least 7.0 x 10 8 or approximately 7.0 x 10 8 g-NK cells, at least 8.0 x 10 8 or approximately 8.0 x 10 8 g-NK cells, at least 9.0 x 10 8 or approximately 9.0 x 10 8 g-NK cells, at least 1.0 x 10 9 or approximately 1.0 x 10 9 g-NK cells, at least 1.5 x 10 9 Or about 1.5 x 10 9 g-NK cells, at least 2.0 x 10 9 Or about 2.0 x 109 g-NK cells, at least 3.0 x 10 9 Or about 3.0 x 10 9 g-NK cells, at least 4.0 x 10 9 or approximately 4.0 x 10 9 g-NK cells, at least 5.0 x 10 9 or approximately 5.0 x 10 9 g-NK cells or more, at least 1.0 × 10 10 or approximately 1.0 x 10 10 g-NK cells or more, at least 1.5 × 10 10 Or about 1.5 x 10 10 g-NK cells or more, at least 2.0 × 10 10 Or about 2.0 x 10 10 g-NK cells or more, or at least 2.5 × 10 10 Or about 2.5 x 10 10 This is carried out until an expansion of 100 g-NK cells or more is achieved.

[0172] In some embodiments, the provided methods result in the preferential expansion of g-NK cells. In some aspects, g-NK cells are identified by the presence or absence or level of surface expression of one or more various markers that distinguish NK cells from other lymphocytes or immune cells and distinguish g-NK cells from conventional NK cells. In various embodiments, surface expression can be determined by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting antibody binding to the marker. Similar methods can also be performed to assess expression of intracellular markers, except that such methods typically include methods for fixation and permeabilization prior to staining to detect intracellular proteins by flow cytometry. In some embodiments, fixation is achieved using formaldehyde (e.g., 0.01%), followed by membrane disruption using a detergent such as Triton, NP-50, Tween 20, saponin, digitonin, or Leucoperm (e.g., 0.1% to 1% detergent, e.g., 0.5% or about 0.5%).

[0173] Using antibodies and other binding entities to detect the expression levels of marker proteins - NK cells can be identified, detected and / or isolated. Suitable antibodies can include polyclonal, monoclonal, fragments (e.g., Fab fragments), single chain antibodies and other forms of specific binding molecules.

[0174] In some embodiments, a cell (e.g., an NK cell subset) is positive for a particular marker (pos) if there is detectable presence of that marker on or in the cell, which can be an intracellular or surface marker. In embodiments, surface expression is positive if staining is detectable at a level substantially greater than that detected using an isotype-matched control and performing the same procedure under otherwise identical conditions, and / or at a level substantially similar to, or in some cases, higher than, and / or higher than that of cells known to be negative for that marker.

[0175] In some embodiments, a cell (e.g., an NK cell subset) is negative for a particular marker if there is no detectable presence on or in the cell of that marker, which can be an intracellular or surface marker. In embodiments, surface expression is negative if staining is not detectable at a level substantially greater than that detected using an isotype-matched control and performing the same procedure under otherwise identical conditions, and / or at a level substantially lower than that of cells known to be positive for that marker and / or at a level substantially similar to that of cells known to be negative for that marker.

[0176] In some embodiments, a cell (e.g., an NK cell subset) has low (lo or min) expression for a particular marker if the detectable presence of that marker on or in the cell is at a low level compared to cells known to be positive for that marker. In embodiments, surface expression can be determined by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting binding of the antibody to the marker, where expression, which is either surface expression or intracellular expression depending on the method used, is low expression if the staining is at a lower level than cells known to be positive for that marker.

[0177] In some embodiments, g-NK cells have a NK cell phenotype (e.g., CD45 pos , CD3 neg and / or CD56 pos ) and express one or more markers that identify or are associated with the g-NK cell subset.

[0178] In some embodiments, g-NK cells are identified as described in Patent Application Publication US2013 / 0295044 or Zhang et al. (2013) J. Immunol., 190:1402-1406.

[0179] In some embodiments, g-NK cells are cells that do not express substantial FcRγ but express at least one marker of a natural killer cell. The amino acid sequence of the FcRγ chain (also known as the human (Homo sapiens) high-affinity immunoglobulin gamma Fc receptor I) is available in the NCBI database under accession number NP_004097.1 (GI:4758344) and is reproduced below as SEQ ID NO:1. TIFF2024161503000017.tif11149

[0180] In some embodiments, the g-NK cell subset of NK cells can be detected by observing whether FcRγ is expressed by a population of NK cells or a subpopulation of NK cells. Optionally, g-NK cells are identified as cells that do not express FcRγ. FcRγ protein is an intracellular protein. Thus, in some aspects, the presence or absence of FcRγ can be detected after treating the cells, such as by fixation and permeabilization, which allows for the detection of intracellular proteins. In some embodiments, the cells are further evaluated for one or more surface markers (CD45, CD3, and / or CD56) prior to intracellular detection, for example, prior to fixation of the cells. In some embodiments, g-NK cells are identified as cells that express CD45 pos / CD3 neg / CD56 pos / FcRγ neg The cells are identified, detected, enriched and / or isolated as being

[0181] In some embodiments, detecting expression of g-NK cells without using intracellular staining can be useful, for example, when cells from a sample are planned to be subjected to cell sorting or functional assays. Although treatments that allow intracellular staining of FcRγ, such as fixation and permeabilization, can be used to confirm the identity of a substantially pure cell population, g-NK cell expression can be detected without using intracellular staining. - When identifying, detecting, or isolating NK cells, it is often possible to use cell surface markers that can be detected without damaging the cells. Thus, in some embodiments, g-NK cells are identified using a surrogate marker profile that correlates with the lack of FcRγ among NK cell subsets. In some embodiments, a surrogate marker profile is particularly useful when assessing the presence or absence of intracellular proteins such as FcRγ is difficult or impossible, depending on the particular application of the cells.

[0182] It is found herein that certain combinations of cell surface markers correlate with the g-NK cell phenotype, i.e., cells lacking or defective intracellular expression of FcRγ, thereby providing a surrogate marker profile for identifying or detecting g-NK cells in a non-toxic manner. In some embodiments, the surrogate marker profile for g-NK cells provided herein includes one or more markers, CD16 (CD16 pos ) or CD57 (CD57pos) and / or positive surface expression of one or more markers CD7 (CD7 dim / neg ), CD161(CD161 neg ) and / or NKG2A (NKG2A neg In some embodiments, the cells are further evaluated for one or more surface markers of NK cells, e.g., CD45, CD3, and / or CD56. In some embodiments, g-NK cells are characterized by the surrogate marker profile CD45 pos / CD3 neg / CD56 pos / CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, g-NK cells are identified, detected, enriched and / or isolated by the surrogate marker profile CD45 pos / CD3 neg / CD56 pos / NKG2A neg / CD161 neg are identified, detected, enriched and / or isolated.

[0183] Provided herein are methods for identifying or detecting g-NK cells in a sample containing a population of cells by using a surrogate marker profile of g-NK cells. In some embodiments, the method includes contacting the cell sample with a binding molecule, such as an antibody or antigen-binding fragment, specific for one or more markers CD16, CD57, CD7, CD161, and / or NKG2A. In some embodiments, the method further includes contacting the cell sample with a binding molecule, such as an antibody or antigen-binding fragment, specific for CD45, CD3, and / or CD56. In some embodiments of the method, one or more binding molecules can be contacted with the sample simultaneously. In some embodiments of the method, one or more binding molecules can be contacted with the sample sequentially. In some embodiments, the method can include one or more washes after contacting under conditions to retain cells bound to one or more binding molecules and / or to separate and remove unbound binding molecules from the sample.

[0184] In some embodiments, each of the one or more binding molecules, such as antibodies, can be directly or indirectly attached to a label to detect marker-positive or marker-negative cells.For example, binding molecules such as antibodies can be conjugated, coupled or linked to a label.Labels are well known to those skilled in the art. Labels contemplated herein include, but are not limited to, fluorescent dyes, fluorescent proteins, radioisotopes, chromophores, metal ions, gold particles (e.g., colloidal gold particles), silver particles, particles with strong light scattering properties, magnetic particles (e.g., magnetic bead particles such as Dynabeads® magnetic beads), polypeptides (e.g., FLAG™ tags, human influenza hemagglutinin (HA) tags, etc.), enzymes such as peroxidases (e.g., horseradish peroxidase) or phosphatases (e.g., alkaline phosphatase), streptavidin, biotin, luminescent compounds (e.g., chemiluminescent substrates), oligonucleotides, members of specific binding pairs (e.g., a ligand and its receptor), and other labels known in the art that are used to visualize or detect binding molecules, e.g., antibodies, when attached directly or indirectly to the antibody.

[0185] Any number of well-known methods can be used to assess the expression level of surface markers or surface proteins, such as affinity-based methods, for example, immunoaffinity-based methods, for example, by flow cytometry in the context of surface markers. In some embodiments, the label is a fluorophore, and the method for detecting or identifying g-NK cells is by flow cytometry. In some embodiments, a different label is used for each different marker by multicolor flow cytometry.

[0186] In some embodiments, the method comprises contacting the sample with binding molecules specific for CD45, CD3, CD56, CD57, CD7, and CD161. In some such embodiments, the g-NK cells exhibit the g-NK cell surrogate marker profile CD45 pos / CD3 neg / CD56pos / CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg The cells are identified or detected as having

[0187] In some embodiments, the method comprises contacting the sample with binding molecules specific for CD45, CD3, CD56, NKG2A, and CD161. In some such embodiments, the g-NK cells exhibit the g-NK cell surrogate marker profile CD45 pos / CD3 neg / CD56 pos / NKG2A neg / CD161 neg The cells are identified or detected as having

[0188] In some embodiments, the provided methods can also include isolating or enriching g-NK cells, e.g., g-NK cells preferentially expanded according to any of the provided methods. In some such embodiments, a substantially pure population of g-NK cells can be obtained, e.g., a cell population containing greater than or greater than about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more g-NK cells, e.g., as determined using any of the panels or combinations of markers described. Antibodies and other binding molecules can be used to identify g-NK cells. - It can be used to detect the presence or absence of expression levels of marker proteins used in isolating or enriching NK cells. In some embodiments, the isolation or enrichment is performed by fluorescence-activated cell sorting (FACs). In an example of such a method, g-NK cells are identified or detected by flow cytometry, in which cells are stained for multiple cell surface markers using the methods described above, and the stained cells are transported in a fluid stream to collect cells that are positive or negative for markers associated with g-NK cells.

[0189] III. Compositions and Pharmaceutical Formulations Provided herein are compositions containing expanded NK cells, such as those produced by any of the provided methods. In some embodiments, the compositions contain NKG2C pos In some embodiments, the compositions contain g-NK cells or a subset thereof. In particular, the provided compositions include compositions of cells enriched for g-NK cells.

[0190] In some embodiments, the composition comprises about 5-99% NKG2C pos NKG2C cells or subsets thereof, or any percentage between 5 and 99% (inclusive) pos In some embodiments, the composition comprises NKG2C cells or a subset thereof. In some embodiments, the composition comprises NKG2C cells or a subset thereof relative to all NK cells or all cells naturally present in the subject from which the cells were isolated. pos an increased or greater percentage of NKG2C relative to total NK cells or total cells compared with the percentage of cells or subsets thereof pos In some embodiments, the percentage is increased by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold or more, or by at least about 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold or more.

[0191] In some embodiments, the composition comprises at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86% or at least about 86%, at least 87% or at least about 87%, at least 88% or at least about 88%, at least 89% or at least about 89%, at least 90% or at least about 90%, at least 91% or at least about 91%, at least 92% or at least about 92%, at least 93% or at least about 93%, at least 94% or at least about 94%, at least 95% or at least about 95%, at least 96% or at least about 96%, at least 97% or at least about 97%, at least 98% or at least about 98%, at least 99% or at least about 99%, or substantially 100% NKG2C pos In some embodiments, the composition may comprise more than 50% NKG2C cells or a subset thereof. pos In another embodiment, the composition comprises more than 70% NKG2C cells or a subset thereof. pos In another embodiment, the composition comprises more than 80% NKG2C cells or a subset thereof. pos In some embodiments, the compositions provided include NKG2C cells or a subset thereof. posIncluded are those in which the cells or subset thereof constitute at least or at least about 60%, at least or at least about 70%, at least or at least about 70%, at least 80%, at least or at least about 80%, at least 85%, at least or at least about 90%, at least or at least about 95% or more of the cells in the composition, or of the NK cells in the composition.

[0192] In some embodiments, the composition comprises about 5-99% g-NK cells, or any percentage of g-NK cells between 5-99%, inclusive. In some embodiments, the composition can comprise an increased or greater percentage of g-NK cells relative to total NK cells or total cells compared to the percentage of g-NK cells relative to total NK cells or total cells naturally present in the subject from which the cells were isolated. In some embodiments, the percentage is increased by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold or more.

[0193] In some embodiments, the composition comprises at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least 118%, at least 119%, at least 120%, at least 121%, at least 122%, at least 123%, at least 124%, at least 125%, at least 126%, at least 127%, at least 128%, at least 129%, at least 130%, at least 131%, at least 132%, at least 133%, at least 134%, at least 135%, at least 136%, at least 137%, at least 138%, at least 139%, at least 140%, at least 141%, at least 142%, at least 143%, at least 144%, at least 145%, at least 146%, at least 147%, The composition may comprise 86% or at least about 86%, at least 87% or at least about 87%, at least 88% or at least about 88%, at least 89% or at least about 89%, at least 90% or at least about 90%, at least 91% or at least about 91%, at least 92% or at least about 92%, at least 93% or at least about 93%, at least 94% or at least about 94%, at least 95% or at least about 95%, at least 96% or at least about 96%, at least 97% or at least about 97%, at least 98% or at least about 98%, at least 99% or at least about 99%, or substantially 100% g-NK cells. In some embodiments, the composition comprises more than 50% g-NK cells. In another embodiment, the composition comprises more than 70% g-NK cells. In another embodiment, the composition comprises more than 80% g-NK cells. In some embodiments, provided compositions include those in which g-NK cells comprise at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 95% or more of the cells in the composition, or of the NK cells in the composition.

[0194] In some embodiments, the composition comprises a population of natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the cells in the composition are CD57 pos In some embodiments, between at or about 70% and at or about 90% of the cells in the composition have the phenotype CD57 pos In some embodiments, at least 72% or at least about 72%, at least 74% or at least about 74%, at least 76% or at least about 76%, at least 78% or at least about 78%, at least 80% or at least about 80%, at least 82% or at least about 82%, at least 84% or at least about 84%, at least 86% or at least about 86%, at least 88% or at least about 88%, at least 90% or at least about 90%, at least 92% or at least about 92%, at least 94% or at least about 94%, at least 96% or at least about 96%, or at least 98% or at least about 98% of the cells in the composition are of the phenotype CD57 pos In some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition have the phenotype CD57 pos In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition are of the phenotype CD57 pos In some embodiments, the phenotype is the surface phenotype CD3 neg In some embodiments, the phenotype is the surface phenotype CD45 pos / CD3neg / CD56 pos In some of any of the provided embodiments, of the cells having such a phenotype, greater than 50% are FcRγ neg and optionally 50% to 90% or about 50% to 90% is FcRγ neg In some of any of the provided embodiments, of the cells having such a phenotype, 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg is.

[0195] In some embodiments, the composition comprises a population of natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, between or about 70% and 90% or about 90% of the cells in the composition have a g-NK cell surrogate marker profile of the phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 negIn some embodiments, at least 72% or at least about 72%, at least 74% or at least about 74%, at least 76% or at least about 76%, at least 78% or at least about 78%, at least 80% or at least about 80%, at least 82% or at least about 82%, at least 84% or at least about 84%, at least 86% or at least about 86%, at least 88% or at least about 88%, at least 90% or at least about 90%, at least 92% or at least about 92%, at least 94% or at least about 94%, at least 96% or at least about 96%, or at least 98% or at least about 98% of the cells in the composition have the phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition have the phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition are of the phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the phenotype is the surface phenotype CD3 neg In some embodiments, the phenotype is the surface phenotype CD45 pos / CD3 neg / CD56 pos In some of any of the provided embodiments, of the cells having such a phenotype, greater than 50% are FcRγ neg and optionally 50% to 90% or about 50% to 90% is FcRγ neg In some of any of the provided embodiments, of the cells having such a phenotype, 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg is.

[0196] In some embodiments, the composition comprises a population of natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the cells in the composition are CD38 neg In some embodiments, between at or about 70% and at or about 90% of the cells in the composition have a phenotype of CD38 neg In some embodiments, at least 72% or at least about 72%, at least 74% or at least about 74%, at least 76% or at least about 76%, at least 78% or at least about 78%, at least 80% or at least about 80%, at least 82% or at least about 82%, at least 84% or at least about 84%, at least 86% or at least about 86%, at least 88% or at least about 88%, at least 90% or at least about 90%, at least 92% or at least about 92%, at least 94% or at least about 94%, at least 96% or at least about 96%, or at least 98% or at least about 98% of the cells in the composition have the phenotype CD38 neg In some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition have the phenotype CD38 neg In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition are of the phenotype CD38 neg In some embodiments, the phenotype is the surface phenotype CD3 neg In some embodiments, the phenotype is the surface phenotype CD45pos / CD3 neg / CD56 pos In some of any of the provided embodiments, of the cells having such a phenotype, greater than 50% are FcRγ neg and optionally 50% to 90% or about 50% to 90% is FcRγ neg In some of any of the provided embodiments, of the cells having such a phenotype, 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg is.

[0197] In some embodiments, the composition comprises a population of natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the cells in the composition are CD16 pos In some embodiments, between at or about 70% and at or about 90% of the cells in the composition have a phenotype of CD16 posIn some embodiments, at least 72% or at least about 72%, at least 74% or at least about 74%, at least 76% or at least about 76%, at least 78% or at least about 78%, at least 80% or at least about 80%, at least 82% or at least about 82%, at least 84% or at least about 84%, at least 86% or at least about 86%, at least 88% or at least about 88%, at least 90% or at least about 90%, at least 92% or at least about 92%, at least 94% or at least about 94%, at least 96% or at least about 96%, or at least 98% or at least about 98% of the cells in the composition have the phenotype CD16 pos In some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition have the phenotype CD16 pos In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition are of the phenotype CD16 pos In some embodiments, the phenotype is the surface phenotype CD3 neg In some embodiments, the phenotype is the surface phenotype CD45 pos / CD3 neg / CD56 pos In some of any of the provided embodiments, of the cells having such a phenotype, greater than 50% are FcRγ neg and optionally 50% to 90% or about 50% to 90% is FcRγ neg In some of any of the provided embodiments, of the cells having such a phenotype, 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg is.

[0198] In some embodiments, the composition comprises a population of natural killer (NK) cell subsets, wherein at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the cells in the composition are NKG2A, NKG3A, NKG4A, NKG5A, NKG6A, NKG7A, NKG8A, NKG9A, NKG10A, NKG11A, NKG12A, NKG13A, NKG14A, NKG15A, NKG16A, NKG17A, NKG18A, NKG19A, NKG20A, NKG21A, NKG22A, NKG23A, NKG24A, NKG25A, NKG26A, NKG27A, NKG28A, NKG29A, NKG2A, NKG2A, NKG2B, NKG2C, NKG2D, NKG2E, NKG2F, NKG2F, NKG2G ... neg / CD161 neg In some embodiments, between or about 70% and 90% of the cells in the composition have a g-NK cell surrogate marker profile of phenotype NKG2A. neg / CD161 neg In some embodiments, at least 72% or at least about 72%, at least 74% or at least about 74%, at least 76% or at least about 76%, at least 78% or at least about 78%, at least 80% or at least about 80%, at least 82% or at least about 82%, at least 84% or at least about 84%, at least 86% or at least about 86%, at least 88% or at least about 88%, at least 90% or at least about 90%, at least 92% or at least about 92%, at least 94% or at least about 94%, at least 96% or at least about 96%, or at least 98% or at least about 98% of the cells in the composition are of the phenotype NKG2A neg / CD161 neg In some of any of the provided embodiments, at least 60% or at least about 60% of the cells in the composition have the phenotype NKG2A neg / CD161 neg In some of any of the provided embodiments, at least 70% or at least about 70% of the cells in the composition are of the phenotype NKG2A neg / CD161 negIn some embodiments, the phenotype is the surface phenotype CD3 neg In some embodiments, the phenotype is the surface phenotype CD45 pos / CD3 neg / CD56 pos In some of any of the provided embodiments, of the cells having such a phenotype, greater than 50% are FcRγ neg and optionally 50% to 90% or about 50% to 90% is FcRγ neg In some of any of the provided embodiments, of the cells having such a phenotype, 70% are FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg is.

[0199] In some of the provided embodiments, the composition comprises 10 6 or about 10 6 From 10 cells 12 or about 10 12 In some of the provided embodiments, the composition comprises 10 cells. 6 Or about 10 6 From, 10 11 Or about 10 11 cells, 10 6 Or about 10 6 From, 10 10 Or about 10 10 cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 cells, 10 7 Or about 10 7 From, 10 12 Or about 10 12 cells, 10 7 Or about 107 From, 10 11 Or about 10 11 cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 cells, or 10 7 Or about 10 7 From, 10 8 Or about 10 8 cells, 10 8 Or about 10 8 From, 10 12 Or about 10 12 cells, 10 8 Or about 10 8 From, 10 11 Or about 10 11 cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 cells, 10 9 Or about 10 9 From, 10 12 Or about 10 12 cells, 10 9 Or about 10 9 From, 10 11 Or about 10 11 cells, 10 9 Or about 10 9 From, 10 10 Or about 10 10 cells, 10 10 Or about 10 10 From, 10 12 Or about 10 12 cells, 10 10 Or about 10 10 From, 10 11 Or about 10 11 cells, or 1011 Or about 10 11 From, 10 12 Or about 10 12 Contains cells.

[0200] In some of the provided embodiments, the composition comprises at least 10 6 or at least about 10 6 In some of the provided embodiments, the composition comprises 10 cells. 6 Or about 10 6 From, 10 10 Or about 10 10 cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 cells, 10 7 Or about 10 7 From, 10 8 Or about 10 8 cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10Contains cells.

[0201] In some of the provided embodiments, the composition comprises at least 10 8 or at least about 10 8 In some of the provided embodiments, the composition comprises at least 10 cells. 9 or about 10 9 In some of the provided embodiments, the composition comprises at least 10 cells. 10 or about 10 10 In some of the provided embodiments, the composition comprises at least 10 cells. 11 or about 10 11 In some of the provided embodiments, the composition comprises 10 cells. 8 or about 10 8 From, 10 11 or about 10 11 In some of the provided embodiments, the composition comprises 10 cells. 8 or about 10 8 From, 10 10 or about 10 10 In some of the provided embodiments, the composition comprises 10 cells. 8 or about 10 8 From, 10 9 or about 10 9 In some of the provided embodiments, the composition comprises 10 cells. 9 or about 10 9 From, 10 11 or about 10 11 In some of the provided embodiments, the composition comprises 10 cells. 9 or about 10 9 From, 10 10 or about 10 10 In some of the provided embodiments, the composition comprises 10 cells. 10 or about 10 10 From, 10 11 or about 10 11 Contains cells.

[0202] In some of the provided embodiments, the composition comprises at least 10 6 or about 10 6 In some of the provided embodiments, the composition comprises 10 g-NK cells. 6 Or about 10 6 From, 10 10 Or about 10 10 g-NK cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 g-NK cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 g-NK cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 g-NK cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 g-NK cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 g-NK cells, 10 7 Or about 10 7 From, 10 8 Or about 10 8 g-NK cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 g-NK cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 g-NK cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 In some of the provided embodiments, the g-NK cells are FcRγ negIn some of the provided embodiments, the g-NK cells are cells having a g-NK surrogate surface marker profile. In some embodiments, the g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg In some embodiments, the g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg In some of any of the provided embodiments, g-NK cells or cells having a g-NK surrogate marker profile have the surface phenotype CD45 pos / CD3 neg / CD56 pos Further includes:

[0203] In certain embodiments of any of the provided compositions, the cells in the composition are derived from the same donor. Thus, the composition does not contain a mixed population of cells from one or more different donors. The expansion methods provided herein result in a high-yield expansion of certain NK cell subsets, particularly g-NK cell subsets, or NK cell subsets associated with or including surrogate markers for g-NK cells, such as any of the NK cell subsets described above, of 500-fold or more, 600-fold or more, 700-fold or more, 800-fold or more, 900-fold or more, 1000-fold or more, or more. In some embodiments, the expansion is 1000-fold or about 1000-fold. In some embodiments, the expansion is 2000-fold or about 2000-fold. In some embodiments, the expansion is 2500-fold or about 2500-fold. In particular embodiments, the expansion results in a 1000-fold or about 1,000-fold increase in the number of certain NK cell subsets, particularly the g-NK cell subset, or NK cell subsets associated with or including surrogate markers for g-NK cells, e.g., any of the NK cell subsets described above.

[0204] In some cases, from an initial source of NK cells obtained from a single donor, the expansion achieved by the provided methods can produce a composition of cells that provides multiple doses for administration to a subject in need. Thus, the provided methods are particularly suitable for allogeneic approaches. In some cases, a single expansion from a starting NK cell population isolated from a single donor by the provided methods can result in more than or about 20 doses for administration to a subject in need, e.g., 30, 40, 50, 60, 70, 80, 90, 100 doses, or about 30, 40, 50, 60, 70, 80, 90, 100 doses, or any value between any of the foregoing. In some embodiments, a single dose is greater than or equal to 1×10 5 Or about 1 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, e.g., 1 x 10 5 Or about 1 x 10 5 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 5 x 105 Or about 5 x 10 5 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 5 x 10 5 Or about 5 x 10 5 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 5 x 10 cells / kg 5 Or about 5 x 10 5cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 5 x 10 6 Or about 5 x 10 6 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg to 5 x 10 6 Or about 5 x 10 6 5 x 10 cells / kg 6 Or about 5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 5 x 10 cells / kg 6 Or about 5 x 10 6 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, or 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 In some embodiments, a single dose is 5 x 10 cells / kg. 7 Or about 5 x 10 7 From 10 x 10 9 Or about 10 x 10 9 , e.g. 5×10 7 Or about 5 x 10 7 From 5 x 10 9 Or about 5 x 10 9 , about 5×10 7 Or about 5 x 10 7 From 1×10 9 Or about 1 x 10 9 , 5×10 7 Or about 5 x 10 7 From 5 x 10 8 Or about 5 x 10 8 , about 5×10 7 Or about 5 x 10 7 From 1×10 8 Or about 1 x 10 8 , 1×10 8 From 10 x 10 9 Or about 10 x 10 9 , 1×10 8 Or about 1 x 10 8From 5 x 10 9 Or about 5 x 10 9 , about 1×10 8 Or about 1 x 10 8 From 1×10 9 Or about 1 x 10 9 , 1×10 8 Or about 1 x 10 8 From 5 x 10 8 Or about 5 x 10 8 , 5×10 8 Or about 5 x 10 8 From 10 x 10 9 Or about 10 x 10 9 , 5×10 8 Or about 5 x 10 8 From 5 x 10 9 Or about 5 x 10 9 , about 5×10 8 Or about 5 x 10 8 From 1×10 9 Or about 1 x 10 9 , 1×10 9 Or about 1 x 10 9 From 10 x 10 9 Or about 10 x 10 9 , 1×10 9 Or about 1 x 10 9 From 5 x 10 9 Or about 5 x 10 9 , or 5 × 10 9 Or about 5 x 10 9 From 10 x 10 9 Or about 10 x 10 9 In any of the above embodiments, the dose is given as the number of g-NK cells or NK cell subsets associated with or including surrogate markers for g-NK cells, e.g., any of the NK cell subsets described above, or the number of viable cells of any of the above. In any of the above embodiments, the dose is given as the number of cells in the expanded cell composition produced by the method, or the number of viable cells of any of the above.

[0205] Compositions include pharmaceutical compositions and formulations for administration, e.g., for adoptive cell therapy. In some embodiments, the engineered cells are formulated with a pharmaceutically acceptable carrier.

[0206] Pharmaceutically acceptable carriers can include any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., compatible with pharmaceutical administration (Gennaro, 2000, Remington: The science and practice of pharmacy, Lippincott, Williams & Wilkins, Philadelphia, PA). Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Non-aqueous vehicles such as liposomes and fixed oils can also be used. Supplementary active compounds can also be incorporated into the composition. Pharmaceutical carriers should be compatible with NK cells, such as saline solution, dextrose solution, or solutions containing human serum albumin.

[0207] In some embodiments, a pharmaceutically acceptable carrier or vehicle for the above-described composition is any non-toxic aqueous solution in which NK cells can be maintained or in which NK cells can remain viable for a sufficient period of time to allow for administration of live NK cells. For example, a pharmaceutically acceptable carrier or vehicle can be a saline solution or a buffered saline solution. A pharmaceutically acceptable carrier or vehicle can also contain various biological substances that can increase the efficacy of NK cells. Cell culture media and cell carriers can be, for example, polysaccharides, such as methylcellulose (MCTate, DA Shear, SW Offman, DG Stein, MC LaPlaca, Biomaterials 22, 1113, 2001, which is incorporated herein by reference in its entirety), chitosan (Suh JKF, Matthew HW T. Biomaterials, 21, 2589, 2000; Lahiji A, Sohrabi A, Hungerford DS, et al., J Biomed Mater Res, 51, 586, 2000, each of which is incorporated herein by reference in its entirety), N-isopropylacrylamide copolymer P(NIPAM-co-AA) (YH Bae, B. Vernon, C.K. Han, S.W. Kim, J. Control. Release 53, 249, 1998; H. Gappa, M. Baudys, J.J. Koh, S.W. Kim, YH Bae, Tissue Eng. 7, 35, 2001, each of which is incorporated herein by reference in its entirety), as well as poly(oxyethylene) / poly(D,L-lactic-co-glycolic acid) (B. Jeong, KM Lee, A. Gutowska, YH An, Biomacromolecules 3, 865, 2002, which is incorporated herein by reference in its entirety), P(PF-co-EG) (Suggs LJ, Mikos A G. Cell Trans, 8, 345, 1999, which is incorporated herein by reference in its entirety), PEO / PEG (Mann BK, Gobin AS, Tsai AT, Schmedlen RH, West J L., Biomaterials, 22, 3045, 2001; Bryant SJ, Anseth K S. Biomaterials, 22, 619, 2001, each of which is incorporated herein by reference in its entirety), PVA (Chih-Ta Lee, Po-Han Kung and Yu-Der Lee, Carbohydrate Polymer, 61, 348, 2005, which is incorporated herein by reference in its entirety), collagen (Lee CR, Grodzinsky AJ, Spector M., Biomaterials 22, 3145, 2001, which is incorporated herein by reference in its entirety), alginate (Bouhadir KH, Lee KY, Alsberg E, Damm KL, Anderson KW, Mooney D J. Biotech Prog 17, 945, 2001; Smidsrd O, Skjak-Braek G., Trends Biotech, 8, 71, 1990, each of which is incorporated herein by reference in its entirety).

[0208] In some embodiments, NK cells, e.g., NKG2C pos The cells or subsets thereof can be present in the composition in an effective amount. In some embodiments, the composition contains an effective amount of g-NK cells, e.g., FcRγ neg The effective amount of cells can vary depending on the type, severity and level of patient and disease.Therefore, physician can determine what is effective amount in consideration of the subject's health condition, the level and severity of disease and other variables.

[0209] In certain embodiments, the number of such cells in the composition is a therapeutically effective amount. In some embodiments, the amount is an amount that reduces the severity, duration, and / or symptoms associated with cancer, viral infection, microbial infection, or septic shock in an animal. In some embodiments, a therapeutically effective amount is a dose of cells that reduces the growth or spread of cancer in a patient or animal administered a composition described herein by at least 2.5%, at least 5%, at least 10%, at least 15%, at least 25%, at least 35%, at least 45%, at least 50%, at least 75%, at least 85%, at least 90%, at least 95%, or at least 99% compared to the growth or spread of cancer in a patient (or animal) or group of patients (or animals) that are not administered the composition. In some embodiments, a therapeutically effective amount is an amount that results in cytotoxic activity that results in activity that inhibits or reduces the growth of cancer, viral, and microbial cells.

[0210] In some embodiments, the composition comprises 10 5 Or about 10 5 From, 10 12 Or about 10 12 NKG2C pos cells or a subset thereof, or 10 5 Or about 10 5 From, 10 8 Or about 10 8 NKG2C pos cells or a subset thereof, or 10 6 Or about 10 6 From, 10 12 Or about 10 12 NKG2C pos cells or a subset thereof, or 10 8 Or about 10 8 From, 10 11 Or about 10 11 NKG2C pos cells or a subset thereof, or 10 9 Or about 10 9 From, 10 10 Or about 1010 NKG2C pos A certain amount of NKG2C cells or a subset thereof pos In some embodiments, the composition comprises 10 5 More than or about 10 5 Over 100 NKG2C pos cells or subsets thereof, 10 6 More than or about 10 6 Over 100 NKG2C pos cells or subsets thereof, 10 7 More than or about 10 7 Over 100 NKG2C pos cells or subsets thereof, 10 8 More than or about 10 8 Over 100 NKG2C pos cells or subsets thereof, 10 9 More than or about 10 9 Over 100 NKG2C pos cells or subsets thereof, 10 10 More than or about 10 10 Over 100 NKG2C pos cells or subsets thereof, 10 11 More than or about 10 11 Over 100 NKG2C pos cells or a subset thereof, or 10 12 More than or about 10 12 Over 100 NKG2C pos In some embodiments, such amounts can be administered to a subject having a disease or condition, for example, a cancer patient.

[0211] In some embodiments, the composition comprises 10 5 Or about 10 5 From, 10 12 Or about 10 12 g-NK cells, or 10 5 Or about 10 5 From, 10 8 Or about 10 8 g-NK cells, or 10 6 Or about 10 6From, 10 12 Or about 10 12 g-NK cells, or 10 8 Or about 10 8 From, 10 11 Or about 10 11 g-NK cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 In some embodiments, the composition comprises an amount of g-NK cells, the amount of g-NK cells being 10 5 More than or about 10 5 More than 10 g-NK cells 6 More than or about 10 6 More than 10 g-NK cells 7 More than or about 10 7 More than 10 g-NK cells 8 More than or about 10 8 More than 10 g-NK cells 9 More than or about 10 9 More than 10 g-NK cells 10 More than or about 10 10 More than 10 g-NK cells 11 More than or about 10 11 >10 g-NK cells, or 10 12 More than or about 10 12 In some embodiments, such an amount can be administered to a subject with a disease or condition, for example, a cancer patient.

[0212] In some embodiments, the volume of the composition is at least 10 mL, 50 mL, 100 mL, 200 mL, 300 mL, 400 mL, or 500 mL or at least about 10 mL, 50 mL, 100 mL, 200 mL, 300 mL, 400 mL, or 500 mL, such as 10 mL to 500 mL or about 10 mL to 500 mL, 10 mL to 200 mL or about 10 mL to 200 mL, 10 mL to 100 mL, 10 mL to 100 mL, In some embodiments, the volume of the composition is at least 1 x 10 mL to 50 mL, 50 mL to 500 mL or about 50 mL to 500 mL, 50 mL to 200 mL or about 50 mL to 200 mL, 50 mL to 100 mL or about 50 mL to 100 mL, 100 mL to 500 mL or about 100 mL to 500 mL, 100 mL to 200 mL or about 100 mL to 200 mL, or 200 mL to 500 mL or about 200 mL to 500 mL (each of which is inclusive). 5 cells / mL, 5 x 10 5 cells / mL, 1 x 10 6 cells / mL, 5 x 10 6 cells / mL, 1 x 10 7 cells / mL, 5 x 10 7 cells / mL or 1 x 10 8 cells / mL or at least approximately 1 x 10 5 cells / mL, 5 x 10 5 cells / mL, 1 x 10 6 cells / mL, 5 x 10 6 cells / mL, 1 x 10 7 cells / mL, 5 x 10 7 cells / mL or 1 x 10 8 In some embodiments, the composition has a cell density of 1 x 10 cells / mL. 5 cells / mL ~ 1 x 10 8 cells / mL or approximately 1 x 10 5 cells / mL ~ 1 x 10 8 cells / mL, 1 x 10 5 cells / mL ~ 1 x 10 7 cells / mL or approximately 1 x 10 5cells / mL ~ 1 x 10 7 cells / mL, 1 x 10 5 cells / mL ~ 1 x 10 6 cells / mL or approximately 1 x 10 5 cells / mL ~ 1 x 10 6 cells / mL, 1 x 10 6 cells / mL ~ 1 x 10 7 cells / mL or approximately 1 x 10 6 cells / mL ~ 1 x 10 7 cells / mL, 1 x 10 6 cells / mL ~ 1 x 10 8 cells / mL or approximately 1 x 10 6 cells / mL ~ 1 x 10 8 cells / mL, 1 x 10 6 cells / mL ~ 1 x 10 7 cells / mL or approximately 1 x 10 6 cells / mL ~ 1 x 10 7 cells / mL, or 1 x 10 7 cells / mL ~ 1 x 10 8 cells / mL or approximately 1 x 10 7 cells / mL ~ 1 x 10 8 cells / mL (both inclusive).

[0213] In some embodiments, compositions, including pharmaceutical compositions, are sterile.In some embodiments, cell isolation or concentration is carried out in a closed or sterile environment, for example, to minimize errors, user handling and / or contamination.In some embodiments, sterility can be easily achieved, for example, by filtration through a sterile filtration membrane.

[0214] Also provided herein are compositions suitable for cryopreserving the provided NK cells. In some embodiments, the compositions comprise a cryoprotectant. In some embodiments, the cryoprotectant is or comprises DMSO and / or s-glycerol. In some embodiments, compositions formulated for cryopreservation can be stored at low temperatures, e.g., cryogenic temperatures, e.g., at temperatures ranging from -40°C to -150°C, e.g., at or about 80°C ± 6.0°C.

[0215] In some embodiments, the compositions can be cryogenically stored prior to administration to a patient. In some embodiments, NK cell subsets, e.g., g-NK cells, can also be isolated, treated, and expanded, e.g., according to the methods provided, and then cryogenically stored prior to administration to a subject.

[0216] A typical method for cryogenic storage on a small scale is described, for example, in U.S. Patent No. 6,0168,991. For small-scale storage, cells can be cryogenically preserved by low-density suspension (e.g., at a concentration of about 200 x 10 / ml) in pre-chilled 5% human albumin serum (HAS). An equal volume of 20% DMSO can be added to the HAS solution. Aliquots of the mixture can be placed in vials and frozen overnight in a cryogenic chamber at about -80°C.

[0217] In some embodiments, cryopreserved NK cells are prepared for administration by thawing. In some cases, the NK cells can be administered to a subject immediately after thawing. In such embodiments, the composition is ready for use without any further processing. In other cases, after thawing, the NK cells are further processed or activated, for example, by resuspension in a pharmaceutically acceptable carrier, incubation with an activating or stimulating agent, washed, and resuspended in a pharmaceutically acceptable buffer prior to administration to a subject.

[0218] IV. Treatment Methods Provided herein are compositions and methods relating to the provided cell compositions, including the g-NK cells described herein, for use in treating a disease or condition in a subject. In some embodiments, provided herein are methods for treating a condition in an individual, comprising administering any of the provided compositions, e.g., a composition comprising g-NK cells, to an individual in need thereof. In certain embodiments, the composition is produced by the methods provided herein. Such methods and uses include therapeutic methods and uses involving administration of therapeutic cells or compositions containing same to a subject with a disease, condition, or disorder. Optionally, the disease or disorder is a tumor or cancer. In some embodiments, the cells or pharmaceutical composition thereof are administered in an amount effective to achieve treatment of the disease or disorder. Uses include the use of the cells or pharmaceutical composition thereof in the methods and treatments described above, and in the preparation of medicaments for carrying out such treatments. In some embodiments, the method thereby treats a disease or condition in a subject.

[0219] In some embodiments, the method of treatment or use involves administering to an individual an effective amount of a composition containing the expanded NK cell composition produced by the provided methods. 5 Or about 10 5 From, 10 12 Or about 10 12 , or 10 5 Or about 10 5 From, 10 8 Or about 10 8 , or 10 6 Or about 10 6 From, 10 12 Or about 10 12 , or 10 8 Or about 10 8 From, 10 11 Or about 10 11 , or 10 9 Or about 10 9 From, 10 10 Or about 10 10In some embodiments, 10 of the expanded NK cells are administered to an individual subject. 5 Pieces or 10 5 More than or about 10 5 Over 10 pieces 6 Pieces or 10 6 More than or about 10 6 Over 10 pieces 7 Pieces or 10 7 More than or about 10 7 Over 10 pieces 8 Pieces or 10 8 More than or about 10 8 Over 10 pieces 9 Pieces or 10 9 More than or about 10 9 Over 10 pieces 10 Pieces or 10 10 More than or about 10 10 Over 10 pieces 11 Pieces or 10 11 More than or about 10 11 More than 10 12 Pieces or 10 12 More than or about 10 12 More than 10 doses of cells containing the expanded NK cells are administered to an individual. In some embodiments, more than 10 doses per kg of cells are administered. 6 or about 10 6 From, 10 10 The expanded NK cells are administered to the subject.

[0220] In some embodiments, the method of treatment or use involves administering to an individual an effective amount of any of the provided NK cell compositions, including any described in Section III. 5 Or about 10 5 From, 10 12 Or about 10 12 , or 10 5 Or about 10 5 From, 10 8 Or about 10 8 , or 10 6 Or about 10 6 From, 10 12 Or about 10 12 , or 108 Or about 10 8 From, 10 11 Or about 10 11 , or 10 9 Or about 10 9 From, 10 10 Or about 10 10 In some embodiments, 10 NK cells from any of the provided compositions are administered to an individual subject. 5 Pieces or 10 5 More than or about 10 5 Over 10 pieces 6 Pieces or 10 6 More than or about 10 6 Over 10 pieces 7 Pieces or 10 7 More than or about 10 7 Over 10 pieces 8 Pieces or 10 8 More than or about 10 8 Over 10 pieces 9 Pieces or 10 9 More than or about 10 9 Over 10 pieces 10 Pieces or 10 10 More than or about 10 10 Over 10 pieces 11 Pieces or 10 11 More than or about 10 11 More than 10 12 Pieces or 10 12 More than or about 10 12 More than 10 doses of NK cell-containing cells from any of the provided compositions are administered to an individual. In some embodiments, more than 10 per kg 6 or about 10 6 From, 10 10 The NK cells of any of the provided compositions are administered to a subject.

[0221] In some embodiments, the method of treatment or use comprises administering to a subject an NKG2C pos In some embodiments, the method involves administering to an individual an effective amount of a composition containing a population of cells or a subset thereof. 5 Or about 10 5 From, 10 12Or about 10 12 NKG2C pos cells or a subset thereof, or 10 5 Or about 10 5 From, 10 8 Or about 10 8 NKG2C pos cells or a subset thereof, or 10 6 Or about 10 6 From, 10 12 Or about 10 12 NKG2C pos cells or a subset thereof, or 10 8 Or about 10 8 From, 10 11 Or about 10 11 NKG2C pos cells or a subset thereof, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 NKG2C pos In some embodiments, 10 5 Pieces or 10 5 More than or about 10 5 Over 100 NKG2C pos cells or subsets thereof, 10 6 Pieces or 10 6 More than or about 10 6 Over 100 NKG2C pos cells or subsets thereof, 10 7 Pieces or 10 7 More than or about 10 7 Over 100 NKG2C pos cells or subsets thereof, 10 8 Pieces or 10 8 More than or about 10 8 Over 100 NKG2C pos cells or subsets thereof, 10 9 Pieces or 10 9 More than or about 10 9 Over 100 NKG2C pos cells or subsets thereof, 10 10 Pieces or 10 10More than or about 10 10 Over 100 NKG2C pos cells or subsets thereof, 10 11 Pieces or 10 11 More than or about 10 11 Over 100 NKG2C pos cells or a subset thereof, or 10 12 Pieces or 10 12 More than or about 10 12 Over 100 NKG2C pos A dose of cells containing the cells or a subset thereof is administered to an individual. In some embodiments, a dose of 10 per kilogram of the subject's body weight is administered. 6 or about 10 6 From, 10 10 g NKG2C pos The cells or a subset thereof are administered to a subject.

[0222] In some embodiments, the treatment method comprises administering to an individual an effective amount of a composition containing g-NK cells. 5 Or about 10 5 From, 10 12 Or about 10 12 g-NK cells, or 10 5 Or about 10 5 From, 10 8 Or about 10 8 g-NK cells, or 10 6 Or about 10 6 From, 10 12 Or about 10 12 g-NK cells, or 10 8 Or about 10 8 From, 10 11 Or about 10 11 g-NK cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 In some embodiments, 10 g-NK cells. 5 Pieces or 10 5 More than or about 10 5 More than 10 g-NK cells 6Pieces or 10 6 More than or about 10 6 More than 10 g-NK cells 7 Pieces or 10 7 More than or about 10 7 More than 10 g-NK cells 8 Pieces or 10 8 More than or about 10 8 More than 10 g-NK cells 9 Pieces or 10 9 More than or about 10 9 More than 10 g-NK cells 10 Pieces or 10 10 More than or about 10 10 More than 10 g-NK cells 11 Pieces or 10 11 More than or about 10 11 >10 g-NK cells, or 10 12 Pieces or 10 12 More than or about 10 12 A dose of cells containing more than 10 g-NK cells is administered to an individual. 6 or about 10 6 From, 10 10 g-NK cells / kg are administered to the subject.

[0223] In some embodiments, the dose for administration according to any of the methods of treatment or uses provided is 1×10 5 Or about 1 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, e.g., 1 x 10 5 Or about 1 x 10 5 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 2.5 x 106 Or about 2.5 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 5 x 10 5 Or about 5 x 10 5 cells / kg, 1 x 10 5 Or about 1 x 10 5 cells / kg to 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 2.5 x 10 5 Or about 2.5 x 10 5 cells / kg to 5 x 10 5 Or about 5 x 10 5 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 1 x 10 7 Or about 1 x 10 7 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 5 x 10 6 Or about 5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 1 x 10 6 Or about 1 x 10 6 5 x 10 cells / kg 5 Or about 5 x 10 5 cells / kg to 7.5 x 10 5 Or about 7.5 x 10 5 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 5 x 106 Or about 5 x 10 6 cells / kg, 1 x 10 6 Or about 1 x 10 6 cells / kg to 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, 2.5 x 10 6 Or about 2.5 x 10 6 cells / kg to 5 x 10 6 Or about 5 x 10 6 5 x 10 cells / kg 6 Or about 5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 5 x 10 cells / kg 6 Or about 5 x 10 6 cells / kg to 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg, or 7.5 x 10 6 Or about 7.5 x 10 6 cells / kg to 1 x 10 7 Or about 1 x 10 7 cells / kg. In some embodiments, the dose is given as the number of g-NK cells, or the number of NK cell subsets associated with or including surrogate markers for g-NK cells, e.g., any of the NK cell subsets described herein, or the number of viable cells of any of the foregoing. In any of the above embodiments, the dose is given as the number of cells in the expanded cell composition produced by the provided methods, or the number of viable cells of any of the foregoing.

[0224] In some embodiments, the dose for administration according to any of the treatment methods or uses is 5×10 7 Or about 5 x 10 7 From 10 x 10 9 Or about 10 x 10 9 , e.g. 5×10 7 Or about 5 x 10 7 From 5 x 10 9 Or about 5 x 10 9 , about 5×10 7 Or about 5 x 10 7 From 1×10 9 Or about 1 x 10 9 , 5×10 7 Or about 5 x 10 7 From 5 x 10 8 Or about 5 x 10 8 , about 5×10 7 Or about 5 x 10 7 From 1×10 8 Or about 1 x 10 8 , 1×10 8 From 10 x 10 9 Or about 10 x 10 9 , 1×10 8 Or about 1 x 10 8 From 5 x 10 9 Or about 5 x 10 9 , about 1×10 8 Or about 1 x 10 8 From 1×10 9 Or about 1 x 10 9 , 1×10 8 Or about 1 x 10 8 From 5 x 10 8 Or about 5 x 10 8 , 5×10 8 Or about 5 x 10 8 From 10 x 10 9 Or about 10 x 10 9 , 5×10 8 Or about 5 x 10 8 From 5 x 10 9 Or about 5 x 10 9 , about 5×10 8 Or about 5 x 10 8 From 1×10 9 Or about 1 x 109 , 1×10 9 Or about 1 x 10 9 From 10 x 10 9 Or about 10 x 10 9 , 1×10 9 Or about 1 x 10 9 From 5 x 10 9 Or about 5 x 10 9 , or 5 × 10 9 Or about 5 x 10 9 From 10 x 10 9 Or about 10 x 10 9 In some embodiments, the dose is given as the number of g-NK cells, or the number of any of the NK cell subsets associated with or including a surrogate marker for g-NK cells, e.g., any of the NK cell subsets described herein, or the number of viable cells of any of the foregoing. In any of the above embodiments, the dose is given as the number of cells in the expanded cell composition produced by the provided methods, or the number of viable cells of any of the foregoing.

[0225] In some embodiments, compositions containing expanded NK cells are administered to an individual immediately after expansion according to the provided methods. In other embodiments, the expanded NK cells are stored or expanded by growth in culture prior to administration, e.g., by the methods described above. For example, the NK cells can be stored for more than 6 months, more than 12 months, more than 18 months, or more than 24 months prior to administration to an individual.

[0226] In some embodiments, provided compositions containing NK cells and subsets thereof, e.g., g-NK cells, can be administered to a subject by any convenient route, including parenteral routes, such as subcutaneous, intramuscular, intravenous, and / or epidural routes of administration.

[0227] The provided NK cells and subsets thereof, e.g., g-NK cells, and compositions can be used in methods of treating individuals with tumors or hyperproliferative disorders or microbial infections, e.g., viral infections, yeast infections, fungal infections, protozoan infections, and / or bacterial infections. The disclosed methods of treating subjects with the provided NK cells and subsets thereof, e.g., g-NK cells, and compositions can be combined with therapeutic monoclonal antibodies, such as anti-tumor antigen antibodies or anti-cancer antibodies, anti-viral antibodies, or anti-bacterial antibodies. The provided NK cells and subsets thereof, e.g., g-NK cells, and compositions can be administered to treat animals, e.g., mammals, e.g., human subjects.

[0228] In some examples, the method includes treating a hyperproliferative disorder, such as a hematological malignancy or a solid tumor. Examples of types of cancers and proliferative disorders that can be treated with the compositions described herein include, but are not limited to, leukemias (e.g., myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic myelocytic (granulocytic) leukemia, and chronic lymphocytic leukemia), lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, endothelial cell carcinoma, Ewing's tumor, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hepatoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung cancer, small cell lung carcinoma, bladder cancer, epithelial carcinoma, glioma, astrocytoma, oligodendroglioma, melanoma, neuroblastoma, retinoblastoma, dysplasia, and hyperplasia. Treating and / or preventing cancer includes, but is not limited to, alleviating one or more symptoms associated with cancer, inhibiting or reducing the progression of cancer, promoting the regression of cancer, and / or enhancing the immune response.

[0229] In some examples, the method involves treating viral infections, such as infections caused by the presence of a virus in the body. Viral infections include chronic or persistent viral infections, which are viral infections that infect a host and can replicate within the host's cells for extended periods of time, usually weeks, months, or years, before becoming fatal. Viruses that cause chronic infections that can be treated according to the present invention include, for example, human papillomavirus (HPV), herpes simplex virus and other herpes viruses, hepatitis B and C viruses and other hepatitis viruses, human immunodeficiency virus, and measles virus, all of which can cause significant clinical illness. Long-term infection can ultimately lead to the induction of fatal disease in the patient, such as liver cancer in the case of hepatitis C virus. Other chronic viral infections that can be treated according to the present invention include Epstein-Barr virus (EBV) and other viruses, such as those that can be associated with tumors.

[0230] Examples of viral infections that can be treated or prevented using the compositions and methods described herein include retroviruses (e.g., human T-lymphotropic virus (HTLV) types I and II and human immunodeficiency virus (HIV)), herpesviruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Ban virus, and cytomegalovirus), arenaviruses (e.g., Lassa fever virus), paramyxoviruses (e.g., viruses of the genus Morbillivirus, human respiratory syncytial virus, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantaviruses), cornaviruses, filoviruses (e.g., These include, but are not limited to, viral infections caused by viruses such as Ebola virus, flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadnaviruses (e.g., hepatitis B virus (HBV)), orthomyoviruses (e.g., Sendai virus and influenza viruses A, B, and C), papovaviruses (e.g., papillomaviruses), picornaviruses (e.g., rhinoviruses, enteroviruses, and hepatitis A virus), poxviruses, reoviruses (e.g., rotaviruses), togaviruses (e.g., rubella virus), and rhabdoviruses (e.g., rabies virus). Treating and / or preventing a viral infection includes, but is not limited to, alleviating one or more symptoms associated with the infection, inhibiting, reducing, or suppressing viral replication, and / or enhancing the immune response.

[0231] In some embodiments, the provided NK cells and subsets thereof, e.g., g-NK cells, and compositions are used in methods of treating yeast or bacterial infections. For example, the provided g-NK cells and compositions and methods described herein can be used to treat Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Corynebacterium diphtheriae, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Klebsiella rhinoscleromotis, Staphylococcus aureus, Vibrio cholerae, and other bacterial strains. cholera, Escherichia coli, Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Campylobacter jejuni, Aeromonas hydrophila, Bacillus cereus, Edwardsiella tarda, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Salmonella typhimurium typhimurium, Treponema pallidumpallidum, Treponema pertenue, Treponema carateneum, Borrelia vincentii, Borrelia burgdorferi, Leptospira icterohemorrhagiae, Mycobacterium tuberculosis, Toxoplasma gondii, Pneumocystis carinii, Francisella tularensis, Brucella abortus, Brucella suis, Brucella melitensis, Mycoplasma spp., Rickettsia typhi Infections associated with Rickettsia prowazeki, Rickettsia tsutsugumushi, Chlamydia spp., Helicobacter pylori, or combinations thereof can be treated.

[0232] A. Combination Therapy In some embodiments, the compositions containing g-NK cells provided herein can be administered in combination with one or more other agents to treat a disease or condition in a subject. In such embodiments, the compositions containing g-NK cells provided herein can be administered before, simultaneously with, or subsequent to (after) the administration of one or more other agents. For example, g-NK cells can be administered simultaneously with or sequentially administered with antimicrobial agents, antiviral agents, and other therapeutic agents. Exemplary combination therapies are described in the following subsections.

[0233] 1. Antibody combination In some embodiments, the compositions containing g-NK cells provided herein are activated by or exhibit enhanced activity when contacted with an antibody or an Fc-containing protein, e.g., compared to conventional NK cells. For example, g-NK cells can be activated by antibody-mediated crosslinking of CD16 by antibody-coated tumor cells.

[0234] In some embodiments, provided herein are methods for treating a condition in an individual, the methods comprising administering g-NK cells or compositions thereof and an antibody to the subject. One skilled in the art can select an appropriate therapeutic (e.g., anti-cancer) monoclonal antibody to administer to a subject together with the provided g-NK cells and compositions described herein, depending, for example, on the particular disease or condition of the individual. Suitable antibodies can include polyclonal, monoclonal, fragments (e.g., Fab fragments), single-chain antibodies, and other forms of specific binding molecules.

[0235] In some embodiments, the antibody may further comprise a humanized or human antibody. A humanized form of a non-human antibody is a chimeric Ig, chimeric Ig chain, or chimeric Ig fragment (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequence of an antibody) that contains minimal sequence derived from a non-human Ig. In some embodiments, the antibody comprises an Fc domain.

[0236] Generally, humanized antibodies have one or more amino acid residues introduced into them from a non-human source. These non-human amino acid residues are often referred to as "import" residues, and they are typically adopted from an "import" variable domain. Humanization is achieved by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody (Jones et al., 1986; Riechmann et al., 1988; Verhoeyen et al., 1988). Such "humanized" antibodies are chimeric antibodies (1989) in which significantly less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some Fc residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies include human antibodies (recipient antibodies) in which residues from the recipient's complementarity-determining region (CDR) are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some cases, corresponding non-human residues replace Fv framework residues of the human antibody. A "humanized antibody" may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, humanized antibodies comprise substantially all of at least one, and typically two, variable domains, with most, if not all, of the CDR regions corresponding to those of a non-human Ig and most, if not all, of the FR regions being those of a human antibody consensus sequence. Optimally, humanized antibodies also comprise at least a portion of an antibody constant region (Fc), typically that of a human antibody (Jones et al., 1986; Presta, 1992; Riechmann et al., 1988).

[0237] Human antibodies can also be produced using a variety of techniques, including phage display libraries (Hoogenboom et al., 1991; Marks et al., 1991) and preparation of human mAbs (Boerner et al., 1991; Reisfeld and Sell, 1985). Similarly, introduction of human Ig genes into transgenic animals in which the endogenous antibody genes have been partially or completely inactivated can also be used to synthesize human Abs. Upon challenge, human antibody production is observed that closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire (1997a;1997b;1997c;1997d;1997;1997;Fishwild et al.,1996;1997;1997;2001;1996;1997;1997;1997;Lonberg and Huszar,1995;Lonberg et al.,1994;Marks et al.,1992;1997;1997;1997).

[0238] Specifically, the cells of the present invention can be targeted to tumors by co-administering them with antibodies that recognize tumor-associated antigens. Those skilled in the art will appreciate that the g-NK cells are suitable for use with a wide variety of antibodies that recognize tumor-associated antigens. Non-limiting examples of tumor-associated antigens include CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor receptor kinase, gangliosides, cytokelene, and frizzled receptor. receptor, VEGF, VEGFR, integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-α, phosphatidylserine, syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin. In some cases, the antibody is an anti-CD20 antibody (e.g., rituximab), an anti-HER2 antibody (e.g., cetuximab), an anti-CD52 antibody, an anti-EGFR antibody, and an anti-CD38 antibody (e.g., daratumumab), or an anti-SLAMF7 antibody (e.g., elotuzumab).

[0239] Non-limiting examples of antibodies that can be used in combination therapy with the cell compositions comprising g-NK cells in the provided methods include trastuzumab (Herceptin®), ramucirumab (Cyramza®), atezolizumab (Tecentriq™), nivolumab (Opdivo®), durvalumab (Imfinzi™), avelumab (Bavencio®), pembrolizumab (Keytruda®), bevacizumab (Avastin®), everolimus (Afinitor®), pertuzumab (Perjeta®), ado-trastuzumab emtansine (Kadcyla®), cetuximab (Erbitux®), denosumab (Xgeva®), rituximab (Ri tuxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), necitumumab (Portrazza™), ibritumomab tiuxetan (Zevalin®), brentuximab vedotin (Adcetris®), siltuximab (Sylvant®), bortezomib (Velcade®), daratumumab (Darzalex™), elotuzumab (Empliciti™), dinutuximab (Unituxin™), olaratumab (Lartruvo™), ocrelizumab, isatuximab, Truxima, Blitzima, Ritemvia, Rituzena, Herzuma, Ruxience, ABP 798, Kanjinti, Ogivry, BI 695500, Novex (RTXM83), tositumomab or Ontruzant, or biosimilars thereof. Exemplary antibodies include rituximab, trastuzumab, aletuzumab, certuximab, daratumumab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, or elotuzumab.

[0240] In some embodiments, the antibody can be an anti-PD-1 antibody or an anti-PD-L1 antibody. Antibodies that target PD-1 or PD-L1 include, but are not limited to, nivolumab, pembrolizumab, or atezolizumab.

[0241] Antibodies specific to the selected cancer type can be chosen, including any antibody approved for the treatment of cancer. Examples include trastuzumab (Herceptin) for breast cancer, rituximab (Rituxan) for lymphoma, and cetuximab (Erbitux) for head and neck squamous cell carcinoma. Those skilled in the art are familiar with FDA-approved monoclonal antibodies capable of binding to specific tumor or disease antigens, any of which can be used in accordance with the provided methods to treat tumors or diseases.

[0242] In some embodiments, the method is for treating adenocarcinoma of the stomach or gastroesophageal junction and the antibody is trastuzumab (Herceptin®) or ramucirumab (Cyramza®).

[0243] In some embodiments, the method is for treating bladder cancer and the antibody is atezolizumab (Tecentriq™), nivolumab (Opdivo®), durvalumab (Imfinzi™), avelumab (Bavencio®), or pembrolizumab (Keytruda®).

[0244] In some embodiments, the method is for treating brain cancer and the antibody is bevacizumab (Avastin®).

[0245] In some embodiments, the method is for treating breast cancer and the antibody is trastuzumab (Herceptin®).

[0246] In some embodiments, the method is for treating cervical cancer and the antibody is bevacizumab (Avastin®).

[0247] In some embodiments, the method is for treating colorectal cancer and the antibody is cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), or ramucirumab (Cyramza®).

[0248] In some embodiments, the method is for treating endocrine / neuroendocrine tumors and the antibody is avelumab (Bavencio®).

[0249] In some embodiments, the method is for treating head and neck cancer and the antibody is cetuximab (Erbitux®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), trastuzumab, or ramucirumab.

[0250] In some embodiments, the method is for treating bone cancer and the antibody is denosumab (Xgeva®).

[0251] In some embodiments, the method is for treating renal cancer and the antibody is bevacizumab (Avastin®) or nivolumab (Opdivo®).

[0252] In some embodiments, the method is for treating leukemia and the antibody is rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), or blinatumomab (Blincyto®).

[0253] In some embodiments, the method is for treating lung cancer and the antibody is bevacizumab (Avastin®), ramucirumab (Cyramza®), nivolumab (Opdivo®), necitumumab (Portrazza™), pembrolizumab (Keytruda®), or atezolizumab (Tecentriq™).

[0254] In some embodiments, the method is for treating lymphoma and the antibody is ibritumomab tiuxetan (Zevalin®), brentuximab vedotin (Adcetris®), rituximab (Rituxan®), siltuximab (Sylvant®), obinutuzumab (Gazyva®), nivolumab (Opdivo®), or pembrolizumab (Keytruda®).

[0255] In some embodiments, the method is for treating multiple myeloma and the antibody is bortezomib (Velcade®), daratumumab (Darzalex™), or elotuzumab (Empliciti™).

[0256] In some embodiments, the method is for treating neuroblastoma and the antibody is dinutuximab (Unituxin™).

[0257] In some embodiments, the method is for treating ovarian epithelial / fallopian tube / primary peritoneal cancer and the antibody is bevacizumab (Avastin®).

[0258] In some embodiments, the method is for treating pancreatic cancer and the antibody is cetuximab (Erbitux®) or bevacizumab (Avastin®).

[0259] In some embodiments, the method is for treating skin cancer and the antibody is ipilimumab (Yervoy®), pembrolizumab (Keytruda®), avelumab (Bavencio®), or nivolumab (Opdivo®).

[0260] In some embodiments, the method is for treating soft tissue sarcoma and the antibody is olaratumab (Lartruvo™).

[0261] The g-NK cells and the additional agent can be administered sequentially or simultaneously. In some embodiments, the additional agent can be administered before the administration of the g-NK cells. In some embodiments, the additional agent can be administered after the administration of the g-NK cells. For example, the g-NK cells can be administered simultaneously with an antibody specific for a selected cancer type. Alternatively, the g-NK cells can be administered at a selected time point different from when the antibody specific for a selected cancer type is administered.

[0262] In certain examples, an effective amount of an antibody is administered to a subject before, after, or substantially simultaneously with the administration of a population of g-NK cells. In some examples, about 0.1 mg / kg to about 100 mg / kg (e.g., about 0.5 to 10 mg / kg, about 1 to 20 mg / kg, about 10 to 50 mg / kg, or about 20 to 100 mg / kg, e.g., about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 8 mg / kg, about 10 mg / kg, about 16 mg / kg, about 20 mg / kg, about 24 mg / kg, about 36 mg / kg, about 48 mg / kg, about 60 mg / kg, about 75 mg / kg, or about 100 mg / kg) of an antibody is administered to a subject. A skilled clinician can select an effective amount of antibody taking into consideration the particular antibody, the particular disease or condition (e.g., tumor or other disorder), the subject's general condition, any additional treatments the subject is receiving or has received in the past, and other relevant factors. The subject is also administered a g-NK cell population described herein. The antibody and g-NK cell population are typically administered parenterally, for example, intravenously, although injection or infusion into or near a tumor (local administration) or administration into the peritoneal cavity can also be used. One skilled in the art can determine the appropriate route of administration.

[0263] 2. Cytokines or growth factors In some embodiments provided herein, g-NK cells can be administered to an individual in combination with cytokines and / or growth factors. According to some embodiments, the at least one growth factor comprises a growth factor selected from the group consisting of SCF, FLT3, IL-2, IL-7, IL-15, IL-12, and IL-21. In certain embodiments, recombinant IL-2 is administered to the subject. In other particular embodiments, recombinant IL-15 is administered to the subject. In some embodiments, g-NK cells and cytokines or growth factors are administered sequentially. For example, g-NK cells can be administered first, followed by cytokines and / or growth factors. In some embodiments, g-NK cells are administered simultaneously with cytokines or growth factors.

[0264] In some embodiments, the subject is administered one or more cytokines (e.g., IL-2, IL-15, IL-21, and / or IL-12) to support the survival and / or growth of the NK cells. The cytokines can be administered before, after, or substantially simultaneously with the NK cells. In some examples, the cytokines can be administered after the NK cells. In one specific example, the cytokines are administered to the subject within about 1-8 hours (e.g., within about 1-4 hours, within about 2-6 hours, within about 4-6 hours, or within about 5-8 hours) of administration of the NK cells.

[0265] 3. Chemotherapeutic agents and multimodality combination therapy In some embodiments, the provided methods can also include administering the g-NK cells in conjunction with a cancer therapeutic agent or treatment, e.g., in conjunction with a chemotherapeutic or cytotoxic agent or other treatment.

[0266] In some embodiments, the provided methods can also include administering g-NK cells to an individual in combination with a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent can include cyclophosphamide, fludarabine, or methylprednazone. In some embodiments, the chemotherapeutic agent can include thalidomide; cisplatin (cis-DDP), oxaliplatin, carboplatin, anthracenedione, mitoxantrone; hydroxyurea, methylhydrazine derivatives, procarbazine (N-methylhydrazine, MM), adrenocortical suppressants, mitotane (omicron, rho-DDD), aminoglutethimide, RXR agonists, bexarotene, tyrosine kinase inhibitors, imatinib, or mechlorethamine. , cyclophosphamide, ifosfamide, melphalan (L-sarcolysin), chlorambucil, ethyleneimine, methylmelamine, hexamethylmelamine, thiotepa, busulfan, carmustine (BCNU), semustine (methyl-CCNTJ), lomustine (CCNU), streptozotocin (streptozotocin), DNA synthesis antagonists, estramustine phosphate, triazines, dacarbazine (OTIC, dimethyl-triazenoimidazole). ruboxamide), temozolomide, folic acid analogs, methotrexate (amethopterin), pyrimidine analogs, fluorouracil (5-fluorouracil, 5-FU, 5FTJ), floxuridine (fluorodeoxyuridine, FUdR), cytarabine (cytosine arabinoside), gemcitabine, purine analogs, mercaptopurine (6-mercaptopurine, 6-MP), thioguanidine (6-thioguanine, TG), pentostatin (2'-deoxycoformycin, deoxycoformycin), cladribine and fludarabine, topoisomerase inhibitors, amsacrine, vinca alkaloids, vinblastine (VLB), vincristine, taxanes, paclitaxel, nab-paclitaxel, (Abraxane), protein-bound paclitaxel (Abraxane®), docetaxel (Taxotere®);Epipodophyllotoxin, etoposide, teniposide, camptothecin, topotecan, irinotecan, dactinomycin (actinomycin D), daunorubicin (daunomycin, rubidomycin), doxorubicin, liposomal doxorubicin (Doxil), bleomycin, mitomycin (mitomycin C), idarubicin, epirubicin, buserelin, corticosteroids, prednisone, progestins, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, anastrozole; testosterone propionate, fluoxymesterone, flutamide, bicalutamide, and leuprolide;

[0267] In some embodiments, the cancer therapeutic agent is a cytotoxic agent, e.g., a cytotoxic small molecule. In some embodiments, the cancer therapeutic agent is an immunomodulatory agent, a Bcl2 inhibitor, a P13K inhibitor, a small molecule proteasome inhibitor, a small molecule tyrosine, a small molecule cyclin-dependent kinase inhibitor, an alkylating agent, an antimetabolite, an anthracillin, an antitumor antibiotic, a topoisomerase inhibitor, a mitotic inhibitor, a corticosteroid, or a differentiating agent.

[0268] In some embodiments, the cancer therapeutic agent is an immunomodulator. In some embodiments, the cancer therapeutic agent is thalidomide or a derivative thereof. For example, in some cases, the cancer therapeutic agent is lenalidomide or pomalidomide. In some cases, the cancer therapeutic agent is lenalidomide.

[0269] In some embodiments, the cancer therapeutic is a Bcl-2 inhibitor. For example, the cancer therapeutic can be venetoclax.

[0270] In some embodiments, the cancer therapeutic is a P13K inhibitor, for example, the cancer therapeutic is Idelaisib.

[0271] In some embodiments, the cancer therapeutic agent is a small molecule tyrosine. For example, the cancer therapeutic agent can be imatinib mesylate.

[0272] In some embodiments, the cancer therapeutic agent is a cyclin-dependent kinase inhibitor. For example, the cancer therapeutic agent can be Sekiclib.

[0273] In some embodiments, the cancer therapeutic agent is an alkylating agent. Examples of alkylating agents include, but are not limited to, altretamine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, lomustine, melphalan, oxaliplatin, temozolomide, or thiotepa.

[0274] In some embodiments, the cancer therapeutic agent is an antimetabolite. Antimetabolites interfere with the elongation of DNA and RNA by replacing the normal building blocks of RNA and DNA. These agents damage cells when their chromosomes are being replicated. They are commonly used to treat leukemia, breast, ovarian, and intestinal cancer, as well as other types of cancer. Examples of antimetabolites include, but are not limited to, 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), capecitabine (Xeloda®), cytarabine (Ara-C®), floxuridine, fludarabine, gemcitabine (Gemzar®), hydroxyurea, methotrexate, or pemetrexed (Alimta®).

[0275] In some embodiments, the cancer therapeutic agent is an anthracycline. Anthracycline drugs work by altering DNA in cancer cells so that it does not elongate or amplify. Anthracyclines are antitumor antibiotics that interfere with enzymes involved in DNA replication during the cell cycle. They are widely used for various cancers. A major concern when administering anthracycline drugs is that they can permanently damage the heart if administered at high doses. Therefore, anthracycline drugs often have a lifetime dose limit. In some cases, the dose and schedule of these drugs can be reduced when administered in combination with FcεRIγ-deficient NK cells (G-NK). Examples of anthracyclines that can be used in the provided combination therapy include, but are not limited to, daunorubicin, doxorubicin (Adriamycin®), epirubicin, or idarubicin.

[0276] In some embodiments, the cancer therapeutic agent is an antitumor antibiotic. Examples of antitumor antibiotics include, but are not limited to, actinomycin-D, bleomycin, mitomycin-C, or mitoxantrone.

[0277] In some embodiments, the cancer therapeutic agent is a topoisomerase inhibitor. Topoisomerase drugs interfere with enzymes called topoisomerases, which help separate DNA strands so they can be copied. Topoisomerase inhibitors are grouped according to the type of enzyme they affect. Topoisomerase inhibitors are used to treat certain leukemias, as well as lung cancer, ovarian cancer, gastrointestinal cancer, and other cancers. Topoisomerase inhibitors can be topoisomerase I inhibitors or topoisomerase II inhibitors. Examples of topoisomerase I inhibitors include, but are not limited to, topotecan or irinotecan (CPT-11). Examples of topoisomerase II inhibitors include, but are not limited to, etoposide (VP-16), teniposide, or mitoxantrone.

[0278] In some embodiments, the cancer therapeutic agent is a mitotic inhibitor. Mitotic inhibitors are compounds that act by stopping cells from dividing to form new cells, but can also damage cells at any stage by preventing enzymes from making proteins necessary for cell reproduction. They are used to treat a wide variety of cancer types, including breast cancer and lung cancer, myeloma, lymphoma, and leukemia. These drugs can cause nerve damage, which can limit the amount that can be administered. In some cases, the dose and schedule of these drugs can be reduced by administering them in combination with FcεRIγ-deficient NK cells (G-NK). Non-limiting examples of mitotic inhibitors include, but are not limited to, docetaxel, estramustine, ixabepilone, paclitaxel, vinblastine, vincristine, or vinorelbine.

[0279] In some embodiments, the cancer treatment drug is a corticosteroid. Corticosteroids, often simply referred to as steroids, are natural hormones and hormone-like drugs that are useful in the treatment of many types of cancer and other diseases. When these drugs are used as part of cancer treatment, they are considered chemotherapeutic drugs. Non-limiting examples of corticosteroids include, but are not limited to, prednisone, methylprednisolone (Solumedrol®) or dexamethasone (Decadron®).

[0280] In some embodiments, the cancer therapeutic agent is a differentiation inducer. Non-limiting examples of differentiation inducers include, but are not limited to, retinoids, tretinoin (ATRA or Atralin®), bexarotene (Targretin®), or arsenic trioxide (Arsenox®).

[0281] In some embodiments, the cancer therapeutic agent is selected from the group consisting of cisplatin, carboplatin, and oxaliplatin. In certain embodiments, the cancer therapeutic agent is selected from the group consisting of paclitaxel, Abraxane®, and Taxotere®. In one embodiment, the chemotherapeutic agent is selected from the group consisting of asparaginase, bevacizumab, bleomycin, doxorubicin, epirubicin, etoposide, 5-fluorouracil, hydroxyurea, streptozocin, and 6-mercaptopurine, cyclophosphamide, paclitaxel, and gemcitabine.

[0282] Other non-limiting examples of cancer therapeutic agents that may be used in combination with g-NK cells include everolimus (Afinitor®), toremifene (Fareston®), fulvestrant (Faslodex®), anastrozole (Arimidex®), exemestane (Aromasin®), lapatinib (Tykerb®), letrozole (Femara®), pertuzumab (Perjeta®), ado-trastuzumab emtansine (Kadcyla®), parvoviral (Pfizer®), and fluconazole (Faslodex®). Ciclib (Ibrance®), ribociclib (Kisqali®), Ziv-aflibercept (Zaltrap®), regorafenib (Stivarga®), lanreotide acetate (Somatuline® depot), sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), temsirolimus (Torisel®), axitinib (Inlyta®), cabozantinib (Cabometyx®), trademark), lenvatinib mesylate (Lenvima®), imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), tretinoin (Vesanoid®), ibrutinib (Imbruvica®), idelalisib (Zydelig®), venetoclax (Venclexta™), ponatinib hydrochloride (Iclusig®), midostaurin (Rydapt®), (R)), crizotinib (Xalkori®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib dimaleate (Gilotrif®), ceritinib (LDK378 / Zykadia™), osimertinib (Tagrisso™), alectinib (Alecensa®), brigatinib (Alunbrig™), Cyramza, denileukin diftitox (Ontak®), vorinostat (Zolinza®),Romidepsin (Istodax®), bexarotene (Targretin®), bortezomib (Velcade®), pralatrexate (Folotyn®), idelalisib (Zydelig®), belinstat (Beleodaq®), bendamustine, carfilzomib (Kyphosis®), panobinostat (Farydak®), ixazomib citrate (Ninlaro®), olaparib (Lynparza™), rucaparib camsylate (Rubraca™), niraparibut tosylate monohydrate (Zejula™), vinorelbine (Navelbine®) ), erlotinib (Tarceva®), sunitinib (Sutent®), vismodegib (Erivedge®), sonidegib (Odomzo®), vemurafenib (Zelboraf®), trametinib (Mekinist®), dabrafenib (Tafinlar®), cobimetinib (Cotellic™), alitretinoin (Panretin®), pazopanib (Votrient®), alitretinoin (Panretin®), trabectedin (Yondelis®), or eribulin (Halaven®).

[0283] In some embodiments, the composition containing g-NK cells is administered in conjunction with radiation therapy.

[0284] In some embodiments, the combination therapy is a multimodality cancer therapy involving a combination of a composition containing g-NK cells provided herein, an antibody, such as any of those described above, and a cytotoxic small molecule or cytotoxic radiation therapy. In some embodiments, the cytotoxic small molecule or radiation therapy is administered to the subject separately, e.g., before or after administration of the composition containing g-NK cells. In some embodiments, the cytotoxic small molecule or radiation therapy is administered to the subject in parallel, e.g., simultaneously or nearly simultaneously, with the composition containing g-NK cells. In some cases, the multimodality cancer therapy can further include administration of one or more cytokines or growth factors, such as IL-2 or IL-15, to provide additional cytokine support.

[0285] Multimodal cancer therapy is a combination of two or more treatment modalities. Multimodal therapy is also called combination therapy. Different effective modalities can be used for various cancers. The distinct biology of tumors and the efficacy of various modalities may determine the specific approach for each. Antibody-based therapy has become increasingly used to treat cancer and other indications. While responses to antibody therapy have focused on the direct inhibitory effects of these antibodies on tumor cells, these antibodies have also been shown to have effects on the host immune system. FcεRIγ-deficient NK cells (G-NK) are immune effector cells that mediate ADCC upon binding to the antibody's Fc receptor (CD16). Provided embodiments are designed to improve the efficacy of antibody therapy when combined with FcεRIγ-deficient NK cells (G-NK) in addition to the addition of small molecules and / or radiation therapy.

[0286] In some embodiments, multimodality treatment of gastric or gastroesophageal junction adenocarcinoma comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is trastuzumab (Herceptin®) or ramucirumab (Cyramza®) and (2) a cancer therapeutic or cytotoxic agent that is radiation therapy, capecitabine, or cisplatin. In certain embodiments, multimodality treatment of gastric or gastroesophageal junction adenocarcinoma comprises administration of a composition of g-NK cells provided herein in combination with trastuzumab (Herceptin®) plus cisplatin.

[0287] In some embodiments, the multimodality treatment of bladder cancer comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is atezolizumab (Tecentriq™), nivolumab (Opdivo®), durvalumab (Imfinzi™), avelumab (Bavencio®), or pembrolizumab (Keytruda®), and (2) a cancer therapeutic or cytotoxic agent that is radiation therapy or cisplatin plus fluorouracil. In certain embodiments, the multimodality treatment of bladder cancer comprises administration of a composition of g-NK cells provided herein in combination with atezolizumab (Tecentriq™) plus cisplatin plus 5-FU.

[0288] In some embodiments, the multimodality treatment of brain cancer comprises the administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is bevacizumab (Avastin®), and (2) a cancer therapeutic or cytotoxic agent that is everolimus (Afinitor®), radiation therapy, carboplatin, etoposide, or temozolomide. In certain embodiments, the multimodality treatment of brain cancer comprises the administration of a composition of g-NK cells provided herein in combination with bevacizumab (Avastin®) plus radiation therapy.

[0289] In some embodiments, the multimodality treatment for breast cancer is (1) a monoclonal antibody that is trastuzumab (Herceptin®), and (2) one of the following: tamoxifen (Nolvadex), toremifene (Fareston®), everolimus (Afinitor®), fulvestrant (Faslodex®), anastrozole (Arimidex®), exemestane (Aromasin®), lapatinib (Tykerb®), gliomas with ... In certain embodiments, the multimodality treatment of breast cancer comprises the administration of a composition of g-NK cells provided herein in combination with a cancer therapeutic or cytotoxic agent that is trastuzumab (Herceptin®), letrozole (Femara®), pertuzumab (Perjeta®), ado-trastuzumab emtansine (Kadcyla®), palbociclib (Ibrance®), ribociclib (Kisqali®), cisplatin / paraplatin, paclitaxel, doxorubicin, or radiation therapy. In certain embodiments, the multimodality treatment of breast cancer comprises the administration of a composition of g-NK cells provided herein in combination with trastuzumab (Herceptin®) plus cisplatin.

[0290] In some embodiments, the multimodality treatment of colorectal cancer comprises the administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), or ramucirumab (Cyramza®), and (2) a cancer therapeutic or cytotoxic agent that is Ziv-aflibercept (Zaltrap®), regorafenib (Stivarga®), radiation therapy, 5-fluorouracil (5-FU), capecitabine, irinotecan, or oxaliplatin. In certain embodiments, the multimodality treatment of colorectal cancer comprises the administration of a composition of g-NK cells provided herein in combination with cetuximab (Erbitux®) plus oxaliplatin.

[0291] In some embodiments, the multimodality treatment of endocrine / neuroendocrine tumors comprises the administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is avelumab (Bavencio®), and (2) a cancer therapeutic or cytotoxic agent that is lanreotide acetate (Somatuline® depot). In certain embodiments, the multimodality treatment of endocrine / neuroendocrine tumors comprises the administration of a composition of g-NK cells provided herein in combination with avelumab (Bavencio®) plus oxaliplatin.

[0292] In some embodiments, the multimodality treatment of head and neck cancer comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is cetuximab (Erbitux®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), trastuzumab, or ramucirumab, and (2) a cancer therapeutic or cytotoxic agent that is radiation therapy, carboplatin, cisplatin, capecitabine, irinotecan, 5-fluorouracil, or paclitaxel. In certain embodiments, the multimodality treatment of head and neck cancer comprises administration of a composition of g-NK cells provided herein in combination with cetuximab (Erbitux®) plus cisplatin.

[0293] In some embodiments, the multimodality treatment of giant cell tumor of bone comprises the administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is denosumab (Xgeva®), and (2) a cancer therapeutic or cytotoxic agent that is radiation therapy, doxorubicin, cisplatin, etoposide, cyclophosphamide, or methotrexate. In certain embodiments, the multimodality treatment of giant cell tumor of bone comprises the administration of a composition of g-NK cells provided herein in combination with denosumab (Xgeva®) plus doxorubicin.

[0294] In some embodiments, the multimodality treatment for renal cancer includes (1) a monoclonal antibody that is bevacizumab (Avastin®) or nivolumab (Opdivo®), and (2) an anti-cancer drug such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), temsirolimus (Torisel®), everolimus (Afinitor®), axitinib (Inlyta®), cabozantinib (Cabome®), or rituximab (Tetrag). tyx™ includes administration of a composition of g-NK cells provided herein in combination with a cancer therapeutic or cytotoxic agent that is lenvatinib mesylate (Lenvima®), vinblastine, 5-fluorouracil (5-FU), capecitabine, or gemcitabine. In certain embodiments, the multimodality treatment of renal cancer includes administration of a composition of g-NK cells provided herein in combination with bevacizumab (Avastin®) plus sorafenib (Nexavar®).

[0295] In some embodiments, the multimodality treatment of leukemia is (1) a monoclonal antibody that is rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), or blinatumomab (Blincyto®), and (2) an anti-cancer drug selected from the group consisting of imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), or blinatumomab (Blincyto®). In certain embodiments, the multimodality treatment of leukemia comprises the administration of a composition of g-NK cells provided herein in combination with a cancer therapeutic or cytotoxic agent that is rituximab (Rituxan®) plus cyclophosphamide.

[0296] In some embodiments, the multimodality treatment of lung cancer is selected from the group consisting of (1) monoclonal antibodies that are bevacizumab (Avastin®), ramucirumab (Cyramza®), nivolumab (Opdivo®), necitumumab (Portrazza™), pembrolizumab (Keytruda™), atezolizumab (Tecentriq™), and (2) crizotinib (Xalkori®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib dimaleate (Gilotrif®), ceritinib (LDK378 / Zykadia™). )), osimertinib (Tagrisso™), alectinib (Alecensa®), brigatinib (Alunbrig™), Cyramza, radiation therapy, cisplatin, carboplatin, paclitaxel (Taxol), nab-paclitaxel, Abraxane), docetaxel (Taxotere), gemcitabine (Gemzar), vinorelbine (Navelbine), irinotecan (Camptosar), etoposide (VP-16), vinblastine, or pemetrexed (Alimta). In certain embodiments, the multimodality treatment of lung cancer comprises administration of a composition of g-NK cells provided herein in combination with necitumumab (Portrazza™) plus carboplatin.

[0297] In some embodiments, the multimodality treatment for lymphoma consists of (1) a monoclonal antibody that is ibritumomab tiuxetan (Zevalin®), brentuximab vedotin (Adcetris®), rituximab (Rituxan®), siltuximab (Sylvant®), obinutuzumab (Gazyva®), nivolumab (Opdivo®), or pembrolizumab (Keytruda®), and (2) a monoclonal antibody that is denileukin diftitox (Ontak®), vorinostat (Zolinza®), romidepsin (Istodax®), bexarotene (Targ In certain embodiments, the multimodality treatment of lymphoma comprises the administration of a composition of g-NK cells provided herein in combination with a cancer therapeutic or cytotoxic agent that is rituximab (Rituxan®), bortezomib (Velcade®), pralatrexate (Folotyn®), ibrutinib (Imbruvica®), idelalisib (Zydelig®), belinstat (Beleodaq®), cyclophosphamide, chlorambucil, bendamustine, ifosfamide, cisplatin, carboplatin, oxaliplatin, fludarabine, gemcitabine, methotrexate, doxorubicin, vincristine, or etoposide (VP-16). In certain embodiments, the multimodality treatment of lymphoma comprises the administration of a composition of g-NK cells provided herein in combination with rituximab (Rituxan®) plus cyclophosphamide.

[0298] In some embodiments, the multimodality treatment of multiple myeloma comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is bortezomib (Velcade®), daratumumab (Darzalex™), or elotuzumab (Empliciti™), and (2) a cancer therapeutic or cytotoxic agent that is carfilzomib (Kyphosis®), panobinostat (Farydak®), ixazomib citrate (Ninlaro®), melphalan, vincristine (Oncovin), cyclophosphamide (Cytoxan), etoposide (VP-16), doxorubicin (Adriamycin), liposomal doxorubicin (Doxil), bendamustine (Treanda). In certain embodiments, the multimodality treatment of multiple myeloma comprises administration of a composition of g-NK cells provided herein in combination with daratumumab (Darzalex™) plus cyclophosphamide.

[0299] In some embodiments, the multimodality treatment of neuroblastoma comprises the administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is dinutuximab (Unituxin™), and (2) a cancer therapeutic or cytotoxic agent that is radiation therapy, cyclophosphamide, cisplatin or carboplatin, vincristine, doxorubicin (Adriamycin), etoposide, topotecan, busulfan, or thiotepa. In certain embodiments, the multimodality treatment of neuroblastoma comprises the administration of a composition of g-NK cells provided herein in combination with dinutuximab (Unituxin™) plus doxorubicin (Adriamycin).

[0300] In some embodiments, the multimodality treatment for ovarian epithelial / fallopian tube / primary peritoneal cancer includes (1) a monoclonal antibody that is bevacizumab (Avastin®), and (2) olaparib (Lynparza™), rucaparib camsylate (Rubraca™), niraparib tosylate monohydrate (Zejula™), cisplatin, carboplatin, paclitaxel (Taxol®), docetaxel (Taxotere®), capecitabine (Xeloda®), cyclophosphamide (Cyclophosphamide), or cyclosphamide. In certain embodiments, the multimodality treatment of ovarian epithelial / fallopian tube / primary peritoneal cancer comprises the administration of a composition of g-NK cells provided herein in combination with a cancer therapeutic or cytotoxic agent that is cyclophosphamide (Cyclohexan®), etoposide (VP-16), gemcitabine (Gemzar®), ifosfamide (Ifex®), irinotecan (CPT-11, Camptosar®), liposomal doxorubicin (Doxil®), melphalan, pemetrexed (Alimta®), topotecan, or vinorelbine (Navelbine®). In certain embodiments, the multimodality treatment of ovarian epithelial / fallopian tube / primary peritoneal cancer comprises the administration of a composition of g-NK cells provided herein in combination with bevacizumab (Avastin®) plus paclitaxel (Taxol®).

[0301] In some embodiments, the multimodality treatment of pancreatic cancer comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is cetuximab (Erbitux®) or bevacizumab (Avastin®), and (2) a cancer therapeutic or cytotoxic agent that is erlotinib (Tarceva®), everolimus (Afinitor®), sunitinib (Sutent®), gemcitabine (Gemzar), 5-fluorouracil (5-FU), oxaliplatin (Eloxatin), albumin-bound paclitaxel (Abraxane), capecitabine (Xeloda), cisplatin, irinotecan (Camptosar), paclitaxel (Taxol), docetaxel (Taxotere), or albumin-bound paclitaxel (Abraxane). In certain embodiments, the multimodality treatment of pancreatic cancer comprises administration of a composition of g-NK cells provided herein in combination with erlotinib (Tarceva®) plus oxaliplatin (Eloxatin).

[0302] In some embodiments, the multimodality treatment of skin cancer is comprised of (1) a monoclonal antibody that is ipilimumab (Yervoy®), pembrolizumab (Keytruda®), avelumab (Bavencio®), or nivolumab (Opdivo®), and (2) a monoclonal antibody that is vismodegib (Erivedge®), sonidegib (Odomzo®), vemurafenib (Zelboraf®), trametinib, or pembrolizumab (Keytruda®). (Mekinist®), dabrafenib (Tafinlar®), cobimetinib (Cotellic™), alitretinoin (Panretin®), radiation therapy, dacarbazine, temozolomide, Nab-paclitaxel, paclitaxel, cisplatin, carboplatin, or vinblastine. In certain embodiments, the multimodality treatment of skin cancer comprises administration of a composition of g-NK cells provided herein in combination with avelumab (Bavencio®) plus cisplatin.

[0303] In some embodiments, the multimodality treatment of soft tissue sarcoma comprises administration of a composition of g-NK cells provided herein in combination with (1) a monoclonal antibody that is olaratumab (Lartruvo™), and (2) a cancer therapeutic or cytotoxic agent that is pazopanib (Votrient®), alitretinoin (Panretin®), radiation therapy, ifosfamide (Ifex®), doxorubicin (Adriamycin®), dacarbazine, epirubicin, temozolomide (Temodar®), docetaxel (Taxotere®), gemcitabine (Gemzar®), vinorelbine (Navelbine®), trabectedin (Yondelis®), or eribulin (Halaven®). In certain embodiments, the multimodality treatment of soft tissue sarcoma comprises administration of a composition of g-NK cells provided herein in combination with olaratumab (Lartruvo™) plus docetaxel (Taxotere®).

[0304] 4. Oncolytic viruses In some embodiments, the provided methods can also include administering g-NK cells together with an oncolytic virus. The combined treatment of g-NK cells and an oncolytic virus can further include administration of one or more other agents, such as antibodies, as described above.

[0305] It is believed that the combination of g-NK cells and oncolytic viruses can promote or increase the activity of one or both of the treatments. In some embodiments, the use of oncolytic viruses can enhance the sensitivity of tumor cells to NK cells. Evidence has been obtained from oncolytic virus treatment that shows that oncolytic viruses activate NK cells (↑IFN-γ) and enhance NK cell migration to tumors in metastatic melanoma, ovarian cancer, and breast cancer models (Miller et al., 2003 Mol Ther 7:741:747; Benencia et al., 2005 Mol Ther 12:789-802; Zhao et al., 2014 PLoS One 9:e93103). In a phase I clinical trial, oncolytic reovirus was found to increase circulating levels of NK cells (White et al., 2008 Gene Ther 15:911-920), and NK cells were found to mediate the antitumor efficacy of oncolytic reovirus and parapoxvirus in animal models of prostate cancer and A549 lung cancer (Gujar et al., 2011 Mol Ther 19:797-804, Rintoul et al., 2012 Mol. Ther. 20:1148-1157). Increased tumor infiltration by NK cells has also been observed in animal models of adenocarcinoma and glioblastoma following the administration of oncolytic coxsackieviruses and measles viruses, and intratumoral NK cell concentrations were positively correlated with survival (Miyamoto et al., 2012 Cancer Res. 72:2609-2621; Allen et al., 2006 Cancer Res. 66:11840-11850). The mechanism linking oncolytic virus activity to NK cell-mediated clearance of tumor cells is enhanced tumor immunogenicity.Specifically, tumors infected with oncolytic viruses are more readily recognized and killed by NK cells, as evidenced by increased cytotoxicity mediated by the natural cytotoxicity receptors NKp30 and NKp44, and enhanced expression of the cytotoxic cytokines IFN-γ, TNF-α, and MIP1α / β (Bhat et al., 2011 Int J Cancer 128:908-919; Dempe et al., 2012 Cancer Immunol Res 61:2113-2123; Bhat et al., 2013 BMC Cancer 13:367). Other oncolytic viruses that have been shown to attract and activate NK cells in vivo include influenza virus (Ogbomo et al., 2010 Med Microbiol Immunol 199:93-101), vesicular stomatitis virus (Heiber et al., 2011 J Virol. 85:10440-10450), and Newcastle disease virus (Jarahian et al., 2009 J Virol. 83:810-821). In a study of postoperative cancer surgery patients, oncolytic vaccinia virus was found to reverse postoperative immunosuppression and prevent metastasis formation (Tai et al., 2014 Front Oncol 4:217). Therefore, oncolytic viruses may enhance NK cell antitumor immunity in otherwise immunocompromised individuals.

[0306] In some embodiments, oncolytic viruses target specific cells, such as immune cells. In some embodiments, oncolytic viruses target tumor cells and / or cancer cells in a subject. Oncolytic viruses are viruses that accumulate in and replicate within tumor cells. Replication within the cells can lyse tumor cells, shrink tumors, and eliminate them. Oncolytic viruses can also have a broad host and cell type range. For example, oncolytic viruses can accumulate in immune-privileged cells or tissues, including tumors and / or metastases, as well as wound tissues and cells, allowing for the delivery and expression of heterologous proteins in a wide range of cell types. Oncolytic viruses can also replicate specifically in tumor cells, resulting in tumor cell lysis and efficient tumor regression.

[0307] Exemplary oncolytic viruses include adenovirus, adeno-associated virus, herpes virus, herpes simplex virus, reovirus, Newcastle disease virus, parvovirus, measles virus, vesicular stomatitis virus (VSV), coxsackievirus and vaccinia virus.In some embodiments, oncolytic viruses specifically colonize solid tumors and do not infect other organs.In some cases, oncolytic viruses can be used as infectious agents for delivering heterologous protein nucleic acid to solid tumors.

[0308] The oncolytic virus can be any known to those skilled in the art, for example, vesicular stomatitis virus, see, e.g., U.S. Pat. Nos. 7,731,974, 7,153,510, 6,653,103 and U.S. Patent Application Publication Nos. 2010 / 0178684, 2010 / 0172877, 2010 / 0113567, 2007 / 0098743, 20050260601, 20050220818 and European Patent Nos. 1385466, 1606411 and 1520175; herpes simplex virus, see, e.g., U.S. Pat. Nos. 7,897,146, 7,897,157, 7,897,160, 7,897,170, 7,897,180, 7,897,190, 7,897,192, 7,897,194, 7,897,196, 7,897,197, 7,897,198, 7,897,199, 7,9 ... Nos. 731,952, 7,550,296, 7,537,924, 6,723,316, 6,428,968 and U.S. Patent Application Publication Nos. 2014 / 0154216, 2011 / 0177032, 2011 / 0158948, 2010 / 0092515, 2009 / 0274728, 2009 / 0285860, 2009 / 0215147, 2009 / 0010889, 2007 / 0110720, 2006 / 0039894, 2004 / 0009604, 2004 / 0063094, International Patent Publication Nos. WO 2007 / 052029, WO 1999 / 038955; retroviruses, see e.g., U.S. Patent Nos. 6,689,871, 6,635,472, 5,851,529, 5,716,826, 5,716,613, and U.S. Patent Application Publication No. 20110212530; vaccinia viruses, see e.g., 2016 / 0339066, and adeno-associated viruses, see e.g., U.S. Patent No. 8,007,780 , 7,968,340, 7,943,374, 7,906,111, 7,927,585, 7,811,814, 7,662,627, 7,241,447, 7,238,526, 7,172,893, 7,033,826, 7,001,765, 6,897,045 and 6,632,670.

[0309] Oncolytic viruses also include viruses that have been genetically modified to attenuate their virulence, improve their safety profile, and enhance tumor specificity, and are equipped with additional genes, such as cytotoxins, cytokines, and prodrug-converting enzymes, to improve the overall efficacy of the virus (see, e.g., Kirn et al., (2009) Nat Rev Cancer 9:64-71; Garcia-Aragoncillo et al., (2010) Curr Opin Mol Ther 12:403-411; U.S. Patent Nos. 7,588,767, 7,588,771, 7,662,398, and 7,754,221; and U.S. Patent Application Publication Nos. 2007 / 0202572, 2007 / 0212727, 2010 / 0062016, and 2009 / 0098). (See, e.g., Nos. 529, 2009 / 0053244, 2009 / 0155287, 2009 / 0117034, 2010 / 0233078, 2009 / 0162288, 2010 / 0196325, 2009 / 0136917, and 2011 / 0064650). In some embodiments, the oncolytic virus can be modified to selectively replicate in cancerous cells and thus be oncolytic. For example, the oncolytic virus is an adenovirus engineered to have improved tropism for tumor therapy and as a gene therapy vector. ONYX-015, H101 and Ad5ΔCR (Hallden and Portella (2012) Expert Opin Ther Targets, 16:945-58) and TNFerade (McLoughlin et al. (2005) Ann. Surg. Oncol., 12:825-30) or the conditionally replicative adenovirus Oncorine® are examples.

[0310] In some embodiments, the oncolytic virus is a modified herpes simplex virus. In some embodiments, the oncolytic virus is Talimogene laherparepvec (also known as T-Vec, Imlygic, or Onco Vex GM-CSF). In some embodiments, the infectious agent is a modified herpes simplex virus, or a variant thereof, as described, for example, in WO 2007 / 052029, WO 1999 / 038955, US 2004 / 0063094, US 2014 / 0154216.

[0311] V. Kits and Manufactured Goods Provided herein are articles of manufacture and kits comprising the provided compositions containing NK cells enriched for a particular subset, e.g., g-NK cells. In some embodiments, the compositions are produced by any of the provided methods. In some embodiments, provided herein are kits comprising the provided compositions and an additional agent. In some embodiments, the additional agent comprises an Fc domain. In some embodiments, the additional agent is an Fc fusion protein or an antibody. In some embodiments, the additional agent is a human antibody, a humanized antibody, or a chimeric antibody. In some of these embodiments, the additional agent is a full-length antibody. Exemplary antibodies include any of the antibodies described.

[0312] Also provided herein are articles of manufacture or kits containing multiple reagents for detecting g-NK surrogate surface marker profiles, such as those described herein. In some embodiments, the reagents include reagents for detecting a panel of surface markers selected from CD16, CD38, CD57, CD7, CD161, and / or NKG2A, e.g., two, three, four, or five surface markers. In some embodiments, the reagents include reagents for detecting a panel of surface markers from CD16, CD57, CD7, and CD161. In some embodiments, the reagents include reagents for detecting a panel of surface markers from CD161 and NKG2A. In some embodiments, the kit can further include one or more additional reagents for detecting one or more other NK cell surface markers. For example, the kit can include one or more additional reagents, e.g., one, two, or three additional reagents, for detecting one or more additional surface markers CD45, CD3, and / or CD56. In some embodiments, the reagents include reagents for detecting a panel of surface markers from CD3, CD56, and CD38. In some embodiments, each of the reagents is a binding molecule for detecting a specific surface marker of the panel.

[0313] In certain embodiments, the reagent comprises an antibody or antigen-binding fragment thereof specific to one or more surface markers of the panel. Optionally, the binding molecule, such as an antibody or antigen-binding fragment, can be directly or indirectly conjugated to a detectable moiety. In some examples, one or more of the antibodies are modified to allow for detection of binding. For example, the antibody can be conjugated to a detectable molecule that allows for direct detection or detection via a secondary agent. In some embodiments, the antibody is directly labeled, for example, with a fluorophore. In some examples, the antibody can be detected using a secondary reagent, such as a secondary antibody reagent that binds to the primary antibody and is coupled to a detectable protein, for example, a fluorescent probe or a detectable enzyme, such as horseradish peroxidase. In some such examples, the kit can further comprise a secondary antibody.

[0314] The kit can optionally include one or more components, such as instructions for use, devices and additional reagents (sterile water or saline for diluting the composition and / or reconstituting lyophilized proteins), and components such as tubes, containers, and syringes for carrying out the method. In some embodiments, the kit can further include reagents for sample collection, sample preparation and processing, and / or reagents for quantifying the amount of one or more surface markers in the sample, such as, but not limited to, detection reagents such as antibodies, buffers, substrates for enzymatic staining, chromogens, or other materials such as slides, containers, microtiter plates, and optionally instructions for carrying out the method. Those skilled in the art will recognize numerous other possible containers, plates, and reagents that can be used in accordance with the provided methods.

[0315] In some embodiments, the kit can be provided as a product containing packaging materials for packaging cells, antibodies, or reagents, or compositions thereof, or one or more other components. For example, the kit can contain containers, bottles, tubes, vials, and any packaging materials suitable for isolating or organizing the components of the kit. One or more containers can be formed from various materials, such as glass or plastic. In some embodiments, one or more containers hold a composition containing cells, antibodies, or other reagents for use in the method. The article of manufacture or kit herein can contain cells, antibodies, or reagents in separate containers or in the same container.

[0316] In some embodiments, the solution or solutions that hold the composition can be single-use vials or multi-use vials that can allow repeated use of the composition. In some embodiments, the product or kit can further include a second container that contains a suitable diluent. The product or kit can further include other materials, such as other buffers, diluents, filters, needles, syringes, therapeutic agents, and / or package inserts containing instructions for use, from a commercial, therapeutic, and use perspective.

[0317] In some embodiments, the kit can optionally include instructions. The instructions typically include clear language describing the cell composition, reagents, and / or antibodies, and optionally other components included in the kit, as well as methods for using them. In some embodiments, the instructions indicate methods for using the cell composition and antibodies for administration to a subject for the purpose of treating a disease or condition, e.g., according to any of the provided embodiments. In some embodiments, the instructions indicate methods for using reagents, such as antibodies, as a panel for detecting a g-NK surrogate marker phenotype, e.g., according to any of the provided embodiments. In some embodiments, the instructions are provided as a label or package insert on or associated with the container. In some embodiments, the instructions may provide directions for reconstituting and / or using the composition.

[0318] VI. Illustrative Embodiments The provided aspects include the following: 1. FcRγ-deficient NK cells (g - 1. A method for increasing NK, comprising: The method comprises: (a) From samples from human subjects, (i) CD3-negative (CD3 neg ), (ii) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (iii) cells that are CD3 negative and CD57 positive (CD3 neg CD57 pos ), or (iv) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are (b) separating the population of enriched NK cells from (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) recombinant IL-2 and culturing the culture in the presence of Including, wherein the method produces an expanded g-NK cell population. The method. 2. The method of embodiment 1, wherein prior to (a), the sample is obtained from the human subject. 3. The method of embodiment 1 or embodiment 2, wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs). 4. The method of any of aspects 1-3, wherein the sample is an apheresis sample or a leukapheresis sample. 5. The method of any of aspects 1 to 4, wherein said selecting comprises immunoaffinity-based selection. 6. The isolating step is performed by isolating CD3-negative (CD3 neg 6. The method of any of embodiments 1 to 5, comprising selecting from the sample a cell that is 7. The isolating step is performed by isolating CD3-negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos 6. The method of any of embodiments 1 to 5, comprising selecting from the sample a cell that is 8. The isolating step is performed by using CD3-negative and CD57-positive (CD3 neg CD57 pos 6. The method of any of embodiments 1 to 5, comprising selecting from the sample a cell that is 9. The isolating step is performed by using CD3-negative and CD16-positive (CD3 neg CD16 pos 6. The method of any of embodiments 1 to 5, comprising selecting from the sample a cell that is 10. The method of any of aspects 1-9, wherein after (a), the isolated population of enriched NK cells is cryopreserved, and before (b), the cryopreserved sample comprising the enriched NK cells is thawed. 11. FcRγ-deficient NK cells (g - 1. A method for increasing NK, comprising: The method comprises: (a) obtaining a population of primary human cells enriched for natural killer (NK) cells, the enriched population of NK cells being (i) CD3-negative (CD3 neg ), (ii) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (iii) cells that are CD3 negative and CD57 positive (CD3 neg CD57 pos ), or (iv) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos the obtaining step comprising a phenotype selected from cells that are (b) separating the population of enriched NK cells from (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) recombinant IL-2 and culturing the culture in the presence of Including, wherein the method produces an expanded g-NK cell population. The method. 12. The method of embodiment 11, comprising thawing a cryopreserved sample comprising enriched NK cells. 13. The population of enriched NK cells is CD3 negative (CD3 neg 13. The method of embodiment 11 or embodiment 12, comprising a cell which is 14. The population of enriched NK cells is CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos 13. The method of embodiment 11 or embodiment 12, comprising a cell which is 15. The population of enriched NK cells is CD3 negative and CD57 positive (CD3 neg CD57 pos 13. The method of embodiment 11 or embodiment 12, comprising a cell which is 16. The population of enriched NK cells is CD3 negative and CD16 positive (CD3 neg CD16 pos 13. The method of embodiment 11 or embodiment 12, comprising a cell which is 17. FcRγ-deficient NK cells (g - 1. A method for increasing NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative and CD57 positive; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population. The method. 18. isolating said population of enriched NK cells from the sample prior to said culturing step; The isolation comprises: (1) selecting cells that are (a) CD3 negative or (b) CD57 positive, thereby enriching the first selected population; and (2) selecting cells from the first selected population for the other of (a) cells that are CD3 negative or (b) cells that are CD57 positive, thereby enriching for cells that are CD3 negative and CD57 positive. 20. The method of embodiment 17, comprising: 19. FcRγ-deficient NK cells (g - 1. A method for increasing NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative and CD16 positive; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population. The method. 20. isolating said population of enriched NK cells from the sample prior to said culturing step; The isolation comprises: (1) selecting cells that are (a) CD3 negative or (b) CD16 positive, thereby enriching the first selected population; and (2) selecting cells from the first enriched selected population for the other of (a) cells that are CD3 negative or (b) cells that are CD16 positive, thereby enriching for cells that are CD3 negative and CD16 positive. 20. The method of embodiment 19, comprising: 21. The method of any of embodiments 17-20, wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs). 22. The method of any one of aspects 17 to 21, wherein the sample is obtained from the human subject prior to the culturing step. 23. The method of any of aspects 17-22, wherein the sample is an apheresis sample or a leukapheresis sample. 24. The method of any of aspects 18 and 19-23, wherein said selecting comprises immunoaffinity-based selection. 25. The method of any of aspects 18-24, wherein the enriched NK cells are derived from a cryopreserved sample previously isolated from a sample from the subject. 26. The method of any one of aspects 1 to 25, wherein the culturing step is further carried out in the presence of (iii) primary human peripheral blood mononuclear cell (PBMC) feeder cells, and the PBMC feeder cells are irradiated. 27. The method of embodiment 26, wherein the ratio of PBMC feeder cells to enriched NK cells is from 1:1 or about 1:1 to 5:1 or about 5:1, inclusive. 28. The method of embodiment 26 or embodiment 27, wherein the PBMC feeder cells are autologous to the subject. 29. At least a portion of the culturing step comprises: at least one stimulatory agent capable of stimulating the activation of one or more of the T cells of the PBMC feeder cells; 29. The method of any of embodiments 26 to 28, wherein the method is carried out in the presence of 30. The method of embodiment 29, wherein the stimulatory agent specifically binds to a member of the TCR complex, and optionally, the agent specifically binds to CD3, optionally CD3 epsilon. 31. The method of embodiment 29 or embodiment 30, wherein the at least one stimulatory agent is an anti-CD3 antibody or an antigen-binding fragment thereof. 32. The method of embodiment 31, wherein the anti-CD3 antibody or antigen-binding fragment thereof is an OKT3 antibody or antigen-binding fragment. 33. The method of embodiment 31 or embodiment 32, wherein the concentration of the anti-CD3 antibody or antigen-binding fragment is from at or about 10 ng / mL to at or about 100 ng / mL. 34. The method of any of aspects 31-33, wherein the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 50 ng / mL. 35. The method of any of embodiments 31-34, wherein the at least one stimulatory agent is added at the beginning of the culturing step or at or about the same time as the irradiated PBMC feeder cells. 36. The method of any of aspects 26-37, wherein the PBMC feeder cells are activated during at least a portion of the culturing step. 37. The method of any of embodiments 1-36, wherein the ratio of AEH feeder cells to NK cells is 1:1 or about 1:1 or greater. 38. The method of any of aspects 1-37, wherein the ratio of AEH feeder cells to NK cells is 1:1 to 5:1, inclusive. 39. The method of any of aspects 1-38, wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 1:1 to 3:1, inclusive. 40. The method of any of aspects 1-29, wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cells is at or about 2.5:1. 41. The method of any of aspects 17-40, wherein the ratio of PBMC feeder cells to enriched NK cells is 5:1 or about 5:1. 42. The method of any of aspects 1-41, wherein the concentration of recombinant IL-2 during at least a portion of the culturing step is from at or about 10 IU / mL to at or about 500 IU / mL. 43. The concentration of recombinant IL-2 during at least a portion of the culturing step is: Recombinant IL-2, 100 IU / mL or approximately 100 IU / mL The method of any one of aspects 1 to 42, wherein 44. The method of any of aspects 1-43, wherein recombinant IL-2 is added beginning at or about the beginning of the culturing step. 45. The method of any of aspects 1-44, further comprising changing the culture medium one or more times during said culturing step. 46. ​​The method of embodiment 45, wherein the changing of the culture medium is performed within 3 to 7 days or about 3 to 7 days after the initiation of the culturing step, optionally starting 5 days or about 5 days after the initiation of the culturing step. 47. The method of embodiment 46, wherein the exchange of culture medium is performed every 2 or 3 days for the remaining duration of the culturing step. 48. The method of any of aspects 45-47, wherein said exchanging of culture medium reduces or removes said at least one stimulatory agent from the culture medium. 49. The method of any of embodiments 45-48, wherein recombinant IL-2 is added to the culture during each change of culture medium. 50. The method of any of aspects 44-49, wherein recombinant IL-2 is added at a concentration of at or about 10 IU / mL to at or about 500 IU / mL, inclusive. 51. The method of any of aspects 44-50, wherein the recombinant IL-2 is added at a concentration of at or about 100 IU / mL of recombinant IL-2. 52. The population of enriched NK cells comprises at least 0.2 x 10 6 Or at least about 0.2 × 10 6 Enriched NK cells, at least 1.0 x 10 6 Or at least about 1.0 × 10 6 enriched NK cells, or 10 x 10 6 Or about 10 x 10 6 52. The method of any of aspects 1-51, comprising enriched NK cells. 53. The population of enriched NK cells at the start of the culturing step is 0.05 x 10 6 or approximately 0.05 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or approximately 1.0 x 10 6 53. The method of any of aspects 1 to 52, wherein the concentration of the enriched NK cells is about 10 ... 54. The population of enriched NK cells at the start of the culturing step is 0.05 x 10 6 or approximately 0.05 x 10 6 From 0.5 x 10 concentrated NK cells / mL6 or approximately 0.5 x 10 6 The method of any of aspects 1 to 53, wherein the concentration of the enriched NK cells is about 10 ... 55. The population of enriched NK cells at the start of the culturing step is 0.2 x 10 6 or approximately 0.2 x 10 6 55. The method of any of aspects 1-54, comprising a concentration of enriched NK cells / mL. 56. The method of culturing comprises culturing at least 2.50 x 10 8 or at least about 2.50 x 10 8 56. The method of any of aspects 1 to 55, wherein the method is carried out until an expansion of g-NK cells is achieved. 57. The step of culturing comprises culturing at least 5.00 x 10 8 or at least about 5.00 x 10 8 The method of any of embodiments 1 to 56, wherein the method is carried out until an expansion of g-NK cells is achieved. 58. The step of culturing comprises culturing at least 1.0 x 10 9 or at least about 1.0 × 10 9 The method of any of embodiments 1 to 57, wherein the method is carried out until an expansion of g-NK cells is achieved. 59. The method of culturing comprises culturing at least 5.0 x 10 9 or at least about 5.0 × 10 9 The method of any of embodiments 1 to 58, wherein the method is carried out until an expansion of g-NK cells is achieved. 60. The culturing step is for 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or for about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or for at least 5, 6, 60. The method of any of embodiments 1-59, wherein the method is carried out over a period of 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. 61. The method of any of aspects 1-60, wherein the culturing step is carried out for 14 days, or about 14 days, or at least 14 days, or at least about 14 days. 62. The method of any of aspects 1-60, wherein the culturing step is carried out for 21 days, or about 21 days, or at least 21 days, or at least about 21 days. 63. The method of any of aspects 1 to 62, wherein an increased number of g-NK cells is produced at the end of said culturing step compared to at the beginning of said culturing step. 64. The method of embodiment 63, wherein the increase is greater than or about 100-fold, greater than or about 200-fold, greater than or about 300-fold, greater than or about 400-fold, greater than or about 500-fold, greater than or about 600-fold, greater than or about 700-fold, or greater than or about 800-fold. 65. g-NK cells express FcRγ neg The method of any one of embodiments 1 to 64, wherein 66. g-NK cells further express CD45 pos / CD3 neg / CD56 pos 66. The method of embodiment 65, 67. The method of any of aspects 1-64, wherein the g-NK cells are cells having a g-NK surrogate surface marker profile. 68. The method of any of aspects 1-70, further comprising purifying or selecting from said expanded cell population a population of cells having a g-NK cell surrogate surface marker profile. 69. g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg 69. The method of embodiment 67 or embodiment 68, wherein 70. g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg 69. The method of embodiment 67 or embodiment 68, wherein 71. g-NK cell surrogate surface marker profile further revealed CD45 pos / CD3 neg / CD56 pos 71. The method of embodiment 69 or embodiment 70, wherein 72. The method of any of aspects 1-71, further comprising formulating the expanded g-NK cell population in a pharmaceutically acceptable excipient. 73. The method of embodiment 72, further comprising the step of cryopreserving and / or formulating the cells in the presence of a cryoprotectant. 74. A composition comprising g-NK cells produced by the method of any one of aspects 1 to 73. 75. At least 10 6 or at least about 10 6 79. The composition of any of embodiments 74 to 78, comprising g-NK cells. 76.10 6 Or about 10 6 From, 10 10 Or about 10 10 g-NK cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 g-NK cells, 10 6 Or about 10 6 From, 10 8Or about 10 8 g-NK cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 g-NK cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 g-NK cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 g-NK cells, 10 7 Or about 10 7 From, 10 8 Or about 10 8 g-NK cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 g-NK cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 g-NK cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 10 76. The composition of embodiment 74 or embodiment 75, comprising g-NK cells. 77. g-NK cells express FcRγ neg 77. The composition of any of embodiments 75-76, wherein 78. g-NK cells further express CD45 pos / CD3 neg / CD56 pos 78. The composition of embodiment 77, wherein 79. The composition of any of aspects 75-76, wherein the g-NK cells are cells having a g-NK surrogate surface marker profile. 80. g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg 80. The composition of embodiment 79, wherein 81. g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg 80. The composition of embodiment 79, wherein 82. A composition comprising a natural killer (NK) cell subset, At least 40%, or at least about 40%, at least 50%, or at least about 50%, at least 60%, or at least about 60%, at least 70%, or at least about 70%, at least 80%, or at least about 80%, or at least about 90% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg having a g-NK cell surrogate marker profile selected from The composition. 83. g-NK cell surrogate surface marker profile is CD45 pos / CD3 neg / CD56 pos 92. The composition of any of embodiments 80-91, further comprising: 84. At least 60% or at least about 60% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg The composition of embodiment 82 or embodiment 83, comprising a g-NK cell surrogate marker profile selected from: 85. At least 70% or at least about 70% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg and NKG2A neg / CD161 neg 85. The composition of any of embodiments 82-84, comprising a g-NK cell surrogate marker profile selected from: 86. Of the cells containing the g-NK cell surrogate marker profile, over 70% were FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg 86. The composition of any of embodiments 83-85, wherein 87. At least 10 6 or at least about 10 6 87. The composition of any of embodiments 83 to 86, comprising the cells. 88.10 6 Or about 10 6 From, 10 10 Or about 10 10 cells, 10 6 Or about 10 6 From, 10 9 Or about 10 9 cells, 10 6 Or about 10 6 From, 10 8 Or about 10 8 cells, 10 6 Or about 10 6 From, 10 7 Or about 10 7 cells, 10 7 Or about 10 7 From, 10 10 Or about 10 10 cells, 10 7 Or about 10 7 From, 10 9 Or about 10 9 cells, 10 7 Or about 10 7 From, 10 8 Or about 10 8 cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 cells, or 10 9 Or about 10 9 From, 10 10 Or about 10 1088. The composition of any of embodiments 83 to 87, comprising the cells. 89. The composition of any of aspects 74-88, comprising a pharmaceutically acceptable excipient. 90. The composition of any of aspects 74-89, comprising a cryoprotectant. 91. The composition of any of aspects 74 to 90, which is sterile. 92. A kit comprising the composition of any of embodiments 74-91 and an additional agent for treating a disease. 93. Instructions for administering the composition and an additional agent to treat a disease or condition. 93. The kit of embodiment 92, further comprising: 94. The composition of any one of embodiments 74 to 91; and instructions for administering the composition in combination therapy with an additional agent to treat a disease; Includes a kit. 95. The kit of any of aspects 92-94, wherein the additional agent is an antibody or an Fc fusion protein. 96. The kit of embodiment 95, wherein the antibody recognizes or specifically binds to a tumor-associated antigen. 97. The antibody is selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate binding protein, and scatter factor (SCF). 97. The kit of embodiment 95 or embodiment 96, wherein the kit recognizes or binds to a cytoplasmic receptor kinase, ganglioside, cytokelin, frizzled receptor, VEGF, VEGFR, integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-α, phosphatidylserine, syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin. 98. The kit of any one of embodiments 95-97, wherein the antibody is a full-length antibody and / or comprises an Fc domain. 99. A method of treating a disease or condition, comprising administering the composition of any of embodiments 74-91 to an individual in need thereof. 100. 1 x 10 8 or about 1 x 10 8 From 1×10 10 cells / m 2 or 1 x 10 6 Or about 1 x 10 6 From 1×10 10 100. The method of embodiment 99, comprising administering NK cells / kg. 101. The method of embodiment 99 or embodiment 100, further comprising administering an additional agent. 102. The method of embodiment 101, wherein the additional agent is an antibody or an Fc fusion protein. 103. The method of embodiment 102, wherein the antibody recognizes a tumor-associated antigen. 104. The antibody is selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor receptor kinase, ganglioside, cytokelen, frizzled receptor, VEGF, VEGFR, and integrin α. 104. The method of embodiment 102 or embodiment 103, wherein the antibody recognizes or specifically binds to Vβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-α, phosphatidylserine, syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin. 105. The method of any one of embodiments 101-104, wherein the antibody comprises an Fc domain and / or is a full-length antibody. 106. The method of any one of embodiments 101-105, wherein the additional agent and the composition are administered sequentially. 107. The method of embodiment 106, wherein the additional agent is administered prior to administration of the composition. 108. The method of any one of embodiments 101-105, wherein the additional agent and the composition are administered simultaneously. 109. The method of any one of embodiments 101-108, wherein the disease or condition is selected from the group consisting of an inflammatory condition, an infectious disease, and a cancer. 110. The method of embodiment 109, wherein the infection is a viral infection or a bacterial infection. 111. The method of embodiment 110, wherein the cancer is leukemia, lymphoma, or myeloma. 112. The method of embodiment 110, wherein the cancer comprises a solid tumor. 113. The method of any one of embodiments 101-112, wherein the individual is a human. 114. The method of any one of aspects 101-113, wherein the NK cells in the composition are allogeneic to the individual. 115. The method of any one of aspects 101-113, wherein the NK cells in the composition are autologous to the subject. 116. A kit comprising multiple reagents for detecting a panel of surface markers selected from CD16, CD57, CD7 and CD161 or NKG2A and CD161. 117. The kit of embodiment 116, wherein the panel of surface markers further comprises CD3, CD45, and CD56. 118. The kit of embodiment 116 or embodiment 117, wherein each of the plurality of reagents is a binding molecule specific for one marker in the panel of surface markers. 119. The kit of embodiment 118, wherein the binding molecule is an antibody or antigen-binding fragment. 120. The kit of embodiment 118 or embodiment 119, wherein the binding molecule is detectably labeled. 121. A method for detecting a g-NK surrogate surface marker profile in a sample containing natural killer (NK) cells, using the kit of any of aspects 116 to 120. 122. (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers selected from CD16, CD57, CD7 and CD161 or NKG2A and CD161; (b) Phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg or NKG2A neg / CD161 neg detecting the presence or absence of cells in the sample, A method for detecting a g-NK surrogate surface marker profile in a sample, comprising: 123. The panel of surface markers further comprises CD45, CD3, and CD56, and the phenotype is CD45. pos / CD3 neg / CD56 pos 123. The method of embodiment 122, further comprising: 124. The method of embodiment 122 or embodiment 123, wherein each of the plurality of reagents is a binding molecule specific for one marker in the panel of surface markers. 125. The method of embodiment 124, wherein the binding molecule is an antibody or antigen-binding fragment. 126. The method of embodiment 124 or embodiment 125, wherein the binding molecule is detectably labeled. 127. The method of any one of embodiments 122 to 126, wherein the detecting is by flow cytometry. [Example]

[0319] VII. Working Examples The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

[0320] Example 1: Identification of g-NK surrogate surface markers Intracellular marker FcRγ negWe conducted a study to identify combinations of extracellular surface markers that can be used as surrogate surface markers to identify g-NK cells that are negative for CD45. The percentage of g-NK cells in human peripheral blood samples was determined by the g-NK cell subset CD45. pos / CD3 neg / CD56 pos / FcRγ neg The NK cell phenotype was determined by flow cytometry using intracellular staining for FceRIγ and extracellular staining for CD45, CD3, and CD56 to identify the g-NK cells. As shown in Figure 1, the NK cell phenotype was significantly higher among the g-NK cells in the samples than among the g-NK cells. pos / CD3 neg / CD56 pos cells having CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg or NKG2A neg / CD161 neg The extracellular surface phenotype of CD16 strongly correlated with the presence of g-NK cells in the samples. pos / CD57 pos / CD7 dim / neg / CD161 neg Within NK cell subsets or NKG2A neg / CD161 neg The percentage of g-NK cells within the NK cell subsets was above 80% in both cases.

[0321] Example 2: FcRγ-deficient NK cells (g - A method for preferentially increasing NK Human peripheral blood mononuclear cells (PBMCs) were isolated from whole blood from CMV-positive human donors or CMV-seronegative donors for comparison by Histopaque® density centrifugation according to the manufacturer's instructions. PBMCs were collected from the buffy coat, washed, and assessed for viable CD45+ cells by flow cytometry (to distinguish PBMCs from residual red blood cells). Approximately two-thirds of the autologous PBMCs were enriched for natural killer (NK) cells by immunoaffinity-based magnetic bead separation using Miltenyi MACS™ microbeads, either by depletion of CD3+ cells to remove T cells (CD3 depletion), CD3 depletion followed by CD57 positive selection to enrich for CD57+ NK cells, or CD16 positive selection (enriching CD16+ NK cells and monocytes). Alternatively, NK enrichment can be performed by CD3 depletion followed by CD56 enrichment (removing T cells and enriching NK cells).

[0322] The percentage of isolated g-NK cells was determined by staining cells with a combination of extracellular surface markers CD45, CD3, CD56, CD16, CD57, CD7, and CD161 or by intracellular staining with anti-FceRI antibody. - The percentage of NK cells is CD45 pos / CD3 neg / CD56 pos / FceRI neg (FcRγ neg If cell sorting is performed before (or after) expansion or functional assays, extracellular surface staining alone can be used, and g - The percentage of NK cells was determined using a surrogate surface marker profile, CD45 pos / CD3 neg / CD56 pos / CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg Lymphocytes or CD45 pos / CD3 neg / CD56 pos / NKG2A neg / CD161 neg , or are identified as surviving cells thereof.

[0323] Freshly isolated NK cells were used immediately for NK cell expansion or cryopreserved and thawed prior to expansion. The NK cell expansion protocol may be used with either frozen / thawed enriched NK cells or NK cells enriched from frozen / thawed PBMCs.

[0324] Prior to expansion, survival CD71 pos (target cell marker) by determining the number of cells bright 221.AEH lymphoma cells were prepared as feeder cells. 221.AEH is a 721.221 cell line that highly expresses HLA-E (HLA-E bright ) (Lee et al. 1998, J Immunol 160:4951-60). 221.AEH target cells, approximately 2.5 times the number of enriched NK cells obtained after magnetic bead separation of PBMCs, were cultured at 1 × 10 in RPMI-1640 + 10% fetal bovine serum (FBS). 6 The 221.AEH cells were resuspended at a concentration of 100 cells / mL. The resuspended 221.AEH cells were irradiated at 100 Gy. In addition, the remaining one-third of the autologous PBMCs isolated above were also irradiated (100 Gy) for use as feeder cells for expansion. While the use of irradiated PBMCs as feeder cells during expansion is not necessary, studies have shown that this improves the efficacy of NK cell expansion.

[0325] 0.2 × 10 cells in culture medium consisting of 95% serum-free medium (e.g., CellGenix GMP Stem Cell Growth Medium (SCGM)) supplemented with 5% human AB (or autologous) serum and 100 IU / mL recombinant IL-2. 6 At a concentration of approximately 10 x 10 NK cells / mL 6Fresh or thawed magnetically enriched NK cells were seeded. Coculture of seeded NK cells with irradiated autologous PBMCs at a 5:1 PBMC-to-NK cell ratio and irradiated 221.AEH feeder cells at a 2.5:1 221.AEH-to-NK cell ratio was initiated on day 0. Optionally, expansion could be performed without irradiated PBMC f...

Claims

1. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method comprises: (a) From a sample from a human subject, (i) CD3-negative and CD57-positive (CD3 neg CD57 pos ), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos ), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg and isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are (b) isolating the population of enriched NK cells; (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 and culturing the culture in the presence of Including, wherein the method produces an expanded g-NK cell population; The method.

2. (a) From a sample from a human subject, (i) CD3-negative and CD57-positive (CD3 neg CD57 pos ), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos ), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg and isolating a population of primary human cells enriched for natural killer (NK) cells, comprising selecting cells that are (b) combining said population of enriched NK cells with irradiated 221.AEH feeder cells and irradiated peripheral blood mononuclear (PBMC) feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is between 1:10 and 10:1, and the ratio of PBMC feeder cells to enriched NK cells is from 1:1 or about 1:1 to 5:1 or about 5:1, inclusive, and optionally the PBMC feeder cells are autologous to the subject; (c) culturing the population of (b) in the presence of recombinant IL-2 and an anti-CD3 antibody or antigen-binding fragment, wherein the cell culture medium is replaced with fresh medium containing recombinant IL-2 within 7 days of the start of the culturing step, and optionally, the cell culture medium is further replaced with fresh medium containing recombinant IL-2 every 2 or 3 days thereafter for the duration of the culturing step, wherein the culturing step produces an expanded g-NH cell population; (d) harvesting the expanded cell population; FcRγ-deficient NK cells (g - A method for increasing NK.

3. 3. The method of claim 1 or claim 2, wherein prior to (a), a sample is obtained from a human subject.

4. The method of any one of claims 1 to 3, wherein the human subject is CMV seropositive.

5. The method of any one of claims 1 to 4, wherein the human subject has a CD16 158V+ NK cell genotype.

6. The method of any one of claims 1 to 5, wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs).

7. The method of any one of claims 1 to 6, wherein the sample is an apheresis sample or a leukapheresis sample.

8. The method of any one of claims 1 to 7, wherein said selecting comprises immunoaffinity-based selection.

9. The step of isolating is a step of isolating (i) and isolating CD3 negative and CD57 positive (CD3 neg CD57 pos 9. The method of claim 1, comprising selecting a cell that is

10. The isolating step is a step of isolating (ii) and isolating CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg 9. The method of claim 1, comprising selecting a cell that is

11. The isolating step is a step of isolating (iii) and isolating CD3 negative (CD3 neg 9. The method of claim 1, comprising selecting a cell that is

12. The isolating step is a step of isolating (iv) and isolating CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos 9. The method of claim 1, comprising selecting a cell that is

13. The isolating step is a step of isolating (v) and isolating CD3 negative and CD16 positive (CD3 neg CD16 pos 9. The method of claim 1, comprising selecting a cell that is

14. The isolating step is a step of isolating (vi) and isolating CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg 9. The method of claim 1, comprising selecting a cell that is

15. 15. The method of any one of claims 11 to 14, wherein after (a), the isolated population of enriched NK cells is cryopreserved, and prior to (b), the cryopreserved sample comprising the enriched NK cells is thawed.

16. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method comprises: (a) obtaining a population of primary human cells enriched for natural killer (NK) cells, the enriched population of NK cells being (i) CD3-negative and CD57-positive (CD3 neg CD57 pos ), (ii) cells that are CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg ), (iii) cells that are CD3 negative (CD3 neg ), (iv) cells that are CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos ), (v) cells that are CD3 negative and CD16 positive (CD3 neg CD16 pos ), or (vi) cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg (b) a phenotype selected from cells that are (b) isolating the population of enriched NK cells; (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 and culturing the culture in the presence of Including, wherein the method produces an expanded population of NK cells enriched for g-NK cells; The method.

17. 17. The method of claim 16, wherein the obtaining step comprises thawing a cryopreserved sample containing the enriched NK cells.

18. The population of enriched NK cells is a population of (i) and is CD3 negative and CD57 positive (CD3 neg CD57 pos 18. The method of claim 16 or 17, comprising a cell which is

19. The population of enriched NK cells is a population (ii) and is CD3 negative, CD56 positive, and CD38 negative (CD3 neg CD56 pos CD38 neg 18. The method of claim 16 or 17, comprising a cell which is

20. The population of enriched NK cells is a population of (iii) and is CD3 negative (CD3 neg 18. The method of claim 16 or 17, comprising a cell which is

21. The population of enriched NK cells is a population (iv) and is CD3 negative (CD3 neg ) and CD56 positive (CD3 neg CD56 pos 18. The method of claim 16 or 17, comprising a cell which is

22. The population of enriched NK cells is a population of (v) and is CD3 negative and CD16 positive (CD3 neg CD16 pos 18. The method of claim 16 or 17, comprising a cell which is

23. The population of enriched NK cells is a population of (vi) and is CD3 negative (CD3 neg ) and CD56 positive, NKG2A negative, and CD161 negative (CD3 neg CD56 pos NKG2A neg CD161 neg 18. The method of claim 16 or 17, comprising a cell which is

24. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative and CD57 positive; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population; The method.

25. isolating said population of enriched NK cells from a sample prior to said culturing step; The isolation comprises: (1) selecting (a) cells that are CD3 negative or (b) cells that are CD57 positive, thereby enriching the first selected population; and (2) selecting cells from the first selected population for the other of (a) cells that are CD3 negative or (b) cells that are CD57 positive, thereby enriching for cells that are CD3 negative and CD57 positive.

25. The method of claim 24, comprising:

26. The isolation comprises: (1) selecting cells from the sample that are CD3 negative to produce a first selected population; and (2) Selecting CD57-positive cells from the first selection population and enriching for CD3-negative and CD57-positive cells.

26. The method of claim 9, claim 24, or claim 25, comprising:

27. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative, CD56 positive, and CD38 negative; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population; The method.

28. isolating said population of enriched NK cells from a sample prior to said culturing step; The isolation comprises: (1) selecting cells that are CD3 negative, thereby enriching the first selection population; (2) selecting from the first selected population (a) cells that are CD56 positive or (b) cells that are CD38 negative, thereby enriching the second selected population; and (3) selecting cells from the second selected population for the other of (a) cells that are CD56 positive or (b) cells that are CD38 negative, thereby enriching for cells that are CD3 negative, CD56 positive, and CD38 negative.

28. The method of claim 27, comprising:

29. The isolation comprises: (1) selecting from the sample those cells that are CD3 negative to produce a first selected population; (2) selecting cells from the first selected population that are CD56 positive to produce a second selected population; and (3) selecting CD38-negative cells from the second selection population and enriching for CD3-negative, CD56-positive, CD38-negative cells; 29. The method of claim 10, claim 27, or claim 28, comprising:

30. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative and CD16 positive; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population; The method.

31. isolating said population of enriched NK cells from a sample prior to said culturing step; The isolation comprises: (1) selecting (a) cells that are CD3 negative or (b) cells that are CD16 positive, thereby enriching the first selected population; and (2) selecting cells from the first enriched selected population for the other of (a) cells that are CD3 negative or (b) cells that are CD16 positive, thereby enriching for cells that are CD3 negative and CD16 positive.

31. The method of claim 30, comprising:

32. The isolation comprises: (1) selecting cells from the sample that are CD3 negative to produce a first selected population; and (2) Selecting CD16-positive cells from the first selection population and enriching for CD3-negative and CD16-positive cells.

32. The method of claim 13, claim 30, or claim 31, comprising:

33. FcRγ-deficient NK cells (g - 1. A method for increasing a cellular NK, comprising: The method includes culturing a population of primary human cells enriched for natural killer (NK) cells from a sample from a human subject; the population of enriched NK cells comprises cells that are CD3 negative, CD56 positive, NKG2A negative, and CD161 negative; The culturing step comprises: (i) irradiated 221.AEH feeder cells, with a ratio of irradiated 221.AEH feeder cells to enriched NK cells ranging from 1:10 to 10:1; and (ii) Recombinant IL-2 In the presence of wherein the method produces an expanded g-NK cell population; The method.

34. isolating said population of enriched NK cells from a sample prior to said culturing step; The isolation comprises: (1) selecting cells that are CD3 negative, thereby enriching the first selection population; (2) selecting from the first selected population those cells that are CD56 positive, thereby enriching the second selected population; (3) selecting from the second selected population for cells that are (a) NKG2A negative or (b) CD161 negative, thereby enriching a third selected population; and (4) selecting cells from the third selected population for the other of (a) cells that are NKG2A-negative or (b) cells that are CD161-negative, thereby enriching for cells that are CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative.

34. The method of claim 33, comprising:

35. The isolation comprises: (1) selecting cells that are CD3 negative to generate a first selection population; (2) selecting cells from the first selected population that are CD56 positive to generate a second selected population; (3) selecting cells from the second selected population that are NKG2A negative to produce a third selected population; and (4) selecting CD161-negative cells from the third selection population and enriching for CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative cells; 35. The method of claim 14, claim 33, or claim 34, comprising:

36. The isolation comprises: (1) selecting cells that are CD3 negative to generate a first selection population; (2) selecting cells from the first selected population that are CD56 positive to generate a second selected population; (3) selecting cells from the second selected population that are CD161 negative to produce a third selected population; and (4) selecting NKG2A-negative cells from the third selection population and enriching for CD3-negative, CD56-positive, NKG2A-negative, and CD161-negative cells; 35. The method of claim 14, claim 33, or claim 34, comprising:

37. The method of any one of claims 24 to 36, wherein the sample is or comprises peripheral blood mononuclear cells (PBMCs).

38. The method of any one of claims 24 to 37, wherein the sample is obtained from the human subject prior to said culturing step.

39. 39. The method of claim 38, wherein the human subject is CMV seropositive.

40. The method of claim 38 or claim 39, wherein the human subject has a CD16 158V+ NK cell genotype.

41. The method of any one of claims 24 to 40, wherein the sample is an apheresis sample or a leukapheresis sample.

42. 42. The method of any one of claims 25, 26, 28, 29, 31, 32, 34, and 35-41, wherein said selecting comprises immunoaffinity-based selection.

43. The method of any one of claims 25 to 42, wherein the enriched NK cells are derived from a cryopreserved sample previously isolated from a sample from the subject.

44. 44. The method of any one of claims 1 and 3 to 43, wherein the culturing step is further carried out in the presence of (iii) primary human peripheral blood mononuclear cell (PBMC) feeder cells, the PBMC feeder cells being irradiated.

45. 45. The method of claim 44, wherein prior to said culturing step, said population of enriched NK cells is combined with irradiated 221.AEH feeder cells and irradiated PBMC feeder cells.

46. 46. ​​The method of claim 44 or claim 45, wherein the ratio of PBMC feeder cells to enriched NK cells is at or about 1:1 to at or about 5:1, inclusive.

47. The method of any one of claims 2 and 44-46, wherein the PBMC feeder cells are autologous to the subject.

48. At least a portion of the culturing step comprises: At least one stimulatory agent capable of stimulating the activation of one or more of the T cells of the PBMC feeder cells. The method of any one of claims 44 to 47, wherein the method is carried out in the presence of

49. 49. The method of claim 48, wherein the stimulatory agent specifically binds to a member of the TCR complex, and optionally, the agent specifically binds to CD3, optionally CD3 epsilon.

50. 50. The method of claim 48 or claim 49, wherein the at least one stimulatory agent is an anti-CD3 antibody or an antigen-binding fragment thereof.

51. The method of claim 2 or claim 50, wherein the anti-CD3 antibody or antigen-binding fragment thereof is an OKT3 antibody or antigen-binding fragment thereof.

52. 52. The method of claim 2, claim 50, or claim 51, wherein the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 10 ng / mL to at or about 100 ng / mL.

53. The method of any one of claims 2 and 50 to 52, wherein the concentration of the anti-CD3 antibody or antigen-binding fragment is at or about 50 ng / mL.

54. 54. The method of any one of claims 50 to 53, wherein said at least one stimulatory agent is added starting at the beginning of said culturing step or at or about the same time as the irradiated PBMC feeder cells.

55. The method of any one of claims 2 and 44-54, wherein the PBMC feeder cells are activated during at least a portion of said culturing step.

56. 221. The method of any one of claims 1 to 55, wherein the ratio of AEH feeder cells to NK cells is 1:1 or about 1:1 or greater.

57. 221. The method of any one of claims 1 to 56, wherein the ratio of AEH feeder cells to NK cells is 1:1 to 5:1, inclusive.

58. The method of any one of claims 1-57, wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 1:1 to 3:1, inclusive.

59. The method of any one of claims 1-58, wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cells is at or about 2.5:

1.

60. 60. The method of claim 59, wherein the NK cells are freshly isolated or have not been previously frozen and thawed.

61. The method of any one of claims 1-58, wherein the ratio of irradiated AEH.221 feeder cells to enriched NK cells is 1:1 or about 1:

1.

62. 62. The method of claim 61, wherein the NK cells have been frozen and then thawed.

63. The method of any one of claims 2 and 44-62, wherein the ratio of PBMC feeder cells to enriched NK cells is at or about 5:

1.

64. 64. The method of any one of claims 1-63, wherein the concentration of recombinant IL-2 during at least a portion of the culturing step is at or about 10 IU / mL to at or about 500 IU / mL.

65. the concentration of recombinant IL-2 during at least a portion of the culturing step is Recombinant IL-2, 100 IU / mL or about 100 IU / mL The method of any one of claims 1 to 64, wherein

66. The method of any one of claims 1 to 65, wherein recombinant IL-2 is added beginning at or about the beginning of said culturing step.

67. 67. The method of any one of claims 1 and 3-66, further comprising changing the culture medium one or more times during said culturing step.

68. 46. ​​The method of claim 2 or claim 45, wherein said exchange of culture medium is performed within 3 to 7 days or about 3 to 7 days after the initiation of said culturing step, optionally starting 5 days or about 5 days after the initiation of said culturing step.

69. 69. The method of claim 68, wherein said changing of culture medium is performed every 2 or 3 days for the remaining duration of said culturing step.

70. 70. The method of any one of claims 2 and 67-69, wherein said exchanging of culture medium reduces or removes said at least one stimulatory agent from the culture medium.

71. The method of any one of claims 67-70, wherein fresh medium containing recombinant IL-2 is added to the culture during each culture medium change.

72. The method of any one of claims 2 and 71, wherein recombinant IL-2 is added at a concentration of at or about 10 IU / mL to at or about 500 IU / mL, inclusive.

73. The method of claim 2, claim 71, or claim 72, wherein the recombinant IL-2 is added at a concentration of 100 IU / mL or about 100 IU / mL of recombinant IL-2.

74. The population of enriched NK cells comprises at least 0.2×10 6 Or at least about 0.2 × 10 6 Enriched NK cells, at least 1.0 x 10 6 Or at least about 1.0 × 10 6 enriched NK cells, or 10 x 10 6 Or about 10 x 10 6 The method of any one of claims 1 to 73, comprising enriched NK cells.

75. The population of enriched NK cells at the start of the culturing step is 0.05×10 6 or about 0.05 x 10 6 From 1.0 x 10 concentrated NK cells / mL 6 or about 1.0 x 10 6 The method of any one of claims 1 to 74, wherein the concentration of enriched NK cells / mL.

76. The population of enriched NK cells at the start of the culturing step is 0.05×10 6 or about 0.05 x 10 6 From 0.5 x 10 concentrated NK cells / mL 6 or about 0.5 x 10 6 The method of any one of claims 1 to 75, wherein the concentration of enriched NK cells / mL.

77. The population of enriched NK cells at the start of the culturing step is 0.2×10 6 or about 0.2 x 10 6 The method of any one of claims 1-76, comprising a concentration of enriched NK cells / mL.

78. The step of culturing comprises culturing at least 2.50×10 8 or at least about 2.50 × 10 8 The method of any one of claims 1 to 77, wherein the method is carried out until an expansion of the g-NK cells is achieved.

79. The step of culturing comprises culturing at least 5.00×10 8 or at least about 5.00 x 10 8 The method of any one of claims 1 to 78, wherein the method is carried out until an expansion of the g-NK cells is achieved.

80. The step of culturing comprises culturing at least 1.0×10 9 or at least about 1.0 × 10 9 The method of any one of claims 1 to 79, wherein the method is carried out until an expansion of individual g-NK cells is achieved.

81. The step of culturing comprises culturing at least 5.0×10 9 or at least about 5.0 × 10 9 The method of any one of claims 1 to 80, wherein the method is carried out until an expansion of g-NK cells is achieved.

82. The step of culturing is for about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or for at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.

82. The method of any one of claims 1-81, wherein the method is carried out for 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days, or for at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.

83. 83. The method of any one of claims 1-82, wherein said culturing is carried out for 14 days, or about 14 days, or at least 14 days, or at least about 14 days.

84. 83. The method of any one of claims 1-82, wherein said culturing is carried out for 21 days, or about 21 days, or at least 21 days, or at least about 21 days.

85. The method of any one of claims 1 to 84, which produces an increased number of g-NK cells at the end of said culturing step compared to at the start of said culturing step.

86. 86. The method of claim 85, wherein the increase is greater than or about 100-fold, greater than or about 200-fold, greater than or about 300-fold, greater than or about 400-fold, greater than or about 500-fold, greater than or about 600-fold, greater than or about 700-fold, or greater than or about 800-fold.

87. 86. The method of claim 85, wherein the increase is greater than or greater than about 1000 fold.

88. The method of any one of claims 1 to 87, wherein after said culturing step, the expanded g-NK cell population produced by said method is harvested.

89. g-NK cells are FcRγ neg The method of any one of claims 1 to 88, wherein

90. g-NK cells further pos / CD3 neg / CD56 pos 90. The method of claim 89, wherein

91. The method of any one of claims 1 to 90, wherein the g-NK cells are cells having a g-NK surrogate surface marker profile.

92. The method of any one of claims 1 to 91, further comprising purifying or selecting from said expanded cell population a population of cells having a g-NK cell surrogate surface marker profile.

93. g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg 93. The method of claim 91 or claim 92, wherein

94. g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg 93. The method of claim 91 or claim 92, wherein

95. g-NK cell surrogate surface marker profile is CD38 neg 93. The method of claim 91 or claim 92, wherein

96. g-NK cell surrogate surface marker profile further increased CD45 pos / CD3 neg / CD56 pos The method of any one of claims 93 to 95, wherein

97. The method of any one of claims 1 to 96, further comprising formulating said expanded g-NK cell population in a pharma- ceutically acceptable excipient.

98. 98. The method of claim 97, further comprising cryopreserving and / or formulating the cells in the presence of a cryoprotectant.

99. A composition comprising g-NK cells produced by the method of any one of claims 1 to 98.

100. At least 10 8 Or at least about 10 8 The composition of claim 99, comprising g-NK cells.

101. The number of g-NK cells in the composition is 10 8 Or about 10 8 From, 10 12 Or about 10 12 Cells, 10 8 Or about 10 8 From, 10 11 Or about 10 11 Cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 Cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 Cells, 10 9 Or about 10 9 From, 10 12 Or about 10 12 Cells, 10 9 Or about 10 9 From, 10 11 Or about 10 11 Cells, 10 9 Or about 10 9 From, 10 10 Or about 10 10 Cells, 10 10 Or about 10 10 From, 10 12 Or about 10 12 Cells, 10 10 Or about 10 10 From, 10 11 Or about 10 11 cells, or 10 11 Or about 10 11 From, 10 12 Or about 10 12 101. The composition of claim 99 or claim 100, wherein the cell is a cell.

102. g-NK cells are FcRγ neg The composition of any one of claims 99 to 101,

103. g-NK cells further pos / CD3 neg / CD56 pos The composition of claim 102,

104. The composition of any one of claims 99 to 101, wherein the g-NK cells are cells having a g-NK surrogate surface marker profile.

105. g-NK cell surrogate surface marker profile is CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg The composition of claim 104,

106. g-NK cell surrogate surface marker profile is NKG2A neg / CD161 neg The composition of claim 104,

107. g-NK cell surrogate surface marker profile is CD38 neg The composition of claim 104,

108. 1. A composition comprising a natural killer (NK) cell subset, comprising: At least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg having a g-NK cell surrogate marker profile that is The composition.

109. At least 70%, or at least about 70%, of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg The composition of claim 108, comprising a g-NK cell surrogate marker profile which is

110. At least 80%, or at least about 80%, of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg The composition of claim 108, comprising a g-NK cell surrogate marker profile which is

111. At least 90%, or at least about 90%, of the cells in the composition are CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg The composition of claim 108, comprising a g-NK cell surrogate marker profile which is

112. 1. A composition comprising a natural killer (NK) cell subset, comprising: At least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are NKG2A neg / CD161 neg having a g-NK cell surrogate marker profile that is The composition.

113. At least 70%, or at least about 70%, of the cells in the composition are NKG2A neg / CD161 neg The composition of claim 112, comprising a g-NK cell surrogate marker profile which is

114. At least 80%, or at least about 80%, of the cells in the composition are NKG2A neg / CD161 neg The composition of claim 112, comprising a g-NK cell surrogate marker profile which is

115. At least 90%, or at least about 90%, of the cells in the composition are NKG2A neg / CD161 neg The composition of claim 112, comprising a g-NK cell surrogate marker profile which is

116. 1. A composition comprising a natural killer (NK) cell subset, comprising: At least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells in the composition are CD38 neg having a g-NK cell surrogate marker profile that is The composition.

117. At least 70%, or at least about 70%, of the cells in the composition are CD38 neg The composition of claim 116, comprising a g-NK cell surrogate marker profile which is

118. At least 80%, or at least about 80%, of the cells in the composition are CD38 neg The composition of claim 116, comprising a g-NK cell surrogate marker profile which is

119. At least 90%, or at least about 90%, of the cells in the composition are CD38 neg The composition of claim 116, comprising a g-NK cell surrogate marker profile which is

120. g-NK cell surrogate surface marker profile is CD45 pos / CD3 neg / CD56 pos 120. The composition of any one of claims 105-119, further comprising:

121. Among cells containing the g-NK cell surrogate marker profile, over 70% were FcRγ neg and optionally 70% to 90% or about 70% to 90% is FcRγ neg The composition of any one of claims 104 to 120,

122. At least 10 8 Or at least about 10 8 The composition of any one of claims 108-121, comprising the cells.

123. The number of g-NK cells in the composition is 10 8 Or about 10 8 From, 10 12 Or about 10 12 Cells, 10 8 Or about 10 8 From, 10 11 Or about 10 11 Cells, 10 8 Or about 10 8 From, 10 10 Or about 10 10 Cells, 10 8 Or about 10 8 From, 10 9 Or about 10 9 Cells, 10 9 Or about 10 9 From, 10 12 Or about 10 12 Cells, 10 9 Or about 10 9 From, 10 11 Or about 10 11 Cells, 10 9 Or about 10 9 From, 10 10 Or about 10 10 Cells, 10 10 Or about 10 10 From, 10 12 Or about 10 12 Cells, 10 10 Or about 10 10 From, 10 11 Or about 10 11 cells, or 10 11 Or about 10 11 From, 10 12 Or about 10 12 The composition of any one of claims 108-122, which is a cell.

124. The composition of any one of claims 99-123, wherein the cells in said composition are from a single donor subject, expanded from the same sample.

125. The composition of any one of claims 99 to 124, comprising a pharma- ceutically acceptable excipient.

126. The composition of any one of claims 99 to 125, comprising a cryoprotectant.

127. The composition of any one of claims 99 to 126, which is sterile.

128. A kit comprising the composition of any one of claims 99-127 and an additional agent for treating a disease.

129. Instructions for administering the composition and an additional agent for treating a disease or condition. The kit of claim 128, further comprising:

130. A composition according to any one of claims 99 to 127; instructions for administering the composition in combination therapy with an additional agent to treat a disease; Including the kit.

131. The kit of any one of claims 128-130, wherein the additional agent is an antibody or an Fc fusion protein.

132. The kit of claim 131, wherein the antibody recognizes or specifically binds to a tumor-associated antigen.

133. The antibody is selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate binding protein, and scatter factor (SCF).

133. The kit of claim 131 or claim 132, which recognizes or binds to a HER2 (HER3) receptor kinase, ganglioside, cytokerain, frizzled receptor, VEGF, VEGFR, integrin alphaVbeta3, integrin alpha5beta1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-alpha, phosphatidylserine, syndecan-1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin.

134. The kit of any one of claims 131 to 133, wherein the antibody is a full-length antibody and / or comprises an Fc domain.

135. The kit of any one of claims 131-134, further comprising an additional agent that is a cytotoxic agent or a cancer therapeutic agent.

136. The kit of any one of claims 128-130, wherein the additional agent is a cytotoxic agent or a cancer therapeutic agent.

137. The kit of any one of claims 128-130, wherein the additional agent is an oncolytic virus.

138. An article of manufacture comprising the kit of any one of claims 128-137.

139. 128. A method of treating a disease or condition, comprising administering to an individual in need thereof the composition of any one of claims 99-127.

140. 1×10 5 or about 1 x 10 5 NK cells / kg to 1 x 10 7 or about 1 x 10 7 140. The method of claim 139, comprising administering to the individual NK cells / kg.

141. 5×10 7 or about 5 x 10 7 From NK cells, 10 × 10 9 or about 10 x 10 9 The method of claim 139, comprising administering to the individual said NK cells.

142. 142. The method of any one of claims 139-141, further comprising administering to the individual an additional agent to treat said disease or condition.

143. The method of claim 142, wherein the additional agent is an antibody or an Fc fusion protein.

144. The method of claim 143, wherein the disease or condition is cancer and the antibody recognizes a tumor antigen associated with cancer.

145. The antibody is selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, mucin, PDGFR-α, TAG-72, CAIX, PSMA, folate binding protein, scatter factor receptor kinase, gangliosides, cytokeratin, frizzled receptor, VEGF, VEGFR, and integrin αVβ. 3, integrin alpha5beta1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-alpha, phosphatidylserine, syndecan-1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin, or tenascin.

146. The method of any one of claims 143 to 145, wherein the antibody comprises an Fc domain and / or is a full-length antibody.

147. The method of any one of claims 143-146, further comprising administering to the subject a cancer therapeutic or cytotoxic agent to treat said disease or condition.

148. 143. The method of claim 142, wherein the additional agent is an oncolytic virus.

149. The method of any one of claims 142-148, wherein said disease or condition is selected from the group consisting of an inflammatory condition, an infectious disease, and a cancer.

150. 150. The method of claim 149, wherein the disease or condition is an infectious disease, and the infectious disease is a viral infection or a bacterial infection.

151. 150. The method of claim 149, wherein the disease or condition is cancer, and the cancer is leukemia, lymphoma, or myeloma.

152. 150. The method of claim 149, wherein the disease or condition is cancer, and the cancer comprises a solid tumor.

153. The method of claim 149 or claim 152, wherein the disease or condition is cancer and the cancer is selected from among gastric or gastroesophageal junction adenocarcinoma, bladder cancer, breast cancer, brain cancer, cervical cancer, colorectal cancer, endocrine / neuroendocrine cancer, head and neck cancer, gastrointestinal stromal cancer, giant cell tumor of bone, renal cancer, liver cancer, lung cancer, neuroblastoma, ovarian epithelial / fallopian tube / primary peritoneal cancer, pancreatic cancer, prostate cancer, skin cancer, and soft tissue cancer.

154. The method of any one of claims 139-153, wherein the individual is a human.

155. The method of any one of claims 139-154, wherein the NK cells in said composition are allogeneic to the individual.

156. The method of any one of claims 139-154, wherein the NK cells in said composition are autologous to the subject.

157. A kit containing multiple reagents for detecting a panel of surface markers including CD16, CD57, CD7, and CD161.

158. A kit comprising multiple reagents for detecting a panel of surface markers including NKG2A and CD161.

159. The kit of claim 157 or claim 158, wherein said panel of surface markers further comprises CD3, CD45, and CD56.

160. A kit containing multiple reagents for detecting a panel of surface markers including CD3, CD56, and CD38.

161. The kit of claim 160, wherein said panel further comprises CD45.

162. The kit of any one of claims 157-161, wherein each of said plurality of reagents is a binding molecule specific for one marker of said panel of surface markers.

163. The kit of claim 162, wherein the binding molecule is an antibody or an antigen-binding fragment.

164. The kit of claim 162 or claim 163, wherein the binding molecule is detectably labeled.

165. The kit of any one of claims 157-164, further comprising instructions for use of said panel of surface markers as surrogate markers for detecting the number of g-NK cells in a cell sample.

166. A method for detecting a g-NK surrogate surface marker profile in a sample containing natural killer (NK) cells using a kit according to any one of claims 157 to 165.

167. (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including CD16, CD57, CD7, and CD161; (b) Phenotype CD16 pos / CD57 pos / CD7 dim / neg / CD161 neg detecting the presence or absence of cells in the sample; A method for detecting a g-NK surrogate surface marker profile in a sample, comprising:

168. (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including NKG2A and CD161; (b) Phenotype NKG2A neg / CD161 neg detecting the presence or absence of cells in the sample; A method for detecting a g-NK surrogate surface marker profile in a sample, comprising:

169. the panel of surface markers further comprises CD45, CD3, and CD56, and the phenotype is CD45 pos / CD3 neg / CD56 pos The method of claim 267 or claim 168, further comprising:

170. (a) contacting a sample containing natural killer (NK) cells with a reagent for detecting a panel of surface markers including CD3, CD56, and CD38; (b) Phenotype CD38 neg / CD56 pos / CD38 neg detecting the presence or absence of cells in the sample; A method for detecting a g-NK surrogate surface marker profile in a sample, comprising:

171. 171. The method of any one of claims 167-170, wherein each of said plurality of reagents is a binding molecule specific for one marker of said panel of surface markers.

172. The method of claim 171, wherein the binding molecule is an antibody or an antigen-binding fragment.

173. 173. The method of claim 171 or claim 172, wherein the binding molecule is detectably labeled.

174. The method of any one of claims 167-173, wherein said detecting is by flow cytometry.